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Abstract 
Polo-like Kinase-1 (PLK1) is an important mediator of the G2/M phase of the cell 
cycle that is down-regulated in a DNA damage dependent manner. In cancer cells 
PLK1 is overexpressed and allows for continued proliferation of the cell by over-
riding this checkpoint. Here I show that PLK1 is down-regulated in a p53-dependent 
manner and that can occur both in response to DNA damage and to a non-genotoxic 
stimulus of the p53 pathway. My data show that p53 is able to repress PLK1 through 
a responsive element in the promoter and that p53 is necessary and sufficient to 
cause PLK1 repression.  When examined in the context of a PLK1 promoter/reporter 
fusion, wild type but not mutated forms of p53 can repress expression. EMSA shows 
that p53 binds to the p53-responsive element and that mutation of this element 
reduces p53 binding. Furthermore, PLK1 repression occurs independently of p21-
mediated arrest at G1/S, a stage of the cell cycle where PLK1 levels are 
physiologically low. PLK1 repression mediated by p21 through the CDE/CHR 
element in the promoter does not appear to cause significant repression of PLK1 but 
may play a minor role. Down-regulation of PLK1 is relieved by the HDAC inhibitor 
TSA and supports the transcriptional repression mechanism described in this thesis. 
Silencing of PLK1 expression by siRNA interferes with cell cycle progression 
consistent with a role in the p53-mediated checkpoint. This thesis provides two 
distinct and perhaps overlapping mechanisms by which p53 may repress PLK1: 1) 
through competitive displacement of an unidentified transcription factor that is 
essential for normal PLK1 expression and 2) through HDAC recruitment leading to 
local repression-associated changes in the chromatin structure. These data establish 
PLK1 as a transcriptional target of p53 that is required for efficient G2/M arrest. 
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Chapter 1: Introduction 
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1.1 p53, Guardian of the Genome 
“If genius is the ability to reduce the complicated to the simple, then the study of p53 
makes fools of us all” (Vousden and Prives, 2009). 
 
1.2 Discovery of p53 
The study of p53 began thirty years ago with the identification of a protein that was 
found bound to the SV40 Large T-antigen and which ran on an SDS-PAGE gel at a 
molecular weight of around 53 kDa (Lane and Crawford, 1979, Linzer and Levine, 
1979). Furthermore, this transformation related protein was found at high levels in 
tumours whereas it was not observed in normal tissue (Rotter, 1983). Other authors 
also showed that there were low levels of p53 in non-transformed cells and high 
levels in transformed cells (DeLeo et al., 1979) and interestingly p53 was found in 
the nucleus in transformed fibroblasts and in the cytoplasm of non-transformed 
fibroblasts (Rotter et al., 1983). On the basis of the above information and the fact 
that p53 was found bound to this viral protein, which is a known oncogene product, 
at high levels in SV40 transformed cells and also in other non-transformed types of 
cancer cells, p53 was considered an oncogene itself (for review see (Levine and 
Oren, 2009)).  
Although during this time data shown by other authors suggested p53 was not an 
oncogene, for example data that showed that Trp53 (Transformation related protein 
53) produced aberrant mRNA due to retroviral insertion of DNA into the first intron 
of the gene in an Abelson murine leukaemia virus transformed mouse cell line (Wolf 
and Rotter, 1984) p53 was continued to be considered an oncogene until the 
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realisation that earlier experiments used cDNA clones that encoded mutant p53. In 
fact, wild type p53 repressed the transformation of cultured cells (Finlay et al., 1989) 
and mutation of p53 is required for transformation of cells, alongside the ras 
oncogene (Hinds et al., 1989). From these and other experiments carried out by 
different groups p53 was re-defined as an anti-oncogene (or recessive oncogene). 
 
1.3 Tumour Suppressor  
Half of all human cancers have a mutation in p53 (Greenblatt et al., 1994). The other 
50% of human cancers are found to have mutations in proteins regulating p53, for 
example MDM2 (as discussed later in this Chapter).  Current success in restoring 
p53 function in tumour cells, by the introduction of small molecules that stabilise 
p53, makes p53 an attractive therapeutic target in the fight against cancer (Brown et 
al., 2009). There are currently over 50,000 papers in the study of p53. To understand 
the impact of the absence of p53 in tumour progression, p53 tumour suppression has 
been studied in many mouse models. As reviewed in Attardi et al, 1999, the first p53 
null mouse was described as developmentally normal but with a higher susceptibility 
to tumours and at an early age (Donehower et al., 1992). p53 heterozygote mice 
were also described, and have been represented as the mouse model for patients with 
Li-Fraumeni syndrome, a syndrome in which humans have one allele of wild type 
p53 and one of mutant p53 and are highly susceptible to tumour formation (Malkin 
et al., 1990, Varley et al., 1997a, Varley et al., 1997b). Mouse studies, involving the 
crossing of p53-null mice and other cancer prone mice, have also revealed the 
importance of other tumour suppressors that interact with p53 in tumour suppression 
and also revealed oncogenes involved in tumour development (for review see 
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(Attardi and Jacks, 1999). For example, Rb (Retinoblastoma) heterozygote mice 
crossed with p53 null mice, produced progeny that showed accelerated 
tumourigenesis compared to that of the Rb-null alone or p53 wild type alone 
progeny, suggesting that Rb and p53 cooperate in tumour suppression. An example 
of mice models that have revealed oncogenes is described, for example, by Hundley 
et al., 1997. These authors describe that the crossing of MMTV ras transgenic mice 
and p53 null mice, give progeny that have an increased instance of tumour 
progression which was faster and earlier in onset than the p53 wild type mice. Their 
data further showed that ras is an oncogene, and when in p53 null mice, leads to 
aggressive tumour formation. In conclusion p53 acts as a barrier to tumourigenesis.  
Overall these mouse studies were vital to defining p53 as a tumour suppressor and 
the role p53 plays in tumour suppression. Indeed, Aranda-anzaldo and Dent, 2007, 
have argued that p53 has been selected mainly for its role in development. They 
argue that since 1) sort-lived organisms don’t need the tumour suppressor roles of 
p53 and 2) p53 tumour suppression is only needed species that live for a long time 
post reproductive age, therefore the development role of p53 must have been 
selected for long before any tumour suppressor role of p53. However this would 
appear counterintuitive since natural selection would not select for traits that occur 
post reproductive phase. Furthermore the tumour suppressive role during 
development is needed during development as p53 mutations are found in childhood 
cancers (Chompret et al., 2000) opposing the theory that p53 mutation only occurs 
after the age of reproduction.  Therefore p53 has a role to play in tumour suppression 
in individuals that have not surpassed the age of reproduction and this suggests that 
tumour suppression is the function of this protein. 
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1.4 The Transcription Factor 
The p53 tumour suppressor is a transcription factor that binds to sequence specific 
DNA at the promoters of genes and also at the non-coding regions of gene (introns) 
(Kern et al., 1991). p53 activates transcription via its trans-activation domains 
(Chang et al., 1995, Fields and Jang, 1990, Raycroft et al., 1990, Walker and Levine, 
1996). The structure of p53 is divided in to three functional domains: the 
aforementioned trans-activation domains are situated at the N-terminus; a DNA 
binding domain; and a C-terminal domain containing a tetramerization domain, 
nuclear localisation signals (NLS’), nuclear export sequence (NES’) and regulatory 
domain, as shown in Figure 1.1.  
 
 
Figure 1.1: The protein domains of p53 
The p53 protein consists of three main domains: the trans-activation domain, DNA binding domain 
and C-terminal domain. The C-terminal domain consists of NLS’, NES, tetramerization domain and 
regulatory domain.  
 
The p53 protein consists of 393 aa residues and forms a tetramer. The crystal 
structure of the wild type p53 and mutant bound DNA complexes were refined by 
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the Fersht laboratory, who show that each monomer binds to a 5 bp sequence (Tidow 
et al., 2007). These authors show that the p53 tetramer forms a tunnel, with the DNA 
binding domain (or core domain, residues 100-300) at one end and the 
tetramerization domain in the C-terminus at the other. The binding of p53 to DNA is 
shown in Figure 1.2 and linking the two domains are four unstructured chains 
(Shakked, 2007). 
 
Figure 1.2: p53 forms a “tunnel” structure around DNA 
The structure of p53 bound to DNA shows that p53 forms a tunnel formation around DNA. The side 
view shows the DNA binding domains on top of the DNA which are linked to the tetramerization 
domains at the bottom via unstructured chains. The straight-on view shows this structure from the 
front and shows the tunnel formation around the DNA. This Figure has been modified from Shakked, 
Z., 2007. Notably the N-terminus (not shown) does not participate in the binding of p53 to DNA. 
 
The next three Sections (Sections 1.4.1-1.4.3) describe in more detail the main roles 
of these domains. 
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1.4.1 Trans-activation Domain 
Activation of transcription by p53 in part occurs through the interaction of the trans-
activation domain (TAD, residues 1-42) in the N-terminus of p53 with the TATA-
Binding Protein (TBP) (Martin et al., 1993) and consequently the general 
transcription factor TFIID complex, which consists of TBP and other Transcription 
Activation Factors (TAFs), (Farmer et al., 1996, Liu et al., 1993) such as TAF1 and 
TAF(II)250. This more stable complex stimulates the binding of p53 to a sequence 
specific DNA binding site (Chen et al., 1993). Interestingly, inactivation of 
TAF(II)250 affects the p53-MDM2 auto-regulatory loop (described in the next 
Section) causing a decrease in the levels of MDM2 and activation of the p53 
pathway (Wasylyk and Wasylyk, 2000). p53 stimulates the TFIID-TFIIA-promoter 
complex assembly by inducing a conformational change in the complex (Xing et al., 
2001). Xing et al., 2001, also show the mechanism by which the SV40 Large T-
antigen induces transformation through inhibition of p53. They show that the Large 
T-antigen, which once bound to the DNA via p53, represses transcription by 
preventing TBP from binding to the TATA box and ultimately inhibits TFIID-TFIIA 
complex assembly, needed for transcription. 
Co-activators of p53 are also required for p53 activated transcription, such as the 
CREB binding protein (CBP) and p300 (both of which are transcriptional co-
activators and histone acetyl-transferases). The p300/CBP complex directly interacts 
with the p53 TAD (TAD1 sub-domain) and stimulates p53 mediated expression of 
genes such as MDM2 (Gu et al., 1997). This was the first description that p53 
activates expression of its negative regulator. Mutation of residues 22 and 23 in 
TAD1 of human p53 abolishes the interaction of p300/CBP to p53 and abolishes p53 
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induced transcription (Gu et al., 1997). Notably, residues 22 and 23 are the initial 
two residues of an LXXLL motif (which forms an α-helix in the DNA); a motif 
necessary for the binding of p300 to p53. Phosphorylation of residues in p53, 
including T18 and S20, are also important in p300 binding and activate p53 by 
stabilising its binding to p300 (Dornan and Hupp, 2001). In addition to this motif, 
the proline repeat motif (proline repeat domain) or proline-rich domain (as shown in 
Figure 1.1) is required for p300 acetylation of p53 (Dornan et al., 2003). Dornan et 
al., 2003 suggest a mechanism whereby the binding of p53 to DNA induces a 
conformational change in p53, which opens up its C-terminus to p300 mediated 
acetylation. Deletion of the LXXLL motif inhibits the binding of p300 to DNA 
bound p53 and p300 acetylation of p53.  Other studies further validate the interaction 
of p53 with p300/CBP and show that the adenovirus viral oncogene E1A inhibits this 
interaction, which may be part of the mechanism by which E1A induces cellular 
transformation (Lill et al., 1997). 
 
1.4.2 DNA Binding Domain 
As p53 is a transcription factor, its primary function is to activate and repress gene 
expression. p53 binds to DNA at sequence specific elements, termed p53 responsive 
elements, through its site-specific DNA binding domain (DBD, residues 98-292).  
The p53 responsive element  generally consists of the two half site sequences (each 
10 bp), separated by a spacer of usually 0-13 bp: half site sequence -
5´PuPuPuC(A/T)(T/A)GPyPyPy-3´ (Pu = Purine (A/G), Py = Pyrimidine (T/C)) (el-
Deiry et al., 1992) (for review see (Riley et al., 2008)). The half site provides the 
binding site for one p53 dimer, which mediates the binding of the second p53 dimer 
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to the second half site to take place, with the outcome of bending of the DNA. 
Therefore at the DNA level p53 is able to form into a tetramer  (Kitayner et al., 
2006), where each p53 monomer binds to 5 bp of a half site sequence, or quarter site.  
p53 responsive elements (or binding sites) are complex and varied. The orientation 
of quarter sites need not be symmetrical, for example the p53 binding sites in the p21 
promoter, which include a p53 binding site which is made up of two generic half 
sites, as described above and another which consists of two half sites, with a 
variability in their quarter sites: AGPyPuPu PuPuPuCA and TGPyPyPy PuPuPuCA 
(el-Deiry et al., 1995). However, more recent data show that there are many more 
p21 promoter p53 binding sites and the orientation of their particular quarter sites are 
also very complex (Saramaki et al., 2006). Interestingly p53 binding sites can be 
found up to 4 Kb upstream of the transcriptional start site of the p21 gene. p21 
promoter p53 binding sites are only some examples of the kind of variability that can 
occur in the p53 binding site and there are many more binding sites in hundreds of 
other gene promoters. These are summarized comprehensively in Riley et al., 2008. 
There is much complexity that surrounds the consistency of a p53 responsive 
element. Another factor to be taken into consideration is the variability in length of 
the spacer between half sites. Introduction of one or more nucleotides into the spacer 
reduces p53 trans-activated gene expression, for example the introduction of an extra 
nucleotide into a spacer between two p53 responsive elements in the promoter of p21 
reduces p53 mediated p21expression significantly (Jordan et al., 2008).  
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1.4.3 C-terminal Domain 
The C-terminus of p53 consists of smaller domains and elements, including the 
tetramerization domain (TD, residues 326-355), nuclear localisation signals (NLS), 
nuclear export signal (NES) and regulatory domain (residues 363-393). The 
tetramerization domain is the site of oligomerization of p53 subunits and permits 
tetramer DNA binding, protein-protein interactions and p53 degradation (for review 
see (Chene, 2001)). Studies have shown that even though p53 can bind to DNA in 
the absence of the TD, its affinity for DNA is 10 to 100 times lower than the full 
length  p53 (Balagurumoorthy et al., 1995). Furthermore, the DNA bending that is 
caused by the binding of tetrameric p53 to DNA is unlike that of the binding of one 
monomer of full length p53 (Nagaich et al., 1999, Pan and Nussinov, 2007). These 
data suggest that the TD stimulates both the strength of binding and the change in 
conformation of the DNA, needed for transcription by p53. 
Other domains found in the C-terminus include the NES, which is important for the 
degradation of p53. In unstressed cell, the p53 regulatory protein, E3 ligase MDM2, 
binds to and ubiquitylates p53 in the DBD and C-terminus. The mechanism behind 
this is that MDM2 binds to p53 which causes a conformational change in p53 that 
exposes certain lysines for ubiquitylation (Sasaki et al., 2007). Ubiquitylation then 
exposes the NES for nuclear export of p53 (Nie et al., 2007). Further regulation of 
p53 through the NES, (found at the C-terminus of p53, residues 340-351), suggested 
by Stommel el al., 1999, occurs through the tetramerization domain of p53. These 
authors show that the p53 NES alone is sufficient to mediate export of p53 from the 
nucleus and mutation of residues in the NES reduces p53 tetramerization (Stommel 
et al., 1999). Furthermore, p53 export is inhibited by the addition of peptides that are 
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of the same sequence to that of the NES and tetramerization domains of p53. 
Therefore these data suggest a model where p53 tetramerization occludes the NES 
and attenuates nuclear export.  
Another domain in the C-terminus that is important for the localisation of p53 is the 
NLS. Shaulsky et al., 1990 show that there are three NLS sequences in the C-
terminus of p53 and NLSI, found at the N-terminus end of the C-terminus, is the 
predominant signal. All three actively mediate nuclear localisation of p53 and NLS 
deprived wild type p53 could not migrate into the nucleus (Shaulsky et al., 1990). In 
addition to the NLSs, other authors report the dependency of two cis acting domains, 
in the C-terminus, that also regulate p53 cellular localisation: a lysine-arginine 
element (residues 305-306) and a cytoplasmic sequestration domain (CSD, residues 
326-355) (Liang and Clarke, 1999). These authors demonstrate that NLSI (the more 
prominent and efficient of the NLS’ in p53) and lys-arg element form a bipartite 
NLS that is regulated by the CSD, which controls the binding of the NLS to the 
Importin α shuttling protein.  
There are many domains and elements in the C-terminus, as discussed above, and in 
addition to these is the regulatory domain. This domain is regulated by various post-
translational modifications including acetylation by p300/CBP proteins and 
ubiquitylation by MDM2 (Gu and Roeder, 1997, Lavin and Gueven, 2006). The C-
terminus of p53 participates in the ability of p53 to be degraded by MDM2 as data 
show that the deletion of this region stabilized p53 without abrogating its ability to 
bind to MDM2 (Kubbutat et al., 1998). Furthermore, the mutation of 6 lysines 
simultaneously (residues 370, 372, 373, 381, 382, and 386) increases the 
transcriptional ability of p53, suggesting that mutation of these residues increases 
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p53 stability by inhibiting degradation mediated by MDM2 (Rodriguez et al., 2000). 
Interestingly, five of these residues (residues 370, 372, 373, 381 and 382) are targets 
of p300 mediated acetylation, which increases p53 sequence specific DNA binding 
activity (Gu and Roeder, 1997). Therefore it was assumed that acetylation regulates 
ubiquitylation and indeed this was shown to be the case. Li et al., 2002, show that 
acetylation of p53 inhibits MDM2 ubiquitylation of p53. Furthermore they show that 
even under unstressed conditions acetylation can inhibit ubiquitylation (Li et al., 
2002). These data together show the complex interplay between p53 post-
translational modifications that regulate p53 stabilisation and degradation.  
The three main protein domains of p53 are targets of many proteins and post-
translational modifications, some of which are mentioned above, and which regulate 
p53. A key example is the regulation of p53 by the oncogene, MDM2, and this is 
discussed in Section 1.5. 
 
1.5 Regulation of p53  
In unstressed conditions p53 is found at very low levels and undergoes rapid 
turnover. When cells are subjected to stress, levels of p53 increase and activate a 
cellular response, such as senescence or apoptosis, depending on the type and 
strength of stress and how much DNA damage has occurred. The principal 
mechanisms that control the p53 induction process are as follows: 
 
13 
 
 
 


 
1.5.1 Interaction of p53 and MDM2 
Under normal circumstances, p53 is regulated by many proteins including the E3 
ubiquitin ligase, MDM2 (See Figure 1.3) (notably other E3 ligases include Cop-1 
and Pirh-2 (Harris and Levine, 2005)). MDM2 binds to p53 and mediates the 
degradation of p53 by the proteosome. The model of MDM2 regulation involves the 
binding of the p53 binding domain of MDM2 to the trans-activation domain of p53, 
in doing so blocking the interaction of p53 with proteins and factors required for p53 
mediated transcriptional activation (Momand et al., 1992). Once bound to this 
domain, a second binding between the acidic domain of MDM2 to the DNA binding 
domain of p53 occurs (Yu et al., 2006), which is essential for the ability of MDM2 
to ubiquitylate p53 (Kawai et al., 2003, Meulmeester et al., 2003, Wallace et al., 
2006). Interestingly, the phosphorylation status of the acidic domain is very 
important for MDM2 mediated ubiquitylation, as data show that the mutation of 
certain serine residues in this domain reduces or abolishes the degradation of p53 by 
MDM2, even though the mutants retained ubiquitylation capacity (Blattner et al., 
2002). Many protein kinases are responsible for the phosphorylation of the acidic 
domain, such as CK2 (Casein Kinase 2), which can be recruited by the transcription 
factor, TAF(II)250 (Allende-Vega et al., 2008). Others kinases that regulate MDM2 
and p53 include GSK3 and CK1. GSK3 inhibition inhibits MDM2 dependent p53 
degradation which interestingly does not inhibit the binding of the MDM2 to p53 
(Kulikov et al., 2005) and indicates that GSK3 negatively regulates p53 by inducing 
MDM2 binding. Similarly, CK1 RNA knock-down activated p53 (Huart et al., 
2009). It is shown that under stressed conditions CK1 phosphorylates MDM2 
(Winter et al., 2004) and is found bound to MDM2 promoting its binding to p53 
(Huart et al., 2009). However, under stressed conditions, CK1 phosphorylates p53 
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(MacLaine et al., 2008, Sakaguchi et al., 2000) and in doing so abrogates the binding 
of p53 to MDM2. Thus CK1 regulates both MDM2 and p53, depending upon 
whether the cell is under stress. 
The third most important and required domain of MDM2 in the regulation of p53 is 
the RING finger (Fang et al., 2000, Honda et al., 1997). Studies suggest that, as an 
E3 ligase, MDM2 is responsible for the mono-ubiquitylation of p53 (see Figure 1.3) 
(Lai et al., 2001) at six individual lysine residues in the C-terminus (Rodriguez et al., 
2000). However, other studies show that low levels of MDM2 induce mono-
ubiquitylation and nuclear export of p53, whereas high levels promote the poly-
ubiquitylation and nuclear degradation of p53 (Li et al., 2003). Li et al., 2003, 
reported that a p53-ubiquitin fusion protein that mimics mono-ubiquitylated p53 
accumulated in the cytoplasm in an MDM2 independent manner and therefore their 
model suggests that mono-ubiquitylation is required for nuclear export of p53 only. 
Generally, ubiquitylation of proteins is thought to require an ubiquitin activating 
enzyme (E1), an ubiquitin conjugating enzyme (E2 or UBC), and an ubiquitin ligase 
(E3). E1 binds and activates ubiquitin through the action of ATP. Ubiquitin is then 
transferred from an E2 in an E3 dependent manner, to a lysine residue on the target 
substrate (for review see (Pickart, 2004). Intriguingly, the type of poly-ubiquitylation 
decides the targets outcome, for example, K48-linked poly-ubiquitin chains target a 
substrate for degradation by the proteosome (Finley et al., 1994) (for review see 
(Pickart, 1997)). Studies show that K63 is used as a linkage site in the formation of 
poly-ubiquitin chain structures that play an important role in DNA repair (Spence et 
al., 1995). 
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Other ligases, such as the intrinsic ubiquitin ligase activity of p300, are also required 
for subsequent poly-ubiquitylation and ubiquitylation mediated proteasomal 
degradation (Grossman et al., 2003). As illustrated by these authors, in vitro, p300 
and MDM2 together, induced p53 poly-ubiquitylation, whereas MDM2 alone could 
only induce p53 mono-ubiquitylation. This data alongside data that show MDM2 has 
a p300 binding site in its acidic domain (Grossman et al., 1998), put forward a model 
that p300 interacts, specifically and independently, with both p53 and MDM2 and 
regulates MDM2 mediated p53 degradation and turnover.  
Evidence of the action of MDM2 as a negative regulator of p53 comes from the fact 
that MDM2 knockout mice have an embryonic lethal phenotype, however this 
lethality can be rescued by knockout of p53 (Jones et al., 1995, Montes de Oca Luna 
et al., 1995). Consistent with the model that MDM2 negatively regulates p53 is that 
the mechanism of induction of p53 requires that the MDM2-p53 interaction must be 
disrupted. 
Further regulation of p53 comes in the form of an auto-regulatory loop, as shown in 
Figure 1.3. When p53 is not bound to MDM2, p53 is able to perform its function as a 
transcription factor and activate or repress down-stream target genes. Interestingly, 
one of these genes is MDM2. By activating the transcription of MDM2, MDM2 
levels increase and in turn MDM2 binds to p53. The binding of p53 to MDM2 
mediates the proteasomal degradation of p53, and itself (Fang et al., 2000), and 
levels of p53 decrease. In turn p53 can no longer activate expression of MDM2 and 
MDM2 levels decrease (Wu et al., 1993). This auto-regulatory feedback loop is the 
principal means of regulating the levels of both p53 and MDM2.  
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Figure 1.3: The p53-MDM2 auto-regulatory feedback loop 
The p53-MDM2 auto-regulatory feedback loop allows p53 to be regulated in unstressed cells. As 
shown, MDM2 is bound to p53 via various interactions (pathway A) and ubiquitylates p53, and itself, 
mediating proteasomal degradation of both MDM2 and p53 (A(I)). Should levels of p53 increase 
(pathway B), the transcriptional function of p53 activates expression of MDM2 (B(I)) and therefore 
levels of MDM2 increase (B(II)). The higher levels of MDM2 are able to bind to the increased levels 
of p53, therefore lowering the level of p53 (B(III)). On the other hand, should levels of MDM2 
increase, MDM2 inhibits p53 by binding to a greater proportion of p53 molecules (C(I)) and inhibits 
transcriptional activity of p53 and expression of MDM2 (C(II)). MDM2 levels decay over time and 
levels of MDM2 gradually decrease (C(III)). 
 
In summary, there is very tight regulation of p53 by MDM2 under unstressed 
conditions, particularly in post-stress conditions. Various studies show that MDM2 
is a potentially oncogenic protein, for example, the overexpression of MDM2 
resulted in the immortalization of primary rat embryo fibroblasts and, alongside the 
activated ras gene, in the transformation of these cells (Finlay, 1993). In addition to 
this, introduction of the MDM2 gene into non-transformed cells induced tumour 
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formation further suggesting that MDM2 is in fact an oncogene (Fakharzadeh et al., 
1991). Consistent with these findings, levels of MDM2 are increased in a number of 
cancers (Abdel-Fattah et al., 2000, Reifenberger et al., 1993) 
In order for the p53 levels to increase and therefore determine cell fate after DNA 
damage, MDM2 regulation must be disrupted. 
 
1.5.2 Stabilisation of p53 through the disruption of the p53-MDM2 complex 
Under stressed conditions (see Section 1.5), the p53 pathway (see next Section) is 
activated and allows stabilisation of p53 and increase in levels of p53. But, how can 
this occur if MDM2 tightly regulates p53, keeping levels low and the protein 
inactive? The answer to this lies in the auto-regulatory loop. DNA damage activates 
many proteins which cause post-translational modification changes of p53 and 
MDM2 causing inhibition of the ubiquitylation of p53 by MDM2, the inhibition of 
the binding of the p53 TAD to the p53 binding site of MDM2 and inhibition of the 
interaction between the MDM2 acidic domain to the DNA binding domain of p53.  
Phosphorylation is the first key step in the stabilisation of p53 (see Figure 1.4). As 
already mentioned, several phosphorylation sites in the p53 trans-activation domain 
of p53, including S15, T18 and S20 are phosphorylated in response to stress. The 
phosphorylation of S15 induces a conformational change in the p53 protein and 
reduces the binding of MDM2 (Shieh et al., 1997), although it is reported by others 
that the phosphorylation of S15 alone is not sufficient for the inhibition of the 
binding of p53 to MDM2, however, it is certainly required for trans-activation of p53 
(Dumaz and Meek, 1999). S20 phosphorylation plays an important role in the 
18 
 
 
 


 
stabilisation of p53. Replacement of S20 with an alanine (a residue incapable of 
being phosphorylated) makes p53 highly sensitive to MDM2 mediated degradation 
(Chehab et al., 1999, Dumaz et al., 2001). There is also involvement of 
phosphorylation of T18 in p53 stabilization (Chao et al., 2000). Interestingly, the 
phosphorylation of S15 facilitates subsequent phosphorylation of T18 and S20 
(Appella and Anderson, 2001). DNA damage induced phosphorylation of N-terminal 
residues S15, S33 and S37 also stabilises the binding of p300 (Dumaz and Meek, 
1999) and CBP to p53. The FAT (transcriptional factor acetyl-transferase) activity of 
these proteins acetylate p53 (see Figure 1.4) (Sakaguchi et al., 1998) at residues 
K370, K371, K372, K381 and K382. This acetylation abrogates the ability for 
MDM2 to ubiquitylate p53 (Li et al., 2002) and also promotes the DNA-binding 
activity of p53 (Gu and Roeder, 1997). Other sites of p53 that are acetylated after 
stress include K120 and K164, via p300/CBP. Mutation of K164 causes a loss of 
acetylation and abolishes the transcriptional activity of p53  (Tang et al., 2008). 
However the mutation of K120 to an R120 residue inhibits p53 mediated 
transcription of pro-apoptotic target genes, such as BAX, but not targets such as p21 
and MDM2 (Sykes et al., 2006), suggesting different acetylated sites mediate p53 
transcription at different gene promoters.  
Other sites phosphorylated in the trans-activation domain in response to stress are 
S33, S37, S46 and S6 and S9 (Meek and Anderson, 2009) and T81. There are also 
sites post-translationally modified in the DNA binding domain under unstressed 
conditions. These include the phosphorylation of S149, T150 and T155. The 
phosphorylation of S215 is well documented to inhibit the binding of p53 to DNA 
(Liu et al., 2004).  
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Phosphorylation of p53 in the C-terminus also occurs after stress, including the 
phosphorylation of S315 and S392 (Meek and Anderson, 2009). Phosphorylation of 
S315 stimulates p53 mediated transcription (Blaydes et al., 2001), whereas 
phosphorylation at S392 stabilizes tetramerization of p53 (Sakaguchi et al., 1997).  
Various residues in the MDM2 protein are also targets for post-translational 
modification (Meek, 2004, Meek and Knippschild, 2003). Phosphorylation of certain 
residues interrupt the binding of p53 to MDM2 and inhibit MDM2 mediated 
proteasomal degradation, such as the phosphorylation of S17, Y394 and S395, which 
are targets of the kinases DNA-PK, c-Abl and ATM proteins respectively (Maya et 
al., 2001, Meek and Anderson, 2009, Meek and Knippschild, 2003). De-
phosphorylation of MDM2 also plays a large part in the interruption of p53 binding 
to MDM2 (see Figure 1.4).  A cluster of serine residues in the central domain of 
MDM2 are constitutively phosphorylated under unstressed conditions and hypo-
phosphorylated after IR (Ionising Radiation). When these phosphorylation sites were 
substituted from serine to alanine, (mutations that abrogate phosphorylation status) 
the ability of MDM2 to degrade p53 was reduced or even abolished (Blattner et al., 
2002).  
Phosphorylation and de-phosphorylation of MDM2 may explain why MDM2 is 
destabilised after DNA damage by auto-ubiquitylation. Auto-ubiquitylation causes 
the half life of MDM2 to decrease in cells that have undergone DNA damage. The 
importance of this destabilisation in p53 activation was shown by an experiment 
which involved the addition of a proteasomal inhibitor which blocks MDM2 
destabilisation (Stommel and Wahl, 2004) and which was used in DNA damaged 
cells. In the presence of the inhibitor, p53 was incapable of transcriptional activation 
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in DNA damaged cells (Stommel and Wahl, 2005). To show this was due to MDM2, 
an inhibitor of the MDM2/p53 interaction, which binds to the p53 binding domain of 
MDM2, was added and p53 transcriptional activity was rescued.  
p53 can be stabilised by the disruption of the p53-MDM2 auto-regulatory loop by 
inhibition of the interaction of p53 to MDM2 via post-translational modification of 
both proteins. However the stabilisation of p53 can also be due to, for example, 
downregulation of MDM2 expression or regulation of the sub-cellular localisation of 
p53 and/or MDM2 (Ashcroft et al., 2000). p14ARF (ARF) is one such protein that 
activates and stabilises p53 (Figure 1.4) and it does this by various mechanisms: it 
binds directly to MDM2, via the MDM2 C-terminus, causing its degradation (Zhang 
et al., 1998) or as other authors suggest, sequesters MDM2 to the nucleolus by 
inhibiting MDM2 nucleolar export allowing nucleo-cytoplasmic p53 activation and 
stabilisation (Weber et al., 1999). ARF also inhibits the nucleo-cytoplasmic shuttling 
of the p53-MDM2 complex (Tao and Levine, 1999). Lastly, ARF is also able to 
inhibit the E3 ligase activity of MDM2 (Honda and Yasuda, 1999). 
Two particular studies describe the down-regulation of the MDM2 gene from two 
forms of DNA damage. Wu et al., 1997 show that high dose UV irradiation induces 
MDM2 repression in a p53 independent manner. Furthermore, the repression of 
MDM2 is temporal as MDM2 is later induced by p53, inhibiting p53 transcriptional 
activity after a sufficient period of time for DNA repair (Wu and Levine, 1997). 
Arriola et al., 1999 show that the addition of the topoisomerase inhibitor, Etoposide, 
inhibits the expression of MDM2 at the mRNA level and therefore there is a 
decrease in MDM2 protein levels. Etoposide does not induce global repression as 
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shown by data that show p21 (p21 is a transcriptional target of p53 (el-Deiry et al., 
1994, el-Deiry et al., 1993)) expression still exists after treatment of Etoposide. 
There are many mechanisms that can stabilize p53 in response to stress and DNA 
damage and some of these are reviewed in Figure 1.4. The mechanisms by which 
they occur vary and depend on the type of stress (or DNA damage) that is applied 
and the strength of the stress. The variety of stresses and mechanisms which stabilise 
and activate p53 and which ultimately activate the DNA damage pathway, after 
DNA damage, is reviewed in Section 1.6. 
 
Figure 1.4: The stabilisation of p53 via the disruption of the p53-MDM2 auto-regulatory 
feedback loop  
The p53-MDM2 auto-regulatory feedback is disrupted by various mechanisms, some of which are 
shown above. This can occur through: (I) the repression of MDM2 expression (II) post-translational 
modifications (red filled P = Phosphorylation, White filled P = de-phosphorylation, green A = 
acetylation) which disrupts the interaction of p53 and MDM2 (III) p14ARF binding inhibits MDM2 
E3 ligase activity from targeting p53 for degradation and (IV) self mediated auto-ubiquitylation of 
MDM2. 
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1.6 Activation of the p53 pathway 
There are many types of stress that cause the stabilisation and activation of p53 and 
the p53 pathway. These include: DNA double strand breaks (DSBs), replication 
stress, hypoxia and oncogenic activation (see Figure 1.5). Various stress response 
pathways are described comprehensively in Anderson et al., 2009. For the purposes 
of this thesis only DNA damage stress, through DSBs and single stranded DNA and 
replication stress, shall be reviewed. This is because this thesis focuses on G2/M 
checkpoint arrest, which, is activated by these kinds of DNA damage.  
 
Figure 1.5: Types of stress that activate p53  
There are a number of stresses that induce the stabilisation, activation and accumulation of p53 in the 
cell. Genotoxic stresses include: double strand breaks, single stranded DNA, transcriptional stress, 
oncogenic activation. Non-genotoxic stresses include Microtubule disruption, ER stress, nucleolar and 
ribosomal stress, nutrition deprivation, ribonucleotide deprivation. 
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1.6.1 Double Strand Breaks (DSBs) 
The most studied type of genotoxic stress that activates p53 is DNA double strand 
breaks (DSBs). The key proteins that are activated by DSBs are the MRN complex 
(Mre11, Nbs1, Rad50) and the protein kinase, ATM (Ataxia- Telangiectasia 
Mutated) a member of the phosphatidylinositol-3-kinase-like kinase (PIKK) family. 
When a DSB has occurred, the MRN complex recognizes the DSB and signals to 
down-stream targets such as ATM (Rupnik et al., 2008). Mre11 binds to DNA and 
has a local DNA unwinding activity. It is also able to bind Nbs1 and Rad50. Rad50 
is able to tether DNA ends together through its dimerization. Nbs1 is responsible for 
the localisation of the complex into large focal structures and also functions in 
downstream signalling through ATM (For review see (Rupnik et al., 2008)). Many 
of these proteins are still being discovered (Lee and Paull, 2007) and therefore the 
exact mechanism of detection of DSBs is unclear and is an active area of study.  
The activation of ATM is not only dependent on the MRN complex but also dimer 
dissociation of ATM. Reports suggest that auto-phosphorylation and other post-
translational modifications of various residues of ATM are important for the 
activation of ATM. These include the phosphorylation of S1981 in ATM, that causes 
dimer dissociation and which initiates ATM kinase activity (Bakkenist and Kastan, 
2003).  Activation is not dependent on direct binding of ATM to DNA strand breaks, 
but may have resulted from changes in the structure of chromatin (Bakkenist and 
Kastan, 2003). Although some reports show that S1981 is indispensible for ATM 
activation, other residues such as S367 and S1893, which were phosphorylated after 
Ionizing Radiation alongside S1981 are also required for ATM activation. Auto-
phosphorylation of all three sites is important in the activation of ATM, as 
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phosphorylation site mutants were each defective in ATM signalling (Kozlov et al., 
2006).  
Activated ATM mediates the activation of a variety of downstream proteins, 
including MDM2, chromatin bound histone H2AX, CHK2 (checkpoint kinase 2) and 
p53 itself (for review see (Kurz and Lees-Miller, 2004)). Phosphorylation of MDM2 
by ATM, occurs at the S395 residue of MDM2 and attenuates MDM2 inhibition of 
p53 (Maya et al., 2001). This phosphorylation and that of S15 of p53 augment 
inhibition of the interaction of p53 to MDM2 and its ability to mediate degradation 
of p53 (Banin et al., 1998). The phosphorylation of CHK2 by ATM at T68 after IR 
exposure (Ahn et al., 2000, Matsuoka et al., 2000) activates CHK2 and therefore 
activates CHK2 mediated phosphorylation of several substrates that mediate cell-
cycle arrest, DNA repair and apoptosis. For example, CHK2 phosphorylates 
CDC25C on Ser 216 which inhibits CDC25C function and CDC25C mediated 
progression through the G2/M checkpoint in the cell cycle (Matsuoka et al., 1998).  
ATM activation, after double strand breaks, mediates cell cycle arrest until the cell 
has repaired the DNA damage. Mutations in the ATM gene are responsible for the 
rare autosomal recessive disorder ataxia–telangiectasia (A–T), characterised by 
many phenotypes including defective DNA damage-induced activation of the cell 
cycle checkpoints at G1, S and G2/M (Chun and Gatti, 2004) and an increased risk 
of cancer.  
Examples of reagents that activate the p53 response by inducing DNA double strand 
breaks are the DNA damaging agents, Etoposide and Genistein, both of which 
mediate their effects by inhibiting topoisomerase II. Topoisomerase II is a protein 
that relaxes the tension in DNA by introducing transient double strand breaks into 
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the DNA. When topological DNA entanglements occur, for example during 
transcription and replication, topoisomerase II is able to break the double strand 
DNA bonds, causing a transient bridge to form, relaxing the tension and then quickly 
re-ligates the DNA back together. It is therefore an essential protein required in 
proliferating cells.  
Etoposide is a widely available anti-cancer drug and its mechanism of action has 
been well studied.  As described by Burden, et al., 1996, Etoposide mediates its 
effect by inhibiting topoisomerase II. The inhibitor Etoposide is able to bind to the 
topoisomerase II protein in such a way that it inhibits the re-ligation of the DNA and 
therefore increases the number of DNA double strand breaks in the cell. The increase 
in double strand breaks causes destabilisation of the genome and ultimately disrupts 
cell viability. Genistein mediates it effects in a similar manner to that of Etoposide 
(Markovits et al., 1989), however its activation of the p53 pathway is dependent 
upon ATM, whereas p53 activation by Etoposide is not ATM dependant (Ye et al., 
2001). Described by Ye et al., 2001, both agents induce an increase in p53 protein 
levels as well as the phosphorylation of p53 at S15 however in ATM deficient cells, 
only Etoposide can induce an increase of p53 and its phosphorylation. This suggests 
that, even though both agents have a similar mechanism of action, Etoposide 
activates other downstream targets as well as ATM. An example of which is the 
ATR (ATM and Rad3 related) protein kinase (Cliby et al., 2002), which is more 
commonly associated with other types of DNA damage.  
Activation of p53 by Etoposide can be induced by direct phosphorylation of p53 via 
ATM, ATR or both protein kinases and their downstream targets, such as CHK1 and 
CHK2, which also phosphorylate and activate p53 (Banin et al., 1998, Shieh et al., 
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2000) (for review see (Bartek and Lukas, 2003)). Furthermore, both PIKK members 
mediate the degradation of MDM2 under stressed conditions which leads to the 
disruption of the p53-MDM2 auto-regulatory feedback loop (Stommel and Wahl, 
2004).  
Clearly all proteins that are mentioned above, from the MRN complex to 
downstream p53 activators such as CHK1 and CHK2, are important for DSB 
induced activation of p53. 
 
1.6.2 Single stranded DNA and replication stress 
The key protein in detecting other types of DNA damage, such as DNA cross-linking 
caused by the DNA damaging agent Cisplatin, is ATR. Cisplatin has been studied in 
depth over the years, and its mechanism of action is thought to cause intra-strand and 
inter-strand cross links. Subsequently DNA adducts are formed by Cisplatin which 
links strands of DNA together and in doing so contorts and bends the DNA. 
However as a result of these effects the transcription machinery cannot transcribe the 
DNA. ATR is activated in response to the blocked transcription and replication 
caused by the DNA adducts produced by Cisplatin and other bulky DNA lesions 
produced by agents such as 5-fluorouracil and UV light (Ljungman and Lane, 2004). 
As reviewed in Ljungman et al., 2004, these types of DNA damage cause the RNA 
polymerase II (Pol II) complex to stall and leads to activation of Pol II dependent 
transcription coupled nucleotide excision repair (CT-NER). They also induce the p53 
pathway (Ljungman et al., 1999).  
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ATR is activated in response to single stranded DNA (ssDNA). ssDNA occurs under 
non stressed conditions, for example, during DNA replication and in stressed 
conditions where DNA damage has occurred (Shechter et al., 2004). In response to 
single stranded DNA, replication protein A (RPA) binds and coats the length of the 
single stranded DNA. This attracts two key complexes: the ATRIP-ATR and 9-1-1 
complex. The ATR binding protein, ATRIP, is bound to ATR and is itself 
phosphorylated by ATR and regulates ATR expression (Cortez et al., 2001). ATR 
and ATRIP both localize to the nucleus after DNA damage or inhibition of 
replication. Interestingly, the deletion of ATR abolished cell cycle checkpoint 
activation by DNA damage (Cortez et al., 2001).  
The 9-1-1 complex consists of the proteins: RAD9, RAD1 and HUS1 which form a 
heterotrimeric ring. The recruitment of the RAD17 RFC protein mediates the 
binding of the 9-1-1 protein onto the DNA (Bermudez et al., 2003). The recruitment 
of a second protein, TopBP1, to the 9-1-1 complex (in particular RAD9) is necessary 
for the binding of the ATR-ATRIP complex to TopBP1 (Lee et al., 2007) and 
TopBP1 in turn activates ATR through its ATR activating domain (Kumagai et al., 
2006). Once activated, ATR phosphorylates downstream targets such as CHK1, 
which is presented to ATR by the protein, Claspin (Kumagai et al., 2004). The 
activation of downstream targets of ATR slow down origin firing and induce cell 
cycle arrest giving the cell time to repair the DNA damage. Once repaired ATR and 
its downstream targets mediate the stabilization and the resumption of stalled 
replication forks (for review see (Cimprich and Cortez, 2008). Shechter et al., 2004, 
suggest that in the event of DNA damage, the stalled fork results in accumulation of 
RPA at sites of single stranded DNA and accumulation of ATR–ATRIP complexes. 
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Alongside Claspin and 9-1-1, ATR initiates the checkpoint block (Shechter et al., 
2004).  
Although CHK1 activates p53, by phosphorylating p53 (Shieh et al., 2000), ATR 
also directly phosphorylates and activates p53 (Tibbetts et al., 1999). After DNA 
damage, ATR phosphorylates p53 at S15 and S37 (Tibbetts et al., 1999). The 
activation of p53 by CHK1 leads to downstream effects such as cellular senescence 
and apoptosis. Other proteins are also activated, such as BRCA1, H2AX and E2F 
and are reviewed in detail in Ljungman et al., 2004.  
The activation of p53 by DNA damage, such as DSBs or replication stress, is very 
complex and the route by which p53 is activated depends on the type of stress and 
the length of time the stress has been applied. It is thought that the ATR pathway 
activates p53 after a longer period of time compared to that of ATM presumably due 
to the slowing of origin firing caused by ATR and the attempt of ATR to rescue the 
cell by repairing DNA damage through the NER pathway. ATM and ATR are not 
the only proteins involved in the DNA damage pathway and other proteins include 
DNA-PK, another PIKK member, however, in their absence, the response to DNA 
damage response is abrogated.  
 
1.6.3 The p53 pathway 
There is a variety of mechanisms by which p53 is activated and these are dependent 
upon the type of stress stimulus. The ATM and ATR pathways play critical roles in 
the induction of p53 in response to DNA damage. However, the activation of p53 
itself is responsible for the regulation of many genes whose products mediate the 
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cellular outcomes of p53 induction, as shown in Table 1.1. One of the most well 
known and comprehensively studied is p21 (also known as WAF1 and CIP1), which 
is required for cell cycle arrest (for reviews see (Shu et al., 2007, Vousden and Lu, 
2002)). Others genes that are regulated by p53 are involved in apoptosis, tumour 
suppression, inhibition of angiogenesis and auto-regulation of p53 (Table 1.1). 
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Protein/Gene Function/Role 
Trans-
activation (T) 
or Repression 
(R) by p53 
Reference(s) 
p21 (CDKN1) Checkpoint Arrest T 
(el-Deiry et al., 1993, 
el-Deiry et al., 1995, 
Saramaki et al., 
2006) 
GADD45 Checkpoint Arrest and DNA Repair T (Kastan et al., 1992) 
14-3-3 Checkpoint Arrest T  (Hermeking et al., 1997) 
Reprimo Checkpoint Arrest T (Ohki et al., 2000) 
CDC25C Progression of Mitosis R (St Clair and Manfredi, 2006) 
MAD1 Progression of Mitosis R (Chun and Jin, 2003) 
MDM2 Down-regulation of p53 T 
(Wu et al., 1993, 
Zauberman et al., 
1995) 
p53 (TP53) Various Cellular Outcome Mediator T (Benoit et al., 2000) 
Survivin  Inhibitor of Apoptosis R (Hoffman et al., 2002)  
BAD Mediates Apoptosis T (Jiang et al., 2006) 
BAX Mediates Apoptosis T 
(Miyashita and Reed, 
1995, Thornborrow 
et al., 2002) 
PUMA  Mediates Apoptosis T (Nakano and Vousden, 2001) 
PTEN Mediates Apoptosis T (Stambolic et al., 2001) 
PTGF Inhibits Tumour Cell Growth T (Tan et al., 2000) 
KAI1 Inhibitor of Tumour Metastasis  T 
(Mashimo et al., 
1998) 
XPC DNA Repair T (Adimoolam and Ford, 2002) 
DDB2/p48  DNA Repair T (Hwang et al., 1999, Tan and Chu, 2002) 
 
Table 1.1: Genes transcriptionally regulated by p53  
This table compromises a list of some of the genes that are transcriptionally regulated by p53. The 
table shows the protein (gene) that is activated or repressed, its function or role in the cell, whether its 
expression is repressed or activated by p53 and its corresponding reference(s).  
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The main fact that p53 can activate the expression of genes involved in different 
cellular pathways suggests that it is involved in many cellular processes that occur 
after DNA damage or other genotoxic and non-genotoxic stresses. These are 
reviewed in the next Section. 
 
1.6.4 Cellular outcomes of p53 activation 
The two main outcomes of p53 activation are cell cycle arrest or programmed cell 
death (apoptosis). The p53 transcribed genes and proteins that are responsible for 
these outcomes can be subdivided into the following: DNA repair, autophagy and 
cell cycle arrest, differentiation, senescence and apoptosis. The type of response is 
dependent on the level of DNA damage (for review see (Helton and Chen, 2007)). 
Given that p53 regulates the expression of literally hundreds of genes, studied 
extensively in Riley et al., 2008, the following discussion will focus on those that are 
relevant to the work described in this thesis.  
 
1.6.4.1 The cell cycle and its arrest 
When the cell has undergone stress and DNA damage has occurred the cell can arrest 
this cycle at two main checkpoints: G1 and G2/M checkpoint. Notably the cell can 
also arrest in S phase. These checkpoints are beneficial in the sense that the cell can 
inhibit the cycle before any mutation can be taken forward into a daughter cell (for 
review see (Vermeulen et al., 2003)). Cancer cells overexpress oncogenes that can 
override the checkpoint allowing the cell to proliferate unrestrained and carry 
forward mutations that may have occurred, into daughter cells.  
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The main proteins that regulate the cell cycle are the Cyclin Dependent Kinases 
(CDKs) and Cyclins. CDKs 2 and 4 are required for G1 phase alongside Cyclins D1, 
D2 and D3. CDK2 alongside Cyclin A is required for S phase and CDK1 with 
Cyclin B is necessary for mitosis. However, arguably the most important CDKs and 
Cyclins in the cell cycle are those that regulate the two checkpoints. CDK2/Cyclin E 
regulates progression of the cell cycle into S phase (G1 checkpoint). Overexpression 
of Cyclin E activates the CDK2/Cyclin E kinase activity and results in a shorter G1 
phase (Ohtsubo et al., 1995). The second important checkpoint proteins are CDK1 
(cdc2) and Cyclin A/B. Knockout of Cyclin A results in premature entry into mitosis 
(Walker and Maller, 1991).  
Under stressed conditions CDK2/Cyclin E is regulated by the p21 protein. p21, is a 
protein that is highly induced by p53 via a sequence specific binding site identified 
in the promoter region of the p21 gene (el-Deiry et al., 1993), as discussed 
previously. Other studies carried out at the same time identified the p21 protein as a 
potent inhibitor of G1 phase Cyclin-Dependent Kinases (CDKs) which are required 
for the progression of the cell cycle (Harper et al., 1993, Xiong et al., 1993). Notably 
the increase of p53 after DNA damage was concomitant with increases in p21 and 
this increase was induced in wild type p53 containing cells after DNA damage and 
could not occur independently of p53 suggesting that p53 is indeed responsible for 
the increase in p21 (el-Deiry et al., 1994). Furthermore, p21 was found bound to 
Cyclin E containing complexes which resulted in a decrease in the CDK kinase 
activity (el-Deiry et al., 1994). All together these data show that via the induction of 
p21, p53 can mediate a G1/S checkpoint arrest in the presence of DNA damage.  
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As a regulator of the G1/S checkpoint, overexpression of p21 results in a profound 
reduction of cells in S phase (el-Deiry et al., 1993). In a p21 null cell line G1  arrest 
mediated by DNA damage arrest is abolished (Waldman et al., 1995). The p21 
protein is responsible for the inhibition of CDK2/Cyclin E complex (and others), and 
inhibits it from phosphorylating and inactivating the stress induced Rb 
(retinoblastoma) protein. Phosphorylated Rb cannot then bind to and inhibit the 
transcription factor E2F (Weinberg, 1995, Weinberg and Denning, 2002). Another 
route by which p21 causes growth arrest is by binding to E2F which inhibits 
transcription at the Cyclin A promoter, which suggests that p21 can also have a role 
to play in the transcription of S phase genes (Delavaine and La Thangue, 1999). 
Other reports suggest that p21 also functions to bind to and inhibit PCNA 
(Proliferating Cell Nuclear Antigen) which is a dual role protein that is involved 
mainly in DNA replication but also DNA repair (Waga et al., 1994). Interestingly, 
p21 inhibits only the DNA replication activity and not the NER repair pathway 
activity of PCNA (Shivji et al., 1994).   
Another protein that is involved in cell cycle arrest is GADD45A (Growth Arrest 
and DNA Damage inducible factor), which is a protein induced after DNA damage 
(Hollander et al., 1993). GADD45A is found to bind to CDK1 (cdc2) and inhibits 
the activity of the CDK1/Cyclin B complex, needed for progression into M phase 
(Zhan et al., 1999). Zhan et al., 1999, show that the addition of GADD45A did this 
by inhibiting the association of Cyclin B to CDK1. Kastan et al., 1992 show that 
GADD45A is a p53 regulated gene, as, in cells that are p53-null, there was no 
increase in GADD45A. Furthermore mutant p53 could not cause an induction of 
GADD45A transcription through a sequence specific binding site (Kastan et al., 
1992). These authors identify a p53 specific binding site in the GADD45A gene at 
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intron 3. Taken together these data show that GADD45A inhibition of CDK1/Cyclin 
B and therefore GADD45A mediated cell cycle arrest is dependent upon p53. 
Other proteins that are regulated during the cell cycle checkpoint, in particular the 
G2/M checkpoint and which are regulated by p53, include 14-3-3 and CDC25C. 14-
3-3 is expressed by p53 upon DNA damage. Studies show that the 14-3-3 σ isoform 
is regulated by p53 through a p53 responsive element in the promoter and was 
shown to be overexpressed after IR induced DNA damage (Hermeking et al., 1997). 
The overexpression of 14-3-3 induced a G2/M checkpoint arrest. 14-3-3 is 
responsible for the cellular localisation of its substrates to various regions of the cell. 
It is also involved in the activation and repression of the enzymatic activity or 
function of proteins as well as being involved in the prevention of degradation of 
some of its protein substrates (Hermeking and Benzinger, 2006). It has many roles in 
checkpoint such as binding phosphorylated CDC25C causing its cytoplasmic 
sequestration, therefore 14-3-3 is an important p53 regulated protein required for p53 
mediated G2/M arrest. 
Another interesting target of p53 is the phosphatase, CDC25C (Cell Division Cycle 
25 homolog C), which is highly involved in the G2/M checkpoint. This particular 
protein is required for the progression of mitosis and is regulated by many proteins 
such as CHK1 and CHK2 (as reviewed in (Hoffmann, 2000)). p53 has also been 
found recently to regulate CDC25C in cooperation with another as yet unknown 
protein. Mutation of the sequence specific p53 binding site abolishes repression of 
CDC25C by p53 (St Clair et al., 2004, St Clair and Manfredi, 2006). The study by St 
Clair et al., 2004, was one of the first that demonstrated that repression by p53 can 
involve direct binding of p53 to sequence specific DNA (p53 Responsive Elements). 
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Incidentally, the first gene found to be repressed by p53 at the transcriptional level 
was Survivin (Hoffman et al., 2002) and is discussed in Section 1.6.4.4. 
The CDC25C protein is important in the cell cycle as proved by the data that its 
inhibition, through microinjection of antibodies, blocks entry into mitosis. 
Furthermore, the introduction of CDC25C, into temperature sensitive CDC25C 
mutant cells rescued the inhibition of entry into mitosis by CDC25C (Millar et al., 
1991). The main role of CDC25C in the cell is the dephosphorylation of CDK1 at 
T14 and T15. Mutation of the catalytic site of CDC25C abolishes the phosphatase 
activity of CDC25 (Gautier et al., 1991). These sites are phosphorylated by Wee1 
and Myt1 in S phase which inhibit the CDK1/Cyclin B complex from entering the 
nucleus via the sequestration of the complex by 14-3-3 in the cytoplasm (for review 
see (Hermeking and Benzinger, 2006)). Evidently, dephosphorylation of the 
CDK1/Cyclin complex allows progression of the cell into mitosis.  
The phosphorylation of residue S216 of CDC25C is of particular importance to the 
sequestration of CDC25C by 14-3-3 in the cytoplasm. Mutation of this residue 
abrogates 14-3-3 binding and overexpression of this mutant resulted in an abrogation 
of G2 delay induced by DNA damage (Peng et al., 1997). Studies of the interaction 
between CDC25C and 14-3-3 show that the binding of 14-3-3 covers the NLS of 
CDC25C, which causes cytoplasmic localisation (Kumagai and Dunphy, 1999, 
Kumagai et al., 1998). CDC25C is inactive for the majority of the cell cycle until 
mitosis, as shown by the fact that CDC25C phosphatase activity is undetectable 
during the other three phases. Activation of CDC25C occurs after the 
dephosphorylation of CDC25C at residues 216 and 287 (Donzelli and Draetta, 
2003). After DNA damage however, the CDC25C protein is phosphorylated by 
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CHK1 and CHK2, at certain individual sites (residue 216 by CHK1/2), therefore 
causing G2/M cell cycle arrest (Chaturvedi et al., 1999, Furnari et al., 1997, Peng et 
al., 1997, Sanchez et al., 1997). As previously stated the CDC25C protein is a target 
of p53 and is repressed by p53 via a p53 responsive element located in its promoter 
(St Clair and Manfredi, 2006). Taking these data together suggest that p53 and 14-3-
3 act co-ordinately to repress CDC25C after DNA damage to cause G2M checkpoint 
arrest. 
There are multiple p53 targeted proteins that are involved in cell cycle and its arrest, 
only some of which have been reviewed in this thesis. However, through the 
activation or repression of these proteins, p53 enables cell cycle checkpoint arrests 
after DNA damage and stress and allows the cell to halt its cycle until the DNA 
damage has been repaired. This cellular outcome of p53 is very important, as without 
it the cell would proliferate with the mutations arising from DNA damage and DNA 
damage would be carried into daughter cells where they may contribute to 
tumourigenesis. 
 
1.6.4.2 DNA repair 
When the cell cycle has arrested due to DNA damage the cell endeavours to repair 
the damage through different types of pathways depending on the type of stress and 
lesion that has occurred. These pathways include the NER (nucleotide excision 
repair) pathway, which can be divided into the TCR (transcription coupled repair) 
and GGR (global genome repair). Others are the BER (base excision repair), MMR 
(mismatch repair pathway), HR (homologous recombination), NHEJ (non-
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homologous end joining) and TLS (translesion synthesis) (for review see (Helton 
and Chen, 2007)).  
Markedly, p53 has been found to play a role in all of these pathways by activating or 
repressing genes either involved in these processes or directly through interaction 
with other proteins at the repair site. The NER pathway is one of particular interest 
in this thesis due to the fact that the drug Cisplatin causes induction of this pathway. 
The NER-TCR and NER-GGR pathways are distinct from each other in the way they 
detect DNA damage. The NER-TCR pathway detects damage through the blockage 
of RNA Pol II elongation and therefore only detects damage in RNA Pol II 
transcribed genes, which makes up only a part of the genome. On the other hand, the 
GGR pathway detects damage through proteins that detect DNA damage including 
DDB1 (p127), DDB2 (p48/XPE) and the XPC/hHR23B complex (Costa et al., 2003) 
in other parts of the DNA.  
Targets of p53 involved the GGR pathway include XPC and DDB2 (p48). These 
genes are targets of p53 activated expression (Helton and Chen, 2007). It has been 
shown that p53 is required for the NER of CPDs (cyclobutane pyrimidine dimers), as 
p53-null cells cannot repair CDPs. Repair of CPDs is independent of the NER-TCR 
pathway (Adimoolam and Ford, 2002). These authors show that the XPC gene is p53 
regulated and is not expressed in p53-null cells.  XPC induction also occurs after 
DNA damage in a p53 dependent manner. Likewise, p48 is also p53 regulated. Data 
show that in p53-null cells p48 was not induced by DNA damage, however in p53 
wild type cells p48 levels increased concomitantly with increases in p53 after DNA 
damage. Furthermore the authors show that a mutant p48 cell line, is defective in 
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GGR of CPDs and therefore suggest that GGR is dependent on both p48 and p53 
(Hwang et al., 1999).   
Less is known about targets of p53 in the TCR pathway however data show that p53 
has been found to bind to proteins involved in the NER pathway including XPB and 
XPD. This suggest that p53 modulates the DNA repair pathway directly as well as 
expression if proteins involved in the DNA repair pathway (Wang et al., 1995).  
DNA repair pathways other than NER include HR and NHEJ. The dependence of 
these pathways on p53 is largely unknown however studies show that mice that 
express mutant p53, ATM or GADD45A have a higher incidence of HR (Bishop et 
al., 2003) suggesting p53 negatively regulates HR. However, which pathway is 
utilized depends on the type of stress, for example Cisplatin induced DNA adducts 
are repaired via the NER pathway whereas Etoposide induced DNA double strand 
breaks are thought to be repaired by HR and NHEJ, if the cell allows for DSB repair 
at all due to the potential of deletion or translocation of DNA that could affect 
genomic stability. DNA repair is nevertheless a major cellular outcome of the 
activation of p53 and is an option to assist the cell in overcoming DNA damage.  
 
1.6.4.3 Senescence 
Senescence is another outcome of p53 activation and is a term used to describe cells 
that no longer replicate, due to shortened telomeres or non-telomeric signals such as 
DNA damage and oncogenic signals  (Dimri, 2005). Senescence limits the 
replicative capacity of cells and therefore inhibits abnormal proliferation. The 
erosion of telomeres activates the DNA damage response similar to that of double 
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strand breaks (d'Adda di Fagagna et al., 2003). d’Adda di Fagagna et al, 2003 show 
that telomeric induced senescent cells have activated CHK1 and CHK2 as well as 
high levels of DNA repair proteins. The activation of these kinases induces p53, and 
in turn, the activation and accumulation of p21, which inhibits CDKs. This inhibition 
of CDKs consecutively causes the levels of hypo-phosphorylated Rb (a tumour 
suppressor) to increase causing further cell cycle arrest and senescence (Dimri, 
2005). Non-telomeric signals, on the other hand,  activate both the CHK1/2-p53-
p21-Rb pathway  and p16INK4a -Rb pathway (p16INK4a is a product of the alternate 
reading frame of CDKN2A, the other product being  p14ARF) (for review see (Dimri, 
2005)) to cause permanent cell cycle arrest. For the purposes of this thesis, the 
discussion of this outcome of p53 activation has been kept short.   
 
1.6.4.4 Apoptosis 
Apoptosis is one of the key main outcomes of p53 activation and allows the cell to 
undergo programmed cell death when DNA damage cannot be repaired. Apoptotic 
cells, from the morphological point of view, are characteristically round and tend to 
have condensed cytoplasm and fragmented nuclei (Elmore, 2007). Apoptotic cells 
degrade their organelles and other cellular contents leading to the formation of 
“membrane blebs”; these are then recognised and digested or phagocytosed by 
macrophages and other surrounding cells. In comparison to cells that have 
undergone necrosis, there is no release of the cellular contents into the surrounding 
tissue and there is no activation of an inflammatory response that occurs in response 
to necrosis (Elmore, 2007). From the biochemical view, cells that are undergoing 
apoptosis show signs of protein cleavage, protein cross-linking, DNA breakdown 
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and phagocytic recognition. These collectively cause the distinctive apoptotic 
pathology that has been described above.  
There are two main apoptosis pathways: the extrinsic (death receptor pathway) and 
the intrinsic (mitochondrial pathway) (Elmore, 2007). The death receptor pathway 
consists of a ligand, for example TNF (Tumour Necrosis Factor), that binds to a 
receptor (TNF Receptor) initiating the binding of other proteins, such as TRADD 
and FADD to the internal component of the receptor. Another example is the Fas 
ligand which binds to the Fas receptor and then mediates the binding of FADD 
(Kischkel et al., 1995). The ligand, receptor and associated proteins together form 
the DISC (Death Induced Signalling Complex). Pro-Caspase 8 (initiator Caspase, 
also known as FLICE) is recruited to the DISC and activated through a series of 
proteolytic cleavage steps. Caspase 8 in turn activates the effector Caspase 3 
(Andersen et al., 2005, Elmore, 2007).  
The intrinsic pathway involves the mitochondrial release of Cytochrome C (which 
mediates apoptosis in a Caspase dependent manner), apoptosis-inducing factor (AIF) 
and endonuclease G (which mediate apoptosis in a Caspase independent manner) 
(Saelens et al., 2004) and is activated by apoptotic stimuli such as chemotherapy and 
UV. These stimuli activate pro-apoptotic proteins, such as BAX, which mediate 
changes in the inner mitochondrial membrane and which result in the opening of the 
mitochondrial permeability transition (MPT) pore and the release of Cytochrome C 
(Jurgensmeier et al., 1998, Pastorino et al., 1998). Other pro-apoptotic proteins 
include BAK, BAD and BID. The mediation of the release of Cytochrome C by 
these proteins allows Cytochrome C to bind to and activate Apaf1 and Caspase 9 (an 
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initiator Caspase), forming the apoptosome. The apoptosome consequently cleaves 
pro-Caspase 3 into its activated from (Saelens et al., 2004).  
Both the intrinsic and extrinsic pathways activate effector Caspase 3 which executes 
the final pathway of apoptosis by cleaving various substrates including cytokeratins 
and PARP and activates both cytoplasmic endonucleases (which degrade nuclear 
material) and proteases (which degrade nuclear and cytoskeletal proteins). 
Apoptosis is one of the key outcomes of p53 activation. p53 regulates apoptosis 
through many mechanisms and one of these key mechanisms includes the activation 
of expression of the pro-apoptotic Bcl-2 members. One example, BAX (Bcl-2 
Associated X protein), binds to the Bcl-2 protein. The binding of these two proteins 
inhibits BAX pro-apoptotic activity. Under stressed conditions, BAX dissociates 
from Bcl-2 and is relocated from the cytosol to the mitochondrial membrane. 
Mutated BAX protein is unable to localise to the mitochondria and this reduces the 
cell death activity of BAX (Wolter et al., 1997). p53 induces BAX expression (Table 
1.1) through a sequence specific p53 DNA binding site in the promoter of the gene 
and mutation of this site abolishes p53 responsiveness of reporter gene plasmids 
suggesting that BAX induction of apoptosis is dependent upon p53 (Miyashita and 
Reed, 1995).  
BAD is another pro-apoptotic protein and member of the Bcl-2 family, which is p53 
regulated (Table 1.1). BAD mediates apoptosis through binding to Bcl-2 and in 
doing so displacing BAX, allowing BAX to promote apoptosis (Yang et al., 1995). 
p53 induces expression of  BAD (Bcl-2 Antagonist of cell Death) (Jiang et al., 
2006). These authors demonstrate that p53 induces the expression of BAD through a 
sequence specific p53 DNA binding site, after DNA damage. Furthermore, the 
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increase in BAD increases the binding of p53 to BAD in the cytoplasm, inhibiting 
p53 from entering the nucleus and which ultimately decreases the expression of 
BAD through a negative feedback loop. BAD instead directs p53 to the mitochondria 
to induce Cytochrome C release. Downregulation of BAD by siRNA reduces 
mitochondrial p53 and increases the resistance to the chemotherapy agent, Etoposide 
(Jiang et al., 2006).  
Proteins that inhibit apoptosis and are p53 regulated include the IAPs (Inhibitors of 
Apoptosis), such as Survivin. Survivin binds to and inhibits the Caspase activity of 
Caspase 3 (Tamm et al., 1998). Survivin is has a role to play in spindle formation as 
the disruption of the Survivin-microtubule complex induces Caspase 3 activity and 
apoptosis (Li et al., 1998). It is also a cell cycle regulated protein and levels of 
Survivin increase and are at their highest during mitosis (Li et al., 1998). Loss of 
Survivin induced apoptosis and this was heightened in p21-null cells, indicating a 
role for Survivin in the protection of the p21-centrosome complex which is required 
for progression of mitotic progression (Li et al., 1999). Taking these data together 
suggests that the down-regulation of Survivin would be beneficial to a cell that is 
required to undergo apoptosis. Work carried out by Hoffman et al., 2002 show that 
p53 binds to the Survivin gene promoter at a p53 responsive element and 
overexpression of p53 down-regulates Survivin. The downregulation of Survivin by 
p53 is not p21 dependent and furthermore overexpression of Survivin in cells that 
are dependent on p53 mediated cell death inhibits apoptosis induced by UV 
(Hoffman et al., 2002). Taken together, these data show that the repression of 
Survivin by p53 is a key mechanism in p53 mediated apoptosis.  
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Examples of proteins that are involved in the extrinsic pathway of apoptosis and that 
are p53 regulated is the Fas (also known as APO-1 or CD95) Receptor (Muller et al., 
1998) and Fas ligand. These authors show that only wild type p53 and not mutant 
p53 up-regulates the Fas Receptor and expression of wild type p53 into a p53-null 
cell background re-establishes CD95 mediated apoptosis. Furthermore these authors 
show that the Fas ligand is up-regulated in response to DNA damage, albeit this up-
regulation is not p53 dependent as this up-regulation occurs in p53-null and p53 
mutant cell lines. However the authors show that p53 activates CD95 expression 
through  p53 responsive elements in the promoter and another in the first intron of 
CD95 and mutant p53 could not induce apoptosis through expression of CD95 
(Muller et al., 1998).  
 
1.7 Gene regulation by p53  
As discussed in Section 1.4.2, p53 binds to DNA via a sequence specific DNA site 
or p53 responsive element from where it then trans-activates or represses 
transcription of the gene. However there are other important transcription factors that 
regulate genes at the promoter other than p53.  For example, the CCAAT box is the 
DNA recognition site for NF-Y (CBF or CP1) (Mantovani, 1999); the TATA box is 
commonly known to be the site at which transcription factor TFIID binds to and 
where the Pol II transcription machinery assembles. The TFIID complex consists of 
many proteins including TAF(II)250, TAFs and TBP (TATA Binding Protein), 
which is the protein required for TFIID and other TAFs to bind to the TATA box 
(Burley and Roeder, 1996, Hernandez, 1993). These sites are also sites that proteins 
such as p53 can act through, such as the binding of p53 to TBP-TATA box complex 
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or p53 binding to the NF-Y-CCAAT box complex (Martin et al., 1993, Truant et al., 
1993). The Sections below aim to discuss the different elements in the activation and 
repression of gene expression and the role p53 has to play in their regulation. 
 
1.7.1 TATA Box, TBP and p53 
TBP is a protein that is essential for transcription (Kim and Iyer, 2004). It interacts 
with and is required by all three types of RNA Polymerase (I-III) for transcription 
(Cormack and Struhl, 1992, Hernandez, 1993) and therefore is recruited to all three 
basal promoter elements. Interestingly, RNA Pol I promoters do not contain a TATA 
box, whereas most RNA Pol II and III do. TBP in this case can bind to TATA-less 
promoters through protein-protein interactions (Hernandez, 1993). Data show that 
TATA-less promoter transcription requires the TFIID complex (Pugh and Tjian, 
1991) and accordingly, RNA Pol II TATA-less promoters can bind TBP through an 
initiator sequence (Hernandez, 1993). Kim et al., 2004, show that TBP can bind to 
TATA-less promoters, show that TBP has a higher affinity for Pol III promoters. 
Furthermore, data show that the transcription of these genes throughout the genome 
are proportional to the occupancy of TBP on their promoters, as alterations in the 
expression of these genes  are concomitant with alterations in TBP recruitment to 
their promoters (Kim and Iyer, 2004), which is regardless of the presence or absence 
of a TATA box.  
The interaction of TBP-TATA box complex and p53 has been well documented 
(Chen et al., 1993, Martin et al., 1993, Seto et al., 1992, Truant et al., 1993, Xing et 
al., 2001). The three earlier publications show that p53 binds to TBP and that the 
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complex can bind directly to the TATA box. Truant et al., 1993 show that mutation 
of residue R175 (which lies in the DNA binding domain of p53) to H175, reduced 
p53 binding to TBP and consequently reduced transcription. The interaction between 
p53 and TBP was further confirmed by Chen et al., 1993 whom show that p53 and 
TBP act co-ordinately to activate gene expression. Furthermore, other reports (Seto 
et al., 1992) suggest that p53 binding to TBP can also cause gene repression. p53 can 
also regulate gene expression by stimulating the assembly of other TAFs onto the 
complex (Xing et al., 2001).  
Interestingly, p53 cooperates with TBP (or TFIID) in binding to DNA which 
contains both a specific p53 responsive element and a TATA box, and both stimulate 
p53 binding to the DNA promoter which contains only a  p53 response element 
(Chen et al., 1993).  However both do not collaborate in the binding of promoters 
with only a TATA box and data show that p53 in fact inhibits TBP binding to the 
TATA box in the absence of a p53 responsive element (Chen et al., 1993). 
It is unclear whether the outcome of gene expression by p53 (whether the gene is 
activated or repressed), is TATA box dependent, as p53 also represses TATA-less 
promoters (Gopalkrishnan et al., 1998). However, what can be concluded is that the 
involvement of p53 with the TBP protein (and TATA box) can regulate gene 
expression.  
 
1.7.2 CDE/CHR (Cell Cycle Regulatory) Element 
The cell cycle-dependent element (CDE) and the cell cycle genes homology region 
(CHR) control the transcription of genes that are expressed in G2 phase and in 
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mitosis, for example CDC25C (Lucibello et al., 1995, St Clair et al., 2004), cdc2 
(Zwicker et al., 1995b) and PLK1 (Uchiumi et al., 1997). The elements’ consensus 
sequence consists of the following: the CDE, N N T/G G/C G C G G N A/G (N 
represents any nucleotide  (Zwicker et al., 1995b)) or CGGCGCC (Muller and 
Engeland, 2010) and the CHR, N G/A T/C T T G A A N N (Zwicker et al., 1995b) 
or TTTGAA (Muller and Engeland, 2010). The CDE was first described in the 
promoter of CDC25C (Lucibello et al., 1995) and is always accompanied by a 
second conserved site, termed CHR (Zwicker et al., 1995b). Interestingly, the 
CDE/CHR element is usually found in promoters that contain multiple CCAAT 
boxes and that lack a TATA box (Muller and Engeland, 2010), such as that of 
CDC25C (Korner et al., 1997). Notably, there is some similarity between CDE and 
the E2F binding site when comparing their consensus sequences and one way of 
distinguishing the two is that the E2F binding site is not found next to a CHR 
element. However, it is not clear how E2F is able to distinguish between the E2F 
binding site and the CDE element or what specificity E2F has for the E2F binding 
site or CDE as data suggests that E2F not only binds its consensus site but also the 
CDE element (Muller and Engeland, 2010). 
The function of the CDE/CHR element is to regulate cell cycle genes, specifically 
those that express proteins required for G2/M by repressing the gene up until the G2 
and mitosis phases of the cell cycle. This function was shown by Lucibello et al., 
1995 whose data identify that mutation of CDE in the CDC25C promoter causes the 
activation of gene expression throughout the cell cycle, specifically the G1 and S 
phases of the cell cycle. Furthermore, mutation of the CHR also deregulates 
CDC25C and other proteins such as Cyclin A and cdc2 in such a way that they are 
continually expressed throughout the cell cycle (Zwicker et al., 1995b). Another 
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example of cell cycle regulated expression of G2/M phase genes through the 
CDE/CHR element is PLK1. As like CDC25C mutation of either the CDE or CHR, 
abrogates G1 and S repression of PLK1 and levels of PLK1 expression are 
constitutively high (Uchiumi et al., 1997).  
Cell cycle regulated genes, in particular those involved in G2 and M phase, are 
repressed by p53 and one of the mechanisms by which p53 can do this is through the 
CDE/CHR element (St Clair et al., 2004). Repression by p21 is also mediated 
through the CDE/CHR element (Zhu et al., 2002). These represent other 
mechanisms for p53 (and p21) dependent cell cycle arrest in response to DNA 
damage and other stresses. St Clair et al., 2004 characterise the extent to which p53 
represses the CDC25C gene and propose that there are two mechanisms by which 
p53 represses CDC25C: through a p53 binding site and through the CDE/CHR 
element. Interestingly, p53 represses expression of a Luciferase reporter gene, not 
only through a p53 responsive element but also through the CDE/CHR element and 
mutation of this element almost abolishes repression of the reporter gene. However 
titring of p21 into the system (rather than p53) does repress expression through the 
CDE/CHR element, suggesting that the induction of p21 may be how p53 represses 
CDC25C. Mutation of the CDE/CHR element completely abolishes repression of the 
reporter gene by p21. Further to this, these authors show that mutation of the 
CDE/CHR element only affects repression and not binding of p53 to DNA. They 
also take into consideration the CCAAT boxes in the CDC25C promoter. Whilst p53 
represses expression through the CCAAT boxes alone, repression does not occur at 
physiological levels of p53, shown by experiments using a cell line that induces p53 
expression on the withdrawal of Tetracyclin. Lastly, they show that p53 is not bound 
to the CCAAT box. A later publication by this group, as already described in this 
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introduction, verifies that there is also a strong involvement for the p53 RE in 
repression of CDC25C by p53 as well as the CDE/CHR element (St Clair and 
Manfredi, 2006).  
Other reports imply that DNA damage induced down-regulation of CDK1 (cdc2) at 
the G2/M checkpoint, is dependent upon p53 mediated repression through the 
CDE/CHR element (Badie et al., 2000). 
Conclusively, the repression of the repressive activities of the CDE/CHR element by 
p53 is clearly another mechanism by which p53 mediates G2/M checkpoint arrest 
induced by DNA damage and other stresses.  
 
1.7.3 CCAAT Box, NF-Y and p53 
Many proteins bind to the CCAAT box, but many of these recognise palindromic 
sequences and rely on surrounding nucleotides to bind. The NF-Y protein in contrast 
only requires these five nucleotides and it is the main protein that binds to the 
CCAAT box (Mantovani, 1999). The CCAAT box is one of the most prevalent 
elements that can be found in eukaryotic gene promoters and found in particular 
promoters involved in cell cycle regulation such as cdc2, CDC25C, Cyclin A and 
Cyclin B1 (Mantovani, 1998, Zwicker et al., 1995a). Interestingly, these particular 
promoters are TATA-less and data show that there is an increased occurrence of 
CCAAT boxes in TATA-less promoters (Mantovani, 1998). These authors also show 
that the position of the CCAAT box is dependent on whether the promoter has a 
TATA box; the CCAAT box is situated nearer the transcriptional start site of the 
gene in the absence of a TATA box, whereas in the presence of a TATA box the 
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CCAAT box is situated on average between -80 and -100 bp upstream of the 
transcriptional start site. Notably the CCAAT box can also be found situated in 
promoters in the reverse orientation (Mantovani, 1998).  
The NF-Y factor itself is made up of three subunits: NF-YA, NF-YB and NF-YC 
(Maity and de Crombrugghe, 1998) and interacts with different transcription factors; 
for example TBP is found to have affinity for NF-YB and NF-YC (Bellorini et al., 
1997); Histone Acetyl-Transferases (HATs) are also associated with NF-Y subunits 
such as hGCN5 to the NF-YB-NF-YC complex (Currie, 1998) and P/CAF to NF-YA 
(Jin and Scotto, 1998) (for review see (Mantovani, 1999)). Both of these HATs act 
co-ordinately with NF-Y to activate transcription. NF-Y is also found to be essential 
in the binding of RNA Pol II to CCAAT box containing promoters and required for 
transcription by RNA Pol II (Kabe et al., 2005).  
NF-Y is a target for p53 and when in complex, these two proteins can negatively 
regulate G2/M promoters (Imbriano et al., 2005). The fact that p53 binds to NF-Y is 
another mechanism by which p53 can mediate G2/M checkpoint arrest. Imbriano et 
al., 2005 show that multiple CCAAT boxes are necessary for the repression of 
transcription induced by DNA damage. Furthermore, they show that p53 and NF-Y 
interact through the α-helix of NF-YC and the C-terminus of p53 (residues 355 to 
375) the tetramerization domain of p53, sites acetylated by P/CAF and p300 
respectively. p53 and NF-Y are co-resident on certain types of promoter, in 
particular those that are involved in the G2/M transition, which contain multiple 
CCAAT boxes and Imbriano et al., 2005 note that after DNA damage the p53-NF-Y 
complex remains bound to the CCAAT box. Taken together these data suggest that 
p53 may induce transcriptional repression through the CCAAT box and that more 
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than one CCAAT box is required for repression. Acetylation status of both p53 and 
surrounding histones also plays a role in repression of transcription by p53 and NF-
Y. The acetylation sites of p53 (K320, K373, and K382) become rapidly acetylated 
and HDACs are recruited to the complex and therefore surrounding histones are 
deacetylated. PCAF and p300, associated with both NF-Y and p53, are then released 
from the promoters. However, the CCAAT box bound p53-NF-Y complex is 
required but not sufficient for HDAC recruitment and repression (Imbriano et al., 
2005). Other factors that bind to NF-Y and inhibit transcription through the CCAAT 
box include the p53 family member, p63 (Testoni and Mantovani, 2006). 
Through the interaction of p53 with NF-Y and the CCAAT box, p53 can repress 
promoters such as cdc2 (Yun et al., 1999), Cyclin B and CDC25C (Manni et al., 
2001) and therefore create a G2/M checkpoint arrest when DNA damage has 
occurred. Therefore NF-Y and the CCAAT box are important in p53 regulated 
transcription.  
 
1.7.4 E2F binding site: p21 mediated negative regulation of E2F by p53 
Another element through which p53 can mediate its regulation of gene expression is 
indirectly through the E2F binding site. The E2F binding site consists of the DNA 
sequence: TTTCGCGC (Zheng et al., 1999). Depending on the stage of the cell 
cycle; which member of the E2F family binds to the consensus sequence; and the 
actual sequence itself, gene expression by E2F can either be activated or repressed 
(Araki et al., 2003, Wells et al., 2000). As the E2F binding site is similar to the CDE 
element it is proposed that the E2F binding site alongside CHR represses 
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transcription whilst E2F alone activates transcription (Zwicker and Muller, 1997). 
The effect different E2F family members have on transcription also has a bearing on 
whether gene transcription is activated or repressed. For example, the presence of 
E2F-4 (in complex with the Rb-related protein, p130) on the cdc2 promoter in cells 
that are undergoing G1 phase represses expression of cdc2 until the complex is 
released during S phase (Tommasi and Pfeifer, 1995). It is shown that the binding of 
Rb to E2F-1 inhibits the trans-activation of E2F-1 (Helin et al., 1993a). Furthermore 
Rb also recruits histone deacetylase to repress transcription (Brehm et al., 1998). 
E2F homo-dimerizes with other members of the E2F family or hetero-dimerizes with 
a close relative, DP1, which enhances the binding of E2F to the binding site and 
enhances trans-activation of gene expression (Helin et al., 1993b). These authors 
also show that this complex is also inhibited by Rb.  
E2F binding sites are included in many promoters most of which are mainly 
involved in cell cycle regulation and DNA replication, such as cdc2 (Tommasi and 
Pfeifer, 1995), Cyclin A (Schulze et al., 1995), Cyclin E (Botz et al., 1996) and 
DNA Polymerase α (Pearson et al., 1991). Therefore the involvement of E2F in 
these cellular mechanisms makes E2F a target for many proteins, such as p21 
(expression of which is dependent upon p53), to inhibit cell cycle progression after 
stress or DNA damage.  
p21, as discussed earlier, is involved in the control of E2F transcriptional activity 
through direct binding (Delavaine and La Thangue, 1999) or through the inhibition 
of CDKs (CDKs phosphorylate and inactivate Rb). p21 mediated activation of Rb 
allows Rb to bind to and inhibit E2Fs (Weinberg, 1995). p21 also disrupts the 
CDK2-p130-E2F1 complex allowing p130-E2F1 to repress transcription (Shiyanov 
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et al., 1996). Taken together these data and the fact that p21 expression is p53 
dependent, E2F (and the E2F binding site) is, in effect, an indirect target of p53. 
Notably, the E2F binding partner DP is also inhibited by p53 (Gopalkrishnan et al., 
1998).  
Together these data show that, through the E2F binding site, p53 can inhibit cell 
cycle progression and that this is another example by which p53 can induce cell 
cycle checkpoint arrest through other binding sites other than the p53 responsive 
element.  
 
1.7.5 Sp1 Sites 
The Sp1 transcription factor binds to sites that are GC rich or GT rich: the GC box, 
GGGGCGGGG (on occasion GGCGGG will suffice alone, for example in the PLK1 
promoter (Uchiumi et al., 1997)) and GT/CACCC box GGTGTGGGG (Suske, 
1999). These sites are found throughout many promoters including PLK1, CDC25C 
(Zwicker et al., 1995a) and p21 (Koutsodontis et al., 2002). In the p21 promoter in 
particular, there are six proposed Sp1 sites that have the sequence similar to 
GGCGGG and are bound by specific members of the Sp1 family. Koutsodontis et 
al., 2002, show that Sp1 and Sp3 are trans-activators of p21 expression and deletion 
of element 1, or a mutant of Sp1, reduced trans-activation. Also mutation of Sp1 
binding element 3 almost abolished all p21 promoter activity. Sp1 trans-activation of 
p21 expression is enhanced by the cytokine TGF-β (Transforming Growth Factor, 
which inhibits cell cycle progression), mediated via the Smad signalling pathway. 
Mutation of Smad inhibits p21 induction by TGF-β (Moustakas and Kardassis, 1998, 
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Pardali et al., 2000). These authors show that activation of p21 requires the binding 
sites for Sp1 on the promoter and that Smad and Sp1 cooperate at the GC rich Sp1 
site in the p21 promoter to trans-activate p21.  
p53 also co-operates acts with Sp1 to trans-activate the p21 promoter (Koutsodontis 
et al., 2001). These authors show that 1) Sp1 acts independently of p53 to trans-
activate the p21 promoter and 2) p53 stimulates p21 expression but requires Sp1 to 
do this, as mutation of either the p53 responsive element or the Sp1 site reduced p21 
trans-activation. Further analysis showed that the p53 binding site is an enhancer of 
the proximal promoter which contains the Sp1 binding sites and that at the Sp1 
binding site p53 interacts with Sp1 to trans-activate p21. Overall these data suggest 
that Sp1 and p53 act in co-operation with each other (or synergism) as a mechanism 
to regulate transcriptional activation of p53 target genes (Koutsodontis et al., 2001).  
Further to the above, the importance of the Sp1 site in promoters for transcriptional 
activation is highlighted by the fact that Sp1 interacts with a subunit of the TFIID 
complex, TAF(II)110 (Gill et al., 1994) . Mutation of certain Sp1 binding sites 
reduced the binding of TAF(II)110 and trans-activation of gene expression (Gill et 
al., 1994). Similarly, Sp1 interacts with E2F (Lin et al., 1996). Both these proteins 
bind to one another and cooperate with each other to activate transcription. Data 
show that Sp1 increases transcription at a promoter containing only an E2F binding 
site and E2F increases transcription at a promoter containing only Sp1 sites (Lin et 
al., 1996). Together these data show the interaction Sp1 has with E2F to activate 
transcription.  
Many publications document the trans-activation capabilities of Sp1, however more 
recent data show that Sp1 (and other members of the Sp family, such as Sp3 and 
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Sp4) can repress transcription. Innocente et al., 2005 show that p53 is able to bind to 
Sp1 and the Sp1 binding site to repress Cyclin B1 transcription and this is p21 and 
NF-Y (CCAAT box) independent. The Sp1 binding site is crucial in the repression 
of Cyclin B transcription as mutation of this abolishes repression (Innocente and 
Lee, 2005). Interestingly, growing evidence suggests that Sp1 is responsible for 
activation of gene transcription and that Sp3 and Sp4 compete with Sp1 for the Sp1 
binding site and in doing so decrease the activation of transcription by Sp1 (Kwon et 
al., 1999).  
Again, it is shown that p53 can activate or indeed repress target genes through 
promoter elements and their component proteins and, in particular, p53 can do this in 
co-operation with Sp1 and the Sp1 binding site. 
 
1.8 Polo-like Kinase-1 (PLK1) 
This thesis focuses on p53 and the mechanism of its repression of proteins involved 
in the progression of G2 and M phase, specifically PLK1. The Sections below give 
an overview of PLK1, including the following: its function and cellular localisation, 
regulation throughout the cell cycle, down-regulation after DNA damage, PLK1 
knockdown and depletion.  
 
1.8.1 PLK Family 
PLKs are a group of ser/thr kinases that cooperate with CDKs to regulate 
progression of the cell cycle (Strebhardt and Ullrich, 2006). First described in 
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Drosophila melanogaster, the mammalian family consist of four PLKs consisting of 
PLK1, PLK2 (Serum inducible kinase, Snk), PLK3 (proliferation-related kinase, 
Prk) and PLK4 (Snk akin kinase, Sak) (Barr et al., 2004, Dai, 2005). PLKs are 
similar in structure to one another and contain two Polo-box domains (PDBs) and a 
ser/thr kinase domain. PLK4 however contains only one PBD. The function of PLK1 
has been extensively studied and is involved in many cellular functions. This will be 
discussed in more detail in the next Section. The function of the other members of 
the family remains relatively elusive. Interestingly PLK2 levels and activity 
increases during the G1 phase of the cycle indicating that it is required for the 
progression of the cell cycle through G1 and S phase (Ma et al., 2003). Silencing of 
PLK2 causes mitotic catastrophe and apoptosis (Burns et al., 2003). Like that of 
PLK1, PLK3 and PLK4 levels increase in G2 and M phase of the cell cycle, however 
constitutive expression of PLK1 transforms NIH3T3 cells whereas constitutive 
expression of PLK3 inhibits proliferation by impeding cytokinesis (Conn et al., 
2000, Sillibourne and Bornens, 2010). Recent studies have demonstrated that PLK3 
is activated during DNA damage checkpoint arrest and inhibits entry into mitosis 
through phosphorylation of CDC25C (Xie et al., 2001). PLK3 transcription is 
activated by p53 through a p53 responsive element in the promoter region of the 
PLK3 gene (Jen and Cheung, 2005). Notably PLK2 is also a target of p53 
transcriptional activity and the promoter region of the PLK2 gene contains three p53 
responsive elements. Data show that p53 activates PLK2 expression through two of 
these sites and represses transcription through the third element (Burns et al., 2003).  
PLK4 is also repressed by p53 (Li et al., 2005). 
The data currently available for the PLK family demonstrate that PLK2 and PLK3 
are transcriptional targets of p53. PLK1 is the most studied of all the members of the 
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PLK family and is required for many cellular processes needed for cell cycle 
progression and although it has been shown to be down-regulated in a DNA damage 
dependent manner (Smits et al., 2000) it is not known whether p53 directly represses 
PLK1 transcription. The next Sections aim to discuss the current knowledge 
surrounding PLK1 function and its down-regulation by DNA damage.  
 
1.8.2 Function and localisation of PLK1  
PLK1 is a protein kinase that phosphorylates many substrates, some of which are 
summarised in Figure 1.6, and is localised to many cellular structures which are also 
shown in Figure 1.6.  
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Figure 1.6: Function and localisation of PLK1 
PLK1 is involved in various functions in the mitosis phase of the cell cycle. Figure derived from 
various authors (Archambault and Glover, 2009, Pines, 2002, Strebhardt and Ullrich, 2006). (I) PLK1 
phosphorylates CDC25C which in turn dephosphorylates and activates the CDK1/Cyclin B complex 
(II) PLK1 phosphorylates Nlp, which dissociates from the centrosome so allow centrosome to mature 
(III) PLK1 mediates cohesion breakdown (IV) PLK1 phosphorylates Bub1 which is needed for 
kinetochore stability (V) PLK1 stimulates the degradation of the Early Mitotic Inhibitor 1 (EMI1), an 
anaphase promoting complex (APC) inhibitor and (VI) PLK1 binds to the central spindle by an 
interaction with Protein Regulator of Cytokinesis 1 (PRC1). PLK1 activates a Rho GTPase that 
stimulates the contraction of the contractile ring required for cytokinesis. 
 
PLK1 was first described by the finding that mutant alleles of Polo (PLK1) caused 
significant aberration of mitotic spindles and abnormal segregation of chromosomes 
in Drosophila (Sunkel and Glover, 1988). Mutants of the Polo homologue in 
S.pombe, plo, cannot mediate chromosome segregation and the PLK1 homologue in 
S.cerevisiae, cdc5, mutation also leads to a mitotic arrest (Ohi et al., 1994, Ohkura et 
al., 1995). The name Polo was derived from the fact that the bipolar spindle (that 
aligns the chromosomes in pairs in the centre of the mitotic spindle), is impaired in 
the absence of PLK1, with the outcome that chromosomes simply align around the 
mono-polar spindle, which encircles the mitotic spindle (Sunkel and Glover, 1988).  
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PLK1 has many roles to play in the latter stages of G2 phase, mitotic entry and 
throughout mitosis and even cytokinesis (Petronczki et al., 2008).  It is localised to 
various cellular structures including the centrosomes in prophase, kinetochores in 
prometaphase and metaphase, central spindle in anaphase, and it also accumulates in 
the midbody during telophase (Petronczki et al., 2008). It is thought that PLK1 
recognises substrates through its PBDs, which recognise particular phospho-peptide 
sequences on the substrate (i.e. the PBDs, Polo Box Domains). Mutation of either of 
the PBDs  causes catastrophic mitotic events, such as randomly orientated spindles 
in prophase and in metaphase and randomly orientated bipolar spindles (Seong et al., 
2002). Overall the mutation caused destabilisation of mitotic spindles and 
cytokinesis failure (Seong et al., 2002). Furthermore, mutation inhibited PLK1 
association with the spindle poles and cytokinetic neck filaments (Lee et al., 1998). 
Interestingly, it was shown that deletion of the C-terminus (now known to harbour 
the PBD) increased the kinase activity of PLK1 significantly, therefore showing that 
the PBD has a role in the regulation of PLK1 activity (Mundt et al., 1997). 
PLK1 is a well known protein kinase and is responsible for phosphorylation of 
diverse number substrate proteins, such as CDC25C and Cyclin B1. The exact 
mechanism by which PLK1 targets its substrates and how the PBD might facilitate 
this is not clearly understood. Some authors suggest that the PBD domain inhibits 
the kinase domain until a phospho-peptide binds to the PBD and which releases the 
kinase domain (Lowery et al., 2005). They also suggest that there are two models by 
which PLK1 targets its substrates:  either 1) PLK1 PBD recognises the phospho-
peptide of a scaffold protein, located at a cellular structure, allowing the kinase 
domain to phosphorylate neighbouring substrates located at the cellular structure 2) 
the PLK1 PBD binds to a substrate phospho-peptide, which then allows the kinase 
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domain to further phosphorylate and activate that substrate (Lowery et al., 2005, 
Lowery et al., 2004). The difference in the models is that the PDB either recognises 
the substrate and directly binds to the substrate to phosphorylate the substrate, or 
recognises a scaffold protein that brings PLK1 to a particular structure in the cell and 
phosphorylates the substrate without actually binding to it.  
PLK1 pays a large role at the centrosomes of the cell. For example, it is responsible 
for the phosphorylation of the centrosomal protein Nlp (Ninein-like protein, which 
regulates microtubule nucleation). The Nlp protein function is to manage 
microtubule minus-end anchoring and nucleation events during interphase, and 
phosphorylation by PLK1 dissociates Nlp from the centrosome in mitosis. This is to 
presumably inhibit the formation of new microtubules and stabilises the already 
formed microtubules (Casenghi et al., 2005, Casenghi et al., 2003). Another 
substrate of PLK1 that is important for entry into mitosis is CDC25C. PLK1 binds to 
phosphorylated CDC25C (which is primed by a phosphorylation group by 
CDK1/Cyclin B complex) through its PBD domain and phosphorylates CDC25C to 
activate CDC25C. Interestingly, mutation of the PBD inhibits the binding of PLK1 
to CDC25C and inhibits centrosomal localisation of PLK1 (Elia et al., 2003a, Elia et 
al., 2003b). 
Another cellular structure at which PLK1 is important is at the kinetochore (the 
protein structure on chromosomes where microtubules attach during division and is 
responsible for the separation of chromosomes). PLK1 is required for the attachment 
of the microtubules to the kinetochores and this can be inhibited by the PLK1 
inhibitor, BI 2536 (Elowe et al., 2007).  A particular PLK1 substrate involved at the 
kinetochore and microtubule interface is Bub1. PLK1 binds to pre-phosphorylated 
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Bub1 (primed by a phospho group by CDK1), and further phosphorylates Bub1 at 
residue S676 creating kinetochore stability (Elowe et al., 2007). These authors also 
show that phosphorylation of Bub1 by PLK1 occurs at prometaphase and is removed 
in metaphase. 
Taken together, these data show that PLK1 has many important roles to play in the 
cell cycle, particularly in mitosis and is associated with many mitotic structures, only 
some of which have been touched upon above. They also show that PLK1 is vital in 
the correct management of mitosis and without it, the integrity of the genome is lost 
and therefore cell cycle progression cannot proceed. 
 
1.8.3 Cell cycle regulation of PLK1 
The regulation of PLK1 is well documented and was first observed by two groups 
who show that the activity and levels of PLK1 increase at the end of G2 phase and 
reach a maximum level in mitosis (Golsteyn et al., 1995, Hamanaka et al., 1995). At 
the end of mitosis PLK1 activity and levels decrease. The factor that is responsible 
for cell cycle regulation of PLK1 levels was identified as being the CDE/CHR 
element in the promoter of PLK1 (Uchiumi et al., 1997), which was previously 
identified in the cell cycle regulated, G2 and M phase protein, CDC25C (Lucibello et 
al., 1995, Zwicker et al., 1995b). Uchiumi et al., 1997 show comprehensively the 
elements in the PLK1 promoter that are responsible for the activation and repression 
of PLK1 expression. They show that activation of PLK1 expression is due to a Sp1 
site, CCAAT box and an element neighbouring and upstream of the Sp1 binding site. 
Mutation of the Sp1 binding site reduces promoter-driven Luciferase expression and 
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removal of the site reduces this further. Mutation or removal of the CCAAT box 
almost abolishes all Luciferase activity (Uchiumi et al., 1997). Furthermore, these 
authors show that cell cycle regulation is regulated by a CDE/CHR element and 
mutation of the CDE or CHR element increases promoter-driven Luciferase 
expression during G1 phase indicating that both elements are involved in PLK1 
transcriptional repression during this phase under normal conditions. Interestingly, 
the CHR mutant alone had a much larger level of promoter-driven Luciferase 
expression in G1 phase extracts compared to the CDE mutant alone. These data 
demonstrate that CHR has the larger role to play in repression of PLK1 during the 
G1 phase of the cell cycle, compared to the CDE. 
Later publications also show the importance of the E2F binding site in PLK1 (130 
base pairs upstream from the transcriptional start site) and regulation by other 
proteins such as RB and the SWI/SNF (chromatin remodelling) complex. As E2F 
members can either activate or repress transcription, the role of the E2F binding site 
of PLK1 was unclear, although it was assumed it was more likely to play a 
repressive role at the PLK1 promoter, like that of the G2/M promoter of cdc2 
(Tommasi and Pfeifer, 1995). E2F binding site deletion does not affect activation of 
transcription of PLK1 (Zhu et al., 2002) and data show that the repressive member 
of the E2F family, E2F4, binds to the E2F binding site in-conjunction with the Rb 
proteins, p107 and p130 and together represses transcription (Gunawardena et al., 
2004). In the presence of Rb, the SWI/SNF histone deacetylation complex is 
recruited and alongside of this complex E2F is able to repress the PLK1 promoter 
further. Notably, the E2F-Rb complex alone could not repress PLK1 transcription to 
the same extent as in the presence of SWI/SNF (Gunawardena et al., 2004) (for 
reviews see (Archambault and Glover, 2009, Martin and Strebhardt, 2006)). The 
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mechanism by which Rb recruits SWI/SNF to repress transcription also occurs at the 
promoters of Cyclin E and cdc2 (Siddiqui et al., 2003, Zhang et al., 2000). Although 
the importance of Rb alone in repression of PLK1 is further illustrated by the fact 
that repression is abrogated in the absence of all three Rb members (Rb, 107 and 
130) (Jackson et al., 2005).  
There are many mechanisms by which PLK1 transcription is regulated, however the 
purpose of this thesis is to ask the question of how is PLK1 down-regulated and is 
down-regulation p53 dependent? The next Section aims to discuss the recent data 
showing that PLK1 is down-regulated after DNA damage. 
 
1.8.4 PLK1 down-regulation by DNA damage and PLK1 Depletion/Knockdown 
Studies show that DNA damage induces the down-regulation of PLK1. In particular, 
DNA damage induced by Adriamycin and Cisplatin, was shown to down-regulate 
PLK1 and that this caused a block of the cell cycle at G2 and in Mitosis  (Ando et 
al., 2004, Smits et al., 2000). DNA damage also down-regulates PLK1 mRNA 
expression suggesting that PLK1 is repressed at the gene level (Ree et al., 2003). 
Although the mechanism by which PLK1 is repressed by DNA damage is unclear 
these authors suggest that there is an involvement of BRCA1 in PLK1 repression. 
PLK1 down-regulation is also ATM and ATR dependent  (van Vugt et al., 2001) and 
occurs concomitantly with increases in p53 and p21 suggesting an involvement of 
p53 in PLK1 down-regulation (Incassati et al., 2006, Kho et al., 2004, Sur et al., 
2009). Kho et al., 2004 show that p53 repression of PLK1 occurs in a p53 wild type 
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cell line and cannot in the p53-null equivalent cell line, when cells are treated with 5-
Flurouracil.  
Not only are protein and mRNA levels down-regulated by DNA damage, PLK1 
activity is inhibited by DNA damage (Smits et al., 2000). This indicates that DNA 
damage inhibits PLK1 activity as well as down-regulating or repressing PLK1. 
 Interestingly, expression of a mutant form of PLK1 that is constitutively active 
over-rides the DNA damage induced G2 arrest (Smits et al., 2000). Data demonstrate 
that PLK1 is essential for the progression of mitosis in DNA damaged cells, unlike 
in undamaged cells, and required for the degradation of Wee1 (inactivates CDK1), 
which itself is needed for cell cycle progression (van Vugt and Medema, 2004, van 
Vugt et al., 2004).  
PLK1 repression is a target of DNA damage. PLK1 knockdown is shown to cause 
considerable inhibition of cellular growth at G2 and M, inhibition of centrosome 
maturation, inhibition of spindle formation and an increase in the number of cells in 
apoptosis (Liu and Erikson, 2002, Spankuch-Schmitt et al., 2002a, Spankuch-
Schmitt et al., 2002b). Interestingly, data show that PLK1 depletion induces 
increased mitotic arrest, and reduced cell survival in the p53-null cell lines 
suggesting that p53 plays a protective role under PLK1 depletion conditions (Guan 
et al., 2005). p53-null cells are sensitive to PLK1 depletion and undergo an increased 
cell death (Liu et al., 2006). Furthermore, PLK1 depletion is reported to promote 
DNA damage (Liu and Erikson, 2003, Yim and Erikson, 2009).   
Taken together these data illustrate that DNA damage induces PLK1 repression and 
that this may be due to p53. However, evidence shows that the mechanism by which 
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p53 does this cannot be replicated by depleting PLK1 and that p53 protects the cell 
under these conditions. The mechanism by which p53 represses PLK1 is unclear and 
this thesis aims to understand how p53 may do this.  
 
1.8.5 PLK1 and cancer 
PLK1 is found to be overexpressed in many cancers including breast, ovarian, 
colorectal and non-Hodgkin lymphoma’s (for review see (Strebhardt and Ullrich, 
2006)). Furthermore, transfection and overexpression of PLK1 into NIH3T3 cells 
causes malignant transformation of these cells (Smith et al., 1997) and therefore is a 
very important potential therapeutic target.  
What makes this target even more interesting is the fact that in cells expressing 
mutant p53 (p53 mutation that occurs in around 50% of human cancers), PLK1 
inhibition/knockdown leads to reduction in the survival of these cells and increased 
mitotic arrest in these cells, compared to their wild type counterparts (Guan et al., 
2005). Other authors also show that in p53 defective cell lines that have been treated 
with Ionising Radiation, PLK1 levels increase suggesting that p53 regulates PLK1 in 
stressed conditions (Sur et al., 2009). They also note that PLK1 inhibitors are much 
more effective in p53 deficient cells.  
Taken together the data above suggest that targeting PLK1 in p53 deficient tumours 
has significant potential as a cancer therapy. However it has also been shown that 
PLK1 depletion can cause DNA damage (Liu and Erikson, 2003, Yim and Erikson, 
2009) and tumour formation (Lu and Yu, 2009) suggesting that, in fact, a normal 
PLK1 level must need to be maintained in tumour cells.  
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1.9 Thesis Aims 
The model shown in Figure 1.7 is a representation of the mechanism(s) we believe 
that p53 utilises to down-regulate PLK1 at the G1/S checkpoint and most 
importantly the G2/M checkpoint. 
This thesis aims to decipher between two possible mechanisms by which p53 down-
regulates PLK1. The first is through CDK inhibition by the p53 inducible CDK 
inhibitor, p21. p21 arrests the cell cycle at the G1/S checkpoint. In some 
circumstances, repression by p21 is also mediated through the CDE/CHR element 
therefore this thesis asks how key the role of p21 has to play in PLK1 down-
regulation or down-regulation through the G1/S checkpoint? Secondly, this thesis 
aims to seek out whether there is a mechanism involving direct p53 binding to the 
PLK1 promoter which represses PLK1. There is supporting evidence for direct 
repression by p53. Here I explore this mechanistically and identify two possible REs 
in the promoter. Therefore does p53 bind to one or both of these? Also what is the 
role of the CDE/CHR element at this stage and can p53 or p21 repress PLK1 
expression sufficiently through this element? Overall, we wish to understand the 
extent of the dependency PLK1 repression has on p53 and is some of this repression 
down to p21? 
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Figure 1.7: Proposed mechanisms of down-regulation and/or repression of PLK1 by p53 and 
p21 
This Figure shows the proposed mechanism(s) by which p53 may down-regulate or repress PLK1. 
p53 mediates G1/S checkpoint arrest by inducing expression of p21 and therefore PLK1 down-
regulation may be due to the fact that PLK1 levels are low in the G1 and S phases of the cell cycle. 
On the other hand, p53 may act to repress PLK1 by directly repressing expression of PLK1 through 
proposed p53 responsive elements at the PLK1 promoter. p21 transcriptional activity may also repress 
PLK1 expression through the CDE/CHR element.  
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Chapter 2: Materials and Methods 
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2.1 Reagents and Buffers 
General chemicals were purchased from Sigma Aldrich unless otherwise stated. 
Deionised water (MilliQ) was used throughout. 
 
Agarose Gel Loading Buffer (5X) 
40 % (w/v) Sucrose 
0.25 % (w/v) Bromophenol Blue 
 
Buffer P1 (Sterile) 
50 mM Tris pH 8 
10 mM EDTA 
100 µg/ml RNase A  
 
Buffer P2 (Sterile) 
0.2 M NaOH 
1 % SDS 
 
Buffer P3 (Sterile) 
3 M KOAc pH 5.5 
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ChIP Collection Buffer  
1 X PBS 
1 X Protease Inhibitor Cocktail 1 (Calbiochem) 
 
ChIP SDS Lysis Buffer  
50 mM Tris-HCl pH 8 
10 mM EDTA pH 8 
1 % (w/v) SDS 
1 X Complete, EDTA-free Protease Inhibitor Cocktail (Roche) 
 
ChIP Dilution Buffer 
20 mM Tris pH 8 
150 mM NaCl 
2 mM EDTA pH 8 
1 % (v/v) Triton X-100 
1 X Complete, EDTA-free Protease Inhibitor Cocktail (Roche) 
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ChIP Low Salt Buffer 
20 mM Tris pH 8 
150 mM NaCl 
2 mM EDTA pH 8 
1 % (v/v) Triton X-100 
0.1 % (w/v) SDS  
1 X Complete, EDTA-free Protease Inhibitor Cocktail (Roche) 
 
ChIP High Salt Buffer  
20 mM Tris pH 8 
500 mM NaCl 
2 mM EDTA pH 8 
1 % (v/v) Triton X-100 
0.1 % (w/v) SDS  
1 X Complete, EDTA-free Protease Inhibitor Cocktail (Roche) 
 
LiCl Buffer 
250 mM LiCl 
10 mM Tris pH 8 
1 mM EDTA pH 8 
1 % (v/v) Igepal 
1 % (w/v) Na Deoxycholate 
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EMSA p53 Binding Buffer 
50 % (v/v) Glycerol 
250 mM KCl 
100 mM HEPES pH 7.4 
5 mM DTT 
5 mg/ml BSA 
0.5 % (v/v) Triton X-100 
 
Enhanced Chemiluminescence (ECL) Solution 1  
2.5 mM Luminol  
396 µM p-coumaric acid  
100 mM Tris, pH 8.5 
 
Enhanced Chemiluminescence (ECL) Solution 2  
0.0192 % (v/v) H2O2 
100 mM Tris, pH 8.5 
 
Flow Cytometry Antibody Buffer 
1 X PBS 
0.5 % (w/v) BSA 
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Non-Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (non-SDS-
PAGE) Running Buffer (10 X) 
250 mM Tris   
1.92 M Glycine  
 
SOB Broth 
2 % (w/v) Tryptone 
0.5 % (w/v) Yeast Extract 
0.05 % (w/v) NaCl  
10 mM MgCl2 
10 mM MgSO4 
 
SOC Medium  
0.02 mM Glucose 
SOB Broth 
 
SDS Sample Buffer (5 X) 
125 mM Tris-HCl pH 6.8 
4 % (w/v) SDS 
20 % (v/v) Glycerol 
0.2 M DTT 
0.1 % (w/v) Bromophenol Blue 
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Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Running Buffer (10 X) 
250 mM Tris   
1.92 M Glycine  
1 % (w/v) SDS 
 
TE (1X) 
10 mM Tris pH 8 
1 mM EDTA pH 8 
 
Transformation Buffer 1, pH 5.8 
100 mM RbCl 
50 mM MnCl2.4H2O 
30 mM KC2H3O2, pH 7.5 
10 mM CaCl2.2H2O   
15 % (v/v) glycerol 
 
Transformation Buffer 2 
10 mM 3-(N-morpholino) propanesulphonic acid (MOPS), pH 6.8 
10 mM RbCl 
74 mM CaCl2.2H2O 
15 % (v/v) glycerol 
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Tris-acetate EDTA (TAE) Buffer (50 X)  
2 M Tris-base 
5.7 % (v/v) Glacial Acetic Acid 
0.1 M Na2EDTA.2H20, pH 8.0 
 
Tris-borate EDTA (TBE) Buffer (10X)  
0.45 M Tris-base 
0.44 M Orthoboric acid   
10 mM Na2EDTA pH 8.0 
 
Trypsin-EDTA (Sterile) 
Trypsin 0.25 % (Gibco) 
1 X PBS 
1 mM EDTA pH 8.0 
 
Western Blocking Buffer  
5 % (w/v) Marvel dried milk 
0.1 % (v/v) Tween 20 
1 X PBS 
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(Light) Western Blocking Buffer 
3 % (w/v) Marvel dried milk 
0.5 % (v/v) Tween 20 
1 X PBS 
 
Western Semi-dry Transfer Buffer 
25 mM Tris base 
192 mM Glycine  
0.1 % (w/v) SDS  
20 % (v/v) Methanol 
  
Western Wet Transfer Buffer  
25 mM Tris base 
192 mM Glycine 
20 % (v/v) Methanol 
 
Western Washing Buffer  
1 X PBS 
0.1 % (v/v) Tween 20 
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2.2 Cell Culture and Related Techniques 
2.2.1 Cell culture maintenance 
Cells lines, described in Table 2.1, were cultured in a humidified 5 % CO2 
atmosphere at 37 °C. Stocks of H1299, SAOS2 and U2OS cells, all available cells 
lines in the laboratory, were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Gibco). DMEM was supplemented with 10 % (v/v) fetal bovine serum 
(FBS, Gibco), 2 mM L-glutamine, 50 units/ml penicillin and 50 µg/ml streptomycin 
(all Gibco). HCT116 p53 wild type, p53-null and p21-null were cultured in McCoy’s 
5A medium (Biosera) which was supplemented with 10 % (v/v) fetal bovine serum 
(FBS, Biosera) and 2 mM L-glutamine. When cells reached 90 % confluency they 
were sub-cultured, as detailed in Table 2.1. Adherent cells were washed twice in PBS 
(37 °C) and then detached from the plates using Trypsin-EDTA (see Section 2.1 
Reagents and Buffers). Detached cells were re-suspended in medium and transferred 
to new plates/flasks with the appropriate fresh medium. 
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Cell Line Derivation Subculture ATCC® 
Number 
H1299 
Human non-small 
cell lung carcinoma - 
p53 null 
1:8 CRL-5803 
HCT116 
(wild type) 
Human colon 
carcinoma 1:6 CCL-247  
SAOS2 
Human osteogenic 
sarcoma – Rb and 
p53 null 
1:2 HTB-85 
U2OS 
Human 
osteosarcoma - ARF 
null 
1:4 HTB-96 
HCT116 
(p53-null, p21-
null) 
Human colon 
carcinoma 1:6 
Vogelstein 
Laboratory* 
 
Table 2.1: Mammalian cell lines 
*Dr. Vogelstein, The Johns Hopkins University, USA 
 
2.2.2 Cell Seeding 
Cell lines were seeded by washing and trypsinising the cells. They were then pooled 
together into a suspension, 10 µl of which was added to each end of a 
haemocytometer (Hawksley, 1/400m2). The cells were counted under the microscope 
and seeded as required.  
 
2.2.3 Drug Time Course 
Cells (HCT116 together with p53-null and p21-null derivatives, B.Vogelstein) were 
seeded at a density of 1 X 106 per 10 cm plate. After 24 h, Etoposide (final 
concentration 100 µM), Nutlin-3 (final concentration 10 µM) or Cisplatin (final 
78 
 
 


 
Concentration 20 µM), all solubilised in DMSO (Dimethyl Sulfoxide), were added 
directly to the cell medium. Cells were then lysed in 500 µl of 5 X Sample Buffer at 
2 h intervals over a 10 h period, with the final time point at 24 h. As controls, cells 
were untreated or treated with 0.1 % DMSO (Dimethyl Sulfoxide) and lysed in 500 
µl of 5 X Sample Buffer.  This was to account for any effects the DMSO alone is 
having on the cells. The samples were then analysed by SDS-PAGE and Western 
blotting.  
 
2.2.4 Drug Titre 
Cells (HCT116, together with p53-null and p21-null derivatives, B.Vogelstein) were 
seeded at a density of 1 X 106 per 10 cm plate. After 24 h, Etoposide was added to 
individual plates to give final concentrations of 5 µM, 10 µM, 20 µM, 50 µM and 
100 µM. After 24 h each plate of cells was lysed in 500 µl of 5 X sample buffer. This 
method was also carried out with Nutlin-3 at 1 µM, 2 µM, 5 µM and 10 µM (final 
concentration) and with Cisplatin at 20 µM, 50 µM, 100 µM and 120 µM (final 
concentration). A plate of untreated cells was also lysed as well as a plate of cells 
treated for 24 h with 0.1 % DMSO, to account for any effects the DMSO is having 
on the cells. The samples were then analysed by SDS-PAGE and Western blotting.  
 
2.2.5 siRNA Transfection 
p21 siRNA tranfection was performed in both HCT116 wild type cells and U2OS 
cells. PLK1 siRNA was performed in HCT116 wild type cells and their p53-null and 
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p21-null derivatives. siRNA was transfected into HCT116 cells and the p53-null and 
p21-null derivatives, using Lipofectamine RNAiMAX (Invitrogen) transfection 
reagent, as instructed by the manufacturer. U2OS were transfected using 
Lipofectamine 2000 (Invitrogen) transfection reagent as described by the 
manufacturer. The siRNA (Thermo Scientific) used is described in Table 2.2. The 
siRNA comprises a pool containing four siRNA oligos. 
HCT116 wild type cells and the p53-null and p21-null derivatives were seeded at a 
density of 1 X 106 per 10 cm plate.  After 24 h, 12 µl of a 20 µM stock of siRNA was 
added to 4 ml Opti-MEM® I Reduced Serum Media (Gibco). 40 µl Lipofectamine 
RNAiMAX was then added and the mixture incubated at room temperature for 20 
min. The medium was removed from the cells and replaced with the transfection 
mixture together with 10 ml fresh media (siRNA final concentration – 30 pmol). 
U2OS cells were seeded at a density of 1 X 106 per 10 cm plate. After 24 h, 40 µl 
Lipofectamine 2000 was added to 800 µl Opti-MEM (mix 1) and incubated at room 
temperature for 5 min. 40 µl siRNA (20 µM) was as added to 800 µl Opti-MEM (mix 
2). Mix 1 was added to mix 2 and incubated at room temperature for 15 min. Media 
on the cells was removed and replaced with the transfection mixture added to up to 
10 ml with fresh media (siRNA final concentration – 100 pmol). 
Post transfection cells were incubated for 48 h before lysing in 500 µl 5 X sample 
buffer or analysed by flow cytometry, as described in Section 2.2.10.  
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Name Sequence Target 
ON-TARGETplus 
SMARTpool 
siRNA 
J-003290-09 
GCACAUACCGCCUGAGUCU human PLK1 
ON-TARGETplus 
SMARTpool 
siRNA 
J-003290-010 
CCACCAAGGUUUUCGAUUG human PLK1 
ON-TARGETplus 
SMARTpool 
siRNA 
J-003290-11 
GCUCUUCAAUGACUCAACA human PLK1 
ON-TARGETplus 
SMARTpool 
siRNA 
J-003290-12 
UCUCAAGGCCUCCUAAUAG human PLK1 
ON-TARGETplus 
SMARTpool 
siRNA 
J-003471-09 
CGACUGUGAUGCGCUAAUG human CDKN1 (p21 CIP) 
ON-TARGETplus 
SMARTpool 
siRNA 
J-003471-10 
CCUAAUCCGCCCACAGGAA human CDKN1 (p21 CIP) 
ON-TARGETplus 
SMARTpool 
siRNA 
J-003471-11 
CGUCAGAACCCAUGCGGCA human CDKN1 (p21 CIP) 
ON-TARGETplus 
SMARTpool 
siRNA 
J-003471-12 
AGACCAGCAUGACAGAUUU human CDKN1 (p21 CIP) 
 
Table 2.2: ON-TARGETplus SMARTpool siRNA (ThermoScientific) 
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2.2.6 Double Thymidine Block and Release 
HCT116 wild type cells were seeded at 2.8 X 105 per 10cm plate. After 24 h 
Thymidine was added to a final concentration of 2 mM for 16 h to block the cells at 
the G1/S phase of the cell cycle. To release cells from the cell cycle block, cells were 
washed twice with warm 1 X PBS and fresh medium was added for a further 8 h. A 
second block was again initiated by the addition of 2 mM Thymidine for 16 h and 
then cells released from the block by washing the cells with warm 1 X PBS and 
adding fresh medium. Cells were subsequently lysed in sample buffer (500 µl) at 2 h 
intervals over a 24 h period and analysed by SDS-PAGE and Western blotting.  
 
2.2.7 Histone Deacetylase Inhibition 
Cells (HCT116 wild type, p53 null) were seeded at a density of 1 X 106 per 10 cm 
plate. After 24 h, Nutlin-3 was added to final concentration of 10 µM and/or 
Trichostatin A was added to a final concentration of 1 µM. Treatments were 
maintained for 16 h and cells lysed in 500 µl of 5 X sample. As controls, cells were 
untreated or treated with DMSO for 16 h to account for any effects the DMSO (the 
vehicle for the drugs) is having on the cells, and then lysed in 500µl of 5 X sample 
buffer. The samples were then analysed by SDS-PAGE and Western blotting.  
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2.2.8 Luciferase Transfections  
Cells (HCT116 and their derivatives p53-null and p21-null derivatives, SAOS2) were 
seeded at a density of 0.3 X 105 per well of a 24 well plate and incubated overnight at 
37 °C. Cells were then transfected with plasmid DNA, as described in Table 2.3. 
Luciferase transfections were performed using FuGENE® 6 Transfection Reagent 
(Roche) and each transfection performed in triplicate. 1 µg total DNA was used in 
each transfection (one transfection per well of cells). Total DNA was added to 50 µl 
serum free media (mix 1). Each µg of DNA required 3 µl FuGENE, therefore 3 µl of 
FuGENE was added to 47 µl serum free media and incubated at room temperature 
for 5 min (mix 2). This was done for each transfection. Mix 2 was added to mix 1 
and left at room temperature for 20 min. Each transfection mixture was then added to 
a seeded well of cells and incubated overnight at 37 °C. 
Cells were then lysed 24 h after transfection with 100 µl 1 X passive lysis buffer 
(Dual Luciferase Reporter Assay System, Promega).    
Transfection 1 2 3 4 5 6 7 
p53 plasmid (ng) 0 1 3 10 30 100 300 
PLK1promoter/ 
pGL3 reporter 
plasmid (ng) 
250 250 250 250 250 250 250 
pCDNA3 empty 
expression 
plasmid (ng) 
745 744 742 735 715 645 445 
SV-Renilla 
plasmid (ng) 5 5 5 5 5 5 5 
 
Table 2.3: Plasmid concentrations used in Luciferase tranfections of cells (each tranfection was 
performed in triplicate 
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2.2.9 Luciferase Assay 
The Luciferase assay was carried out by adding 20 µl of each sample into individual 
wells of a 96 well plate. The plate was then read by a Microlumat LB 96V 
luminometer (Berthold EG&G Instrument), using Luciferase Assay Buffer/Substrate 
and Stop & Glo® Buffer/Substrate from the Dual Luciferase Reporter Assay System 
(Promega). Variations in transfection efficiencies were corrected by determining the 
ratio of activity of Luciferase to Renilla in the sample. The average of each triplicate 
of ratios was then taken and plotted in a graph. Standard deviation was calculated 
and added as error bars to the graph.   
 
2.2.10 Flow Cytometry 
In order to measure progression through the cell cycle cells (either having been 
treated with a drug or siRNA, etc), cells are stained with 5-bromo-2-deoxyuridine 
(BrdU) and Propidium Iodide (Invitrogen). BrdU is a synthetic nucleoside that is an 
analogue of Thymidine and incorporates into the DNA only when the cell is 
synthesizing new DNA in Synthesis Phase (S Phase), therefore it is a marker of cells 
in S Phase of the cell cycle. BrdU itself cannot be detected in flow cytometry 
analysis on its own and so flow cytometry requires the use of an anti-BrdU antibody 
(Becton Dickinson) and secondary anti-mouse-IgG-FITC-conjugated antibody.  
Propidium Iodide is a fluorescent molecule that intercalates into DNA and is used to 
determine DNA content of the cell. By knowing the DNA content of a cell, the phase 
of the cell cycle a cell is in can also be determined. For example, cells in G2 Phase of 
the cell cycle have double the DNA content of those in G1 Phase of the cell cycle, 
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therefore there is double the amount of Propidium Iodide in a G2 Phase cell than that 
of a G1 Phase cell. This can be plotted and shown in a graph. When used together, 
these two reagents are used to define the progression of cells through the cell cycle. 
Cells were labelled by adding BrdU to a final concentration of 30 µM and incubated 
for 15 min at 37 °C. Cells were then washed with 1 X PBS and trypsinised, then 
centrifuged at 1000 rpm for 5 min. After centrifugation, cells were re-suspended in 1 
ml of 1 X PBS to which 3 ml cold 100 % ethanol was added. Subsequently this was 
then incubated overnight at 4 °C. The suspension was centrifuged at 2500 rpm for 5 
min and the pellet re-suspended in 2 ml pre-warmed pepsin (1 mg/ml) in 30 mM HCl 
(pH 1.5) and incubated at 37 °C for 30 min with agitation. Following another 
centrifugation step, the pellet was re-suspended in 1 ml of 2 M HCl and incubated at 
room temperature for 15 min, after which a further 1 ml of 1 X PBS was added and 
sample centrifuged. The pellet was once again washed with 1 X PBS, centrifuged 
and washed with flow cytometry antibody buffer (See Section 2.1 Reagents and 
Buffers). The pellet was re-suspended in 1 ml of antibody buffer containing Anti-
BrdU antibody at a dilution of 1 in 50 and incubated at room temperature for 1 h. 
The volume in the tube was consequently made up to 1 ml 1 X PBS and centrifuged. 
The pellet was re-suspended in 1 ml antibody buffer containing anti-mouse IgG  
FITC conjugated antibody (diluted 1 in 64) and incubated at room temperature for 30 
min. The volume in the tube was made up to 1 ml 1 X PBS and centrifuged, and then 
the pellet re-suspended in 500 µl 1 X PBS containing 25 µg/ml propidium iodide. 
The tubes were wrapped in aluminium foil and analysed on the fluorescence-
activated cell sorter (FACScan flow cytometer, Becton Dickinson).  
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2.2.11 RNA Extraction  
RNA extraction was carried out using the RNeasy Mini Kit and QIAshredder 
(Qiagen). RLT Lysis Buffer, supplied with the kit, was supplemented with 2-
mercaptoethanol (4 % w/v final concentration). From this 250 µl was added to each 
plate of HCT116 (HCT116 and the p53-null and p21-null derivatives) cells. Each 
lysate was collected and put into individual QIAshredder mini spin columns and 
centrifuged at 14000 rpm for 2 min. 350 µl 70 % ethanol was added to the 
supernatant of each sample and each lysate put into individual RNeasy mini spin 
columns and centrifuged at 14000 rpm for 15 sec. The columns were washed with 
700 µl RW1 Wash Buffer, the supernatants were discarded and then the columns 
were washed twice with 500 µl RPE Wash Buffer, discarding the supernatants after 
each centrifugation. The RNA was then eluted from each column with 30 µl RNase 
free ddH2O.  
The concentration of RNA was determined by measuring of the absorbance at 260 
nm (A260) in an Ultraspec 2000 UV/visible spectrophotometer (Pharmacia Biotech). 
 
2.2.12 cDNA Synthesis 
Total RNA extracted, as described in the previous Section, was used as the template 
for the production of cDNA. To ensure there was no DNA in the RNA sample a 
DNase reaction was carried out by incubating 1 µg RNA with 2 µl 5 X First Strand 
Buffer (Promega), 1 µl RQ1 DNase (Promega) made up to 10 µl with 
Diethylpyrocarbonate (DEPC) treated H2O (RNase free water) (Fisher Scientific) and 
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subsequently incubated at 37 °C for 30 min. 1 µl of RQ1 DNase Stop Solution 
(Promega) was added to each sample which was then incubated at 65 °C for 10 min 
to stop the reaction.  
cDNA was synthesised by reverse transcription, this reaction was initiated by adding 
11 µl of the previous reaction to 2 µl DEPC treated H2O and 1 ul (300 ng) random 
hexamer (Invitrogen) and incubating at 70 °C for 10 min before chilling on ice.  
After chilling, 2 µl 5 X First Strand Buffer, 2 µl PCR Nucleotide Mix (40 mM, 
Promega) , 1 µl 0.1 M DTT and 1 µl MMLV Reverse Transcriptase (Invitrogen) was 
then added and reaction mixes incubated at 25 °C 10 min, 37 °C 1 h and 70 °C 15 
min. The subsequent synthesized cDNA was then diluted back to a ratio of 1:36.  
 
2.2.13 Taqman Real Time PCR 
cDNA, synthesised as described in the previous Section, was used as the template for 
Taqman RT-PCR. For this particular Taqman reaction, two primers and a probe are 
required, as shown in Figure 2.1. The primers (Applied Biosystems) are designed to 
bind to a particular sequence of the cDNA, which encodes the gene of interest. The 
probe (Applied Biosystems) is also specific for a target cDNA sequence and is 
labelled with a 5’ 6-FAM (6-carboxyfluorescein) reporter dye and a 3’ TAMRA 
(tetramethylrhodamine) quencher dye. Together, the primers amplify the region in 
the gene of interest, in doing so dislodge or cleave the probe from the DNA. The 
cleavage results in the reporter dye being separated from the quencher dye allowing 
it to emit fluorescence which can then be measured. The amount of fluorescence is 
directly proportional to the amount of product generated by the PCR, and to the cycle 
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at which the fluorescence reaches a threshold where it is significantly higher than 
background. This threshold can be converted to the value “counts to threshold” or CT 
value. The CT value characterises the reaction.  
 
Figure 2.1: Representation of the Real Time Taqman PCR reaction 
The probe consists of a reporter (R), in this case FAM and a Quencher (Q), TAMRA. The primers and 
probe attach to their target sequences on the cDNA. When initiated, the polymerase chain reaction 
allows the primers to synthesise a new copy of the DNA, in doing so, the 5' nuclease activity of Taq 
DNA polymerase cleaves off the probe and quencher, allowing the probe to fluoresce in the absence 
of the quencher. 
 
Taqman reactions were carried out in MicroAmp optical 96 well reaction plates. 
Each well contained 0.6 µl Taqman Gene Expression Assay 20 X Mix (consisting of 
primers and probe, Applied Biosystems), either for PLK1 or β-ACTIN, (see Table 
2.4) 6 µl Taqman 2 X Universal PCR Mix (Applied Biosystems), made up to 10 µl 
88 
 
 


 
with DEPC treated H2O and 2 µl cDNA. Amplification and analysis were carried out 
in an ABI PRISM 7700 Sequence Detector (Applied Biosystems). The PCR reaction 
itself was carried out as follows: 50 °C for 2 min, 95 °C for 10 min and 40 cycles of 
95 °C for 15 sec followed by 60 °C for 1 min. All reactions were performed in 
triplicate and to check there was no contamination. Control reactions containing no 
DNA were carried out alongside the other samples in separate wells. The probes used 
are given below in Table 2.4. 
 
Gene Target of Primers/Probe Number 
PLK1 00983229_m1 
β-ACTIN Hs99999903_m1 
 
Table 2.4: Gene expression Assays used in Taqman Real Time PCR 
 
2.2.14 Chromatin Immunoprecipitations (ChIP) 
Chromatin Immunoprecipitations involve immunoprecipitation of protein/DNA 
complexes. This involves the conjugation of an antibody to a protein which is bound 
to a proposed sequence of DNA, as shown in Figure 2.2. The method, initially 
involves the cross linking of DNA or protein/DNA complexes in the cell. Once cross 
linked, the cells can then be collected and lysed. Following this the sample is 
sonicated to further lyse the cells and to shear the DNA to produce fragments smaller 
than 1 Kb. Subsequently the sample can then be used in an immunoprecipitation 
reaction. The protein of interest together with any associated proteins are then 
indirectly bound to synthetic beads that recognize and bind to the antibody. The 
89 
 
 


 
beads are then serially washed allowing purification of the bead and protein complex. 
Once purified, the protein and any bound DNA is eluted. This is followed by the 
reversal of the cross linking of protein to DNA and the DNA subsequently purified 
ready for amplification, either by Polymerase Chain Reaction (PCR) or Taqman Real 
Time PCR.  
 
 
Figure 2.2: Representation of Chromatin Immunoprecipitation 
Chromatin Immunoprecipitations require an antibody that binds specifically to the protein of interest. 
The protein binds specific DNA sequences, and the whole complex can be purified by binding the 
antibody to protein A beads. Once purified, the complex is disrupted and the DNA itself purified. The 
DNA can then be amplified up using PCR. 
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Cells (U2OS) were seeded at 2 X 106 per 10 cm plate and maintained in the 
incubator overnight at 37 °C. Etoposide (100 µM final concentration) and Nutlin-3 
(10 µM) were added for 6 h (for each treatment, 3 plates were treated), after which 
the medium was removed and the cells cross linked by adding 1.5 % (w/v) 
paraformaldehyde for 10 min. The plates were subsequently washed with cold 1 X 
PBS and cells scraped into ChIP Collection Buffer (see Section 2.1 Reagents and 
Buffers). Cells were centrifuged at 1000 rpm for 10 min at 4 °C, the supernatant was 
removed and the cell pellet lysed in 150 µl ChIP Lysis Buffer. Lysates were 
incubated on ice for 10 min. In order to fully lyse the cells and reduce the length of 
the DNA to below 1Kb the lysates were sonicated for 20 sec at 10 microns, 7 times 
each, leaving 1 min on ice in between each sonication to prevent the overheating and 
DNA denaturation. A small sample of the lysate was run on a gel to check sonication 
efficiency, which if efficient should yield DNA of fragments of around 200-1000 bp 
DNA. The lysate was then centrifuged and supernatant diluted 7-fold into ChIP 
Dilution Buffer, 500 µl of lysate was used for each immunoprecipitation. In order to 
remove any unspecific DNA, the lysate was pre-cleared with 20 µl of a 50 % (w/v) 
slurry of Protein A beads and Salmon testes DNA (2 µg) on a rotating wheel for 2 h 
at 4 °C. After this, the lysate was then centrifuged at 2000 rpm for 3 min and 400 µl 
of the supernatant removed into a fresh tube, to which 3 µg anti-p53 (DO-1) antibody 
was added overnight at 4 °C. The remaining 100 µl of lysate was stored at -80 °C for 
use as an input sample to show overall protein and DNA in the lysate. To remove any 
unspecific binding of proteins and/or DNA, the beads were then serially washed with 
ChIP Low Salt Buffer, ChIP High Salt Buffer, ChIP LiCl Buffer (as described in the 
Buffers and Reagents Section) and twice with 1 X TE on a rotating wheel at 4 °C for 
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5 min then centrifuged at 4 °C, 2000 rpm 3 min. The protein/DNA complexes were 
then eluted from the beads by the addition of 50 µl 1 % (w/v) SDS/0.1 M NaHCO3 
for 15 min on a rotating wheel at room temperature. This step was repeated so that 
there was a final volume of 100 µl. Reversal of cross linking of the samples and 
inputs was achieved by adding 4 µl 5M NaCl and 1 µl RNase A and placing in a 
water bath at 65 °C overnight. The next day DNA was recovered by adding 4 µl 1M 
Tris pH 6.5, 2 µl 0.5M EDTA pH 8 and 2 µl of 10 mg/ml Proteinase K and placing 
samples in a water bath at 45 °C for 1 h. Finally DNA was purified from the sample 
using the QIAquick gel extraction kit (Qiagen) and stored at -20 °C. PCR was 
performed on the DNA and is described in 2.4.16. 
 
2.2.15 Electrophoretic Mobility Shift Assay (EMSA) 
Electrophoretic mobility shift assay is an in vitro technique used to identify proteins 
binding to specific DNA sequences or oligonucleotides which are labeled with, for 
example, 32P. When the DNA is bound to a protein, the complex moves slowly 
through the gel compared to the uncomplexed DNA and an overall shift can be seen 
when the gel is exposed to X-ray film. To further identify the protein which has 
bound to the DNA, an antibody against the protein can be used. This will cause a 
further shift in the gel which can be seen when the gel is exposed to X-ray film.   
The first step of the EMSA was to anneal the pairs of oligonucleotides together into 
double stranded DNA (see Table 2.5). This was done by boiling the oligonucleotides 
(50 µl 100 pmol/µl), with 100 µl 10 X TE, 25 µl 4 M NaCl and 775 µl ddH2O at 100 
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°C for 10 min and then cooling to room temperature. After this reaction, double 
stranded DNA is 5 pmol/µl.  
The DNA was then labelled with 32P by adding the DNA (2 µl, 10 µg/µl) to 1 µl 10 X 
Buffer for T4 Polynucleotide Kinase (Promega), 7µl [γ-32P] ATP (0.37 Mbq/µl) and 
1 µl diluted T4 PNK (10 U/µl) and incubating at 37 °C for 30 min. The sample was 
then run on an 8 % TBE gel for 30 min at 150 V. Once run, the gel was then exposed 
to Fuji-Super RX Medical X-ray film and developed in a Fuji film processor. The 
position of DNA was marked on the gel and the marked site was excised from the 
gel. The gel slice was then incubated in 0.5 ml 1 X TE at 37 °C overnight. The next 
day the tube was centrifuged and the supernatant containing the labelled DNA was 
transferred into a fresh tube and stored at -20 °C.  
The binding reaction of the EMSA was assembled by adding 2 µl 32P labelled DNA 
to 2 µl EMSA p53 5 X Binding Buffer (see Section 2.1 Reagents and Buffers), 1 µl 
purified p53 protein (generously supplied by Prof Ted Hupp, University of 
Edinburgh), 1 µl PAb421 antibody, which is a specific antibody for p53, and 4 µl 
ddH2O. Reactions were incubated at 4 °C for 20 min followed by 10 min at room 
temperature. The bound samples were then run on a 4 % polyacrylamide gel for 2 h 
30 min at 150 V at 4 °C, the gel was then vacuum dried and exposed to Fuji-Super 
RX Medical X-ray film and developed.  
 
 
 
93 
 
 


 
Name and pairs 
of Oligo-
nucleotides 
Sequence 
PLK1 for  
PLK1 rev 
GCCGGGCATGGTGGTGCATGCTTGTA 
TACAAGCATGCACCACCATGCCCGGC 
PLK1mut for 
PLK1mut rev 
GCCGGGCATGGTGGTGGATTGTTGTA 
TACAACAATCCACCACCATGCCCGGC 
PG for 
PG rev 
AGCTTAGACATGCCTAGACATGCCTA 
AGCTTAGGCATGTCTAGGCATGTCTA 
TL for 
TL rev 
TATGTCTAAGGGACCTGCGGTTGGCATTGATCTTG 
GTGCCAAGATCAATGCCAACCGCAGGTCCCTTAGACA 
 
Table 2.5: Sequences of oligonucleotides used in EMSA.  
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2.3 Protein Biology Techniques 
2.3.1 SDS PAGE Analysis of Proteins 
Analysis of proteins by SDS-PAGE was carried out using the method of Laemmli 
(Laemmli, 1970) with a vertical Slab Electrophoresis Chamber apparatus (Atto) and 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) Running 
Buffer (1 X). The resolving gel contained 382 mM Tris-HCl, pH 8.8, 0.1 % (v/v) 
SDS, 0.1 % (v/v) ammonium persulfate, plus acrylamide added to the desired 
concentration (7.5 % - 15 %) from a stock of 30 % (w/v) acrylamide, 0.8 % (w/v) 
bis-acrylamide (Severn Biotech Ltd.). Polymerisation was initiated by the addition of 
0.7 µl/ml N,N,N’,N’-tetramethylethylenediamine (TEMED). The resolving gel was 
overlaid with a stacking gel consisting of 123 mM Tris-HCl, pH 6.8, 1 % (v/v) SDS, 
0.1 % (v/v) ammonium persulfate, 4.9 % (v/v) acrylamide and 1.16 µl/ml TEMED. 
Protein samples containing 5 X SDS sample buffer were incubated at 100 °C for 3 
min and centrifuged at 14000 rpm for 30 sec. Samples were loaded onto the gel and 
subjected to electrophoresis at 120 V until the samples passed into the resolving gel, 
where the voltage was increased to 180 V and run until the dye front had reached the 
bottom of the resolving gel. 5 µg of Pageruler Prestained Protein Ladder (Fermentas) 
was loaded on the gel, along with the samples, to estimate the molecular weight of 
proteins. 
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2.3.2 Western blotting  
Following the separation of proteins by SDS-PAGE, proteins were transferred to a 
Hybond ECL nitrocellulose membrane (Amersham) using either semi-dry blotting 
apparatus (Biometra) or wet transfer blotting apparatus (Bio-Rad) in the appropriate 
Western transfer buffer. Semi-dry transfer was carried out at 200 mA for 45 min and 
wet transfer was carried out at 25 mA overnight or 1 h at 200 mA. Subsequently the 
membrane was blocked for 1 h at room temperature (RT) in Western blocking buffer 
and then incubated overnight at 4 °C with the primary antibody (See Table 2.6). 
The membrane was washed for 3 x 5 min in Western blocking buffer, then incubated 
with the appropriate horseradish peroxidase-conjugated secondary antibody (see 
Table 2.7) in Western blocking buffer for 1 h at RT. Subsequently the membrane was 
washed for 1 x 5 min in Western blocking buffer and 3 x 5 min in Western washing 
buffer, before the addition of enhanced chemiluminescence reagents (See Section 2.1 
Reagents and Buffers). Equal volumes of ECL solution 1 and ECL solution 2 were 
mixed together and applied uniformly to the membrane for 1 min. Excess solution 
was removed from the membrane and the membrane exposed to Fuji-Super RX 
Medical X-ray film and developed in a Fuji film processor.  
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Antibody Species Supplier Epitope Western Blot Concentration 
Cyclin A Rabbit Abcam aa 26-144 1:1000 
MDM2 
(SMP14) Mouse Santa cruz aa 154-167 1:2000 
MDM2 (4B2) Mouse Moravian N-terminus 1:2000 
p53 (DO-1) Mouse Santa cruz aa11-25 1:1000 
p21 (H-164) Rabbit Santa cruz C-terminus 1:1000 
PLK1 Rabbit Cell Signalling Technology C-terminus 1:1000 
PLK1 Mouse Zymed aa402-603 1:1000 
phospho-
Histone 3 Rabbit Upstate aa7-20 1:5000 
acetyl-
Histone 3 Rabbit Upstate aa 1-20 1:5000 
PARP 
(Cleaved) Mouse AbDSerotec C-terminus  1:5000 
14-3-3 Goat Santa cruz C-terminus 1:1000 
β-Actin (20-
33) Rabbit Sigma aa 20-33 1:5000 
 
Table 2.6: List of primary antibodies used in Western blotting 
 
Antibody Species Supplier Western Blot Concentration 
Anti Mouse Horse Radish 
Peroxidase Conjugated Mouse Santa Cruz 1:2000 
Anti Rabbit Horse Radish 
Peroxidase Conjugated Goat Santa Cruz 1:5000 
Anti Goat Horse Radish 
Peroxidase Conjugated Donkey Santa Cruz 1:1000 
 
Table 2.7: List of secondary antibodies used in Western blotting 
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2.4 DNA Purification, Amplification and Manipulation Techniques 
2.4.1 Preparation of plasmid DNA  
Plasmid DNA was isolated from an overnight culture of E.coli, grown at 37 °C, 
using the PureLink Hipure Plasmid DNA purification kit from Invitrogen, Mini 
Preparation. A single colony of bacteria was used to inoculate 5 ml of LB, 
supplemented with the appropriate selective antibiotic (Ampicillin 100 µg/ml) and 
grown overnight at 37 °C. Following the user manual given with the kit, DNA was 
purified from 3 ml of the overnight culture and was eluted into 50 µl ddH2O. Each 
prep gives up to 20-30 µg DNA.  
In a scaled up plasmid preparation, a single colony of bacteria was used to inoculate 
5 ml LB, supplemented with the appropriate antibiotic and grown overnight. 400 ml 
of LB, supplemented with the appropriate antibiotic was then inoculated with 1ml of 
the initial inoculation and grown overnight at 37 °C. The PureLink Hipure Plasmid 
DNA purification kit, Maxi Procedure, was used to isolate the DNA from the 
bacteria and DNA was eluted into 300 µl ddH2O.  
For each plasmid preparation from the large scale method, the concentration of 
plasmid  DNA was determined by measurement of the absorbance at 260 nm (A260) 
in an Ultraspec 2000 UV/visible spectrophotometer (Pharmacia Biotech), assuming 
that a solution of double-stranded DNA at 50 µg/ml has an A260 of 1.0. Stocks of 
plasmids were made at 1 µg/µl. 
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2.4.2 Preparation of BAC DNA  
Bacterial Artificial Chromosome (BAC) DNA was isolated from an overnight culture 
of E.coli, grown at 37 °C in LB supplemented with Chloramphenicol (20 µg/ml).  
3ml of the overnight culture was centrifuged at 3000 rpm for 3 min, re-suspended in 
300 µl Buffer P1, and lysed by the addition of 300 µl Buffer P2.  300 µl Buffer P3 
was then added and the lysate incubated on ice for 5 min. The lysate was then spun at 
10,000 rpm for 10 min at 4 °C and the supernatant then transferred into a tube 
containing 800 µl ice cold isopropanol before further incubation on ice for a 5 min. 
The lysate was incubated at -80 °C for 30 min, after which the lysate was spun again 
at 10,000 rpm for 15 min. The supernatant was removed and 500 µl 70 % (v/v) 
ethanol added to the pellet and before centrifuging for 5 min, this step was then 
repeated. The supernatant was removed and the pellet was then air dried and re-
suspended in 50 µl ddH2O. The concentration of BAC DNA was determined by 
spectrometry.  
 
2.4.3 Separation of DNA using agarose gel electrophoresis 
For separating out DNA, a 1 % agarose gel was made containing 1 X TAE, agarose 
and ethidium bromide (400 ng/ml). Agarose Gel Loading buffer (5 X) was added to 
the samples which were subsequently run on a gel submerged in 1 X TAE buffer for 
1 h at 100 V using a horizontal submerged agarose gel electrophoresis unit (Atto). 5 
µg of a 1 Kb DNA ladder (Invitrogen) was also run on the gel in order to determine 
the size of the electrophoresed DNA. The DNA in the gel was then visualized using a 
UV-transilluminator and photographed.  
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2.4.4 Amplification of DNA using PCR (Polymerase Chain Reaction) 
DNA was amplified by Polymerase Chain Reaction using a thermal cycler (Techne). 
The PCR reaction consisted of: 1 µl DNA from the preparation of BAC DNA, 10 µl 
5 X Phusion GC Buffer (Finnzymes), 1 µl PCR Nucleotide Mix (Promega), 2.5 µl 
forward and 2.5 µl reverse primers (5 pmol each, MWG) (Table 2.8), 1 µl DMSO 
(Sigma), 0.5 µl (1 U) Phusion High fidelity DNA polymerase (Finnzymes) and 
ddH2O up to a volume of 50 µl. The PCR cycle was as follows: Initial denaturation 
95 °C 5 min, followed by 30 cycles of the following steps, denaturation at 95 °C 1 
min, annealing at 59 °C 1 min, extension at 72 °C 2 min 30 secs. After the 30 cycles 
there was a final extension at 72 °C for 7 min.  
 
Name of Primer Sequence 
PLK23 GAATTAAGGAGGAAGCCACCTG 
PLK25 GCTCCTCCCCGAATTCAAAC 
 
Table 2.8: Sequences of primers used in PCR reaction to amplify PLK1 promoter 
 
2.4.5 Purification of PCR products using electrophoresis 
Amplified DNA from the PCR reaction was separated using agarose gel 
electrophoresis and subsequently purified using electrophoresis. The band was 
extracted from the gel using a sterile scalpel under UV light. The gel slice was put 
into dialysis membrane (Size 1 12-14kDa, Medicell International) and the tubing 
filled with 1 X TAE. This was then electrophoresed for 1 h to elute the DNA from 
the gel slice and reverse electrophoresed for 1 min to remove the DNA from the 
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tubing. The eluted DNA was then put into a tube and 10 % (w/v) sodium acetate pH 
5.4 and three times the volume of 100 % (v/v) ethanol added to it. The sample was 
then incubated on dry ice for 20 min, and centrifuged before re-suspending the pellet 
in ddH2O.  
 
2.4.6 Ligation of PCR DNA into plasmid 
Purified PCR DNA was ligated into a plasmid vector (pSC-B), using the following 
reaction: 3 µl StrataClone™ Blunt Cloning Buffer, 2 µl PCR product and 1 µl 
StrataClone™ Blunt Vector Mix (all StrataClone), see Figure 2.3. The mixture was 
incubated at room temperature for 5 min and transformed into StrataClone SoloPack 
competent cells, as described in the next Section.  
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Figure 2.3: pSC-B plasmid vector from the Strataclone™ Blunt PCR Cloning Kit  
The vector consists of a PCR insertion site, Ampicillin resistance gene and origin of replication site. 
The PCR product was inserted into the PCR insertion site. Figure taken from StrataClone Blunt 
Cloning Kit Manual, Stratagene.  
 
2.4.7 Transformation of plasmid DNA into competent StrataClone SoloPack 
competent bacteria  
StrataClone SoloPack competent bacteria (Stratagene, 50 µl) were thawed out on ice 
and 2 µl of ligation mix added. Cells were kept on ice for 20 min and then heat 
shocked at 42 °C for 45 sec before returning to ice for a further 2 min. SOC Broth 
was prepared from SOB Broth (see Section 2.1, Reagents and Buffers), 250 µl of 
which was then added to the cells which were then left to recover for 1 h at 37 °C 
with agitation. LB-Ampicillin (100 µg/ml) -Xgal, (5-Bromo-4-chloro-3-indoyl-β-D-
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Galactopyranside, 100 µg/ml) plates were prepared and the transformation mixture 
spread over the plate. The plate was incubated at 37 °C overnight.  
 
2.4.8 DNA sequencing 
DNA sequencing was carried out by the DNA Analysis Facility, Human Genetics 
Unit, University of Dundee, Ninewells Hospital and Medical School, Dundee, 
Scotland.  
 
2.4.9 Restriction enzyme digestion 
Restriction digests were carried out using the appropriate restriction enzymes and 
buffers (NEB) which were supplemented with BSA, 100 µg/ml (NEB), if needed 
according to the manufacturer’s instructions. 1 µg DNA was digested if the reaction 
was carried out for analytical purposes or 5 µg DNA was digested if the digested 
DNA was to be excised and purified for use in further cloning. 10 U of restriction 
enzyme was used in a 20 µl digestion reaction and the reaction incubated at 37 °C for 
1 h. The digested DNA was run on a 1 % agarose gel and the appropriate band of 
DNA excised using a sterile scalpel under UV light before being purified. 
 
2.4.10 Purification of restriction enzyme digested DNA 
Restriction enzyme digested DNA was purified from the agarose gel slice using the 
following method. A 0.5 ml microtube was pierced with a hole in the bottom and 
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filled with glass fibre. The gel slice was then added to this and then incubated on dry 
ice for 15 min. The microtube was then placed into an eppendorf tube and 
centrifuged at 14000 rpm for 10 min. The microtube was discarded and the volume 
of supernatant was added up to 150 µl with ddH2O and 150 µl butanol before a 
further centrifugation step. A bilayer formed with the top phase containing the 
butanol and ethidium bromide, which was then removed by pipette. 50 µl 3 M 
sodium acetate, pH 5.4, and 1 ml 100 % ethanol was added and the sample 
centrifuged again. The supernatant was then removed and the pellet washed with 70 
% ethanol. The ethanol was removed and the pellet, containing the DNA, was re-
suspended in ddH2O.  
 
2.4.11 Ligation of digested DNA into the plasmid vector, pGL3 
Restriction enzyme digested DNA was ligated into the pGL3-Basic Vector plasmid 
(Figure 2.4) (Plasmid DNA was digested with restriction enzymes that would 
produce complementary overhangs to overhangs created by other restriction enzymes 
in the insert DNA). The ligation reaction was carried out using a 1:5 molar ratio of 
vector to insert with 10 X ligase buffer (Promega) and 1 U of T4 DNA Ligase 
(Promega). The reaction was incubated at 16 °C overnight.  
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Figure 2.4: pGL3 vector (Promega)  
The vector consists of an Ampicillin resistance gene, Luciferase gene and origin of replication site. 
The restriction enzyme digested DNA was inserted into the plasmid via two restriction digest sites 
situated upstream of the Luciferase gene (Luc+).  Figure taken from pGL3 Vectors Manual, Promega. 
 
2.4.12 Transformation of competent E.coli bacteria 
Transformation of competent E.coli cells was carried out using 50 µl of DH5α 
competent cells. 10 µl ligation mixture, or 10 ng uncut plasmid was incubated with 
50 µl cells for 30 min at 4 °C and cells then heat shocked at 37 °C for 3 min. The 
transformation reaction was further incubated on ice for 2 min and then incubated 
with 1 ml LB for 1 h at 37 °C with agitation, to allow the cells to recover. LB-
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Ampicillin (100 µg/ml plates were prepared and the transformation mixture spread 
over the plate. The plate was incubated at 37 °C overnight.  
 
2.4.13 Preparation of competent cells 
An overnight culture of the appropriate E. coli strain was used to inoculate  200 ml of 
fresh LB and grown until the cells reached mid log phase (OD600 = 0.3).  The culture 
was transferred to sterile centrifuge tubes and incubated on ice for 30 min. Cells were 
pelleted by centrifugation at 2,000 rpm for 5 min at 4 °C. The bacterial pellets were 
then re-suspended in 16 ml of Transformation buffer 1 (see Section 2.1 Reagents and 
Buffers) per 50 ml of original culture and incubated on ice for 15 min. The cells were 
pelleted by centrifugation as before and re-suspended in 4 ml of Transformation 
buffer 2 per 50 ml of original culture. The competent cells were aliquoted, snap-
frozen in liquid nitrogen and stored at -80 °C. 
 
2.4.14 Bacterial glycerol stocks  
Stocks of transformed bacteria were prepared for future use and stored in 25 % 
glycerol at -80 °C. A single colony of transformed bacteria was grown up overnight 
at 37 °C in 5 ml of LB medium containing the appropriate selective antibiotic. 1 ml 
of the overnight culture was then mixed with 1 ml of sterile 50 % (v/v) glycerol and 
cells were then snap frozen on dry ice and stored at -80 °C. 
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2.4.15 Site Directed Mutagenesis 
In order to introduce a mutation(s) to a particular sequence of the DNA in the 
PLK1promoter/pGL3-Basic Vector plasmid, QuikChange® Site Directed 
Mutagenesis Kit from Stratagene was used. In principle, PCR, using primers 
designed with the desired mutation, is carried out using the nonstrand-displacing 
action of the PfuTurbo DNA polymerase, supplied with the kit, which creates nicked 
circular strands. Once the PCR has been carried out, Dpn1 which is an enzyme that 
digests the methylated or the parental DNA, is then added to the PCR reaction. After 
the parental DNA has been digested the daughter DNA can then be transformed into 
XL1-Blue supercompetent cells (supplied with the kit) which have the ability to 
repair the nicks in the mutated plasmid.  
Plasmid DNA (50 ng) was added to 5 µl 10 X Reaction Buffer and 1 µl PfuTurbo 
DNA polymerase (supplied with the kit), 1.25 µl (125 ng each) of forward and 
reverse primers (Table 2.9), 1 µl PCR Nucleotide Mix (Promega), in a total volume 
of 50 µl. The PCR cycle was as follows: Initial denaturation 95 °C 4 min, followed 
by 18 cycles of the following steps, denaturation at 95 °C 30 sec, annealing at 65 °C 
1 min and extension at 68 °C 8 min. 
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Name of Primer Sequence 
PLKmut1 GGGCATGGTGGTGGATTGTTGTAATTCCAGCTGC 
PLKmut1rev GCAGCTGGAATTACAACAATCCACCACCATGCCC 
DMCDECHR5 GTAACGTTCCCATATCCGCGTTCACATTCGGGGAG
GAG 
DMCDECHR3 CTCCTCCCCGAATGTGAACGCGGATATGGGAACGT
TAC 
 
Table 2.9: Sequence of primers used to incorporate the mutation(s) into the PLK1 promoter 
 
After PCR, 1 µl Dpn I restriction enzyme, supplied with the kit, was added and 
incubated at 37 °C for 1 h to digest the un-mutated, template plasmid DNA. Once 
digested, 1µl of the digestion reaction was transformed into XL1-Blue 
supercompetent cells, supplied with the kit, by incubating the cells and DNA on ice 
for 15 min, heat-shocking at 42 °C for 45 sec and incubating with 1 ml LB for 1h at 
37 °C with gentle agitation.  LB-Ampicillin (100 µg/ml) plates were prepared and the 
transformation mixture spread over the plate. The plate was incubated at 37 °C 
overnight.  
 
2.4.16 Amplification of ChIP DNA using PCR 
DNA from the ChIP protocol was amplified by Polymerase Chain Reaction using a 
thermal cycler (Techne). The PCR reaction consisted of: 2.5 µl input DNA or 1 µl IP 
DNA, 10 µl 10 X Buffer (Promega), 1 µl PCR Nucleotide Mix (Promega), 4 µl 
forward and 4 µl reverse primers (5 pmol each, MWG) (Table 2.10), 3 µl MgCl2 
(Promega), 0.25 µl (1 U) Flexi GoTaq polymerase (promega) and ddH2O up to a 
volume of 50 µl. The PCR cycle was as follows: Initial denaturation 95 °C 4 min, 
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followed by 30 cycles of the following steps, denaturation at 95 °C 30 sec, annealing 
at 60/62 °C (p21 and PLK1 promoter primers respectively) 1 min, extension at 72 °C 
45 secs. After the 30 cycles there was a final extension at 72 °C for 5 min.  Samples 
were subsequently run on a non-Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis (non-SDS-PAGE) gel and subjected to electrophoresis with non-
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (non-SDS-PAGE) 
Running Buffer (1 X) at 120 V until the samples passed into the resolving gel, where 
the voltage was increased to 180 V and run until the dye front had reached the 
bottom of the resolving gel. 5 µg of a 1 Kb DNA ladder (Invitrogen) was also run on 
the gel in order to determine the size of the electrophoresed DNA. The DNA in the 
gel was then visualized using a UV-transilluminator and photographed.  
 
Name of 
Primer Target of Primers Sequence 
DMplk1RE25 PLK1 promoter AAAACCCCGCAAGACACATT 
DMplk1RE23 PLK1 promoter TGGTCAGAGGGAGGGAAGGT 
DMplk1RE2a5 PLK1 promoter GAGGCCAAACAAAACCCC 
DMplk1RE2a3 PLK1 promoter TGGACACTCAGTTTCTTCCTCA 
DMp215 p21 promoter GTGGCTCTGATTGGCTTTCTG 
DMp213 p21 promoter CTGAAAACAGGCAGCCCAAG 
 
Table 2.10: Sequences of primers used for PCR amplification of DNA from ChIP protocol 
 
2.4.17 Other plasmids 
pCDNA3 empty vector was provided by the lab of Professor Steve Keyse, bug stock 
number 439. Wild type human p53 full length in pCDNA3 was provided by Dr Nico 
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Dumaz, bacterial stock number 715. SV-Renilla Luciferase vector was provided by 
Dr Jean-Christophe Bourdon, bacterial stock 1427. p53 mutant his175ala in 
pCDNA3, was provided by Dr Jean-Christophe Bourdon and p53 mutant his273ala 
in pCDNA3 was provided by Dr Mark Saville, bacterial stocks 1509 and 1510, 
respectively. Lastly, p53 mutant L22Q/W23S in pCDNA3 and p21 HA tagged 
plasmid was provided by Dr Frances Fuller-Pace, bacterial stock 1582.  
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Chapter 3: p53 down-regulation of 
PLK1 
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3.1 Background 
The tumour suppressor, p53, is a major player in the DNA damage pathway which 
activates the expression of genes that promote cell cycle inhibition, senescence and 
apoptosis, depending on the type and level of DNA damage (Resnick-Silverman and 
Manfredi, 2006). Furthermore p53 mediates the repression of genes involved in cell 
growth and proliferation (Banerjee et al., 2009, St Clair and Manfredi, 2006). Many 
genes regulated by p53 are gradually coming to light and this chapter aims to show 
that Polo-like Kinase 1 or PLK1, a crucial regulator of the cell cycle, is down-
regulated by p53. 
In this chapter the down-regulation of PLK1 by p53 was investigated by using drug 
treatments and other approaches in established cell lines including HCT116 cells. 
HCT116 cells are a well characterised cell line originating from a human colon 
cancer tumour (Bunz et al., 1998). Of significant value, p53-null and p21-null 
derivatives of these cells are available and accordingly, are ideal cell lines to use in 
this study as they allow the contribution of p53 and p21 to be assessed (Bunz et al., 
1998, Bunz et al., 1999). The drug treatments utilised vary in terms of their 
mechanisms of action and allow the effects of p53 activation through different 
pathways to be assessed. Furthermore, they could potentially reveal differences in 
the mechanisms of PLK1 down-regulation depending on the pathways that have 
been activated.  
The down-regulation of PLK1 could occur at transcriptional or post-translational 
levels and so for this reason mRNA levels have also been considered in this chapter. 
Moreover, repression involves a variety of other proteins and pathways, as discussed 
in chapter 1, therefore this chapter has assessed the involvement of these. 
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3.2 Aims 
The aim of this chapter is to determine whether repression of Polo-Like Kinase 
(PLK1) occurs via the tumour suppressor, p53. 
 
3.3 Induction of p53 levels by Etoposide results in the decrease of PLK1 levels 
As discussed in Chapter 1, Etoposide is a potent activator of the p53 pathway and 
induces expression of p53. Figure 3.1 (A) shows the increase of p53, after the 
addition of Etoposide to HCT116 cells, over a 24 h period.  This is concomitant with 
an increase of its downstream target, p21, as expected. Notably, this is also 
concomitant with a decrease in PLK1. As a control β-Actin has also been probed to 
show that the protein levels are equal in each lane. Figure 3.1 (B) shows a titration of 
increasing concentrations of Etoposide on HCT116 cells. The results demonstrate 
p53 is induced by Etoposide in a concentration-dependent manner concomitantly 
with increasing p21 protein levels. In contrast, PLK1 protein levels decrease 
concentration-dependently. 
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Figure 3.1: PLK1 down-regulation is concomitant with increasing levels of p53 and p21 after 
Etoposide treatment in HCT116 wild type cells 
A) HCT116 wild type cells were treated with 100µM Etoposide and lysed at 2 h intervals over a 10 
h period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 3 independent experiments. B) HCT116 wild type cells were 
treated with increasing concentrations of Etoposide for 24 h. Lysates were then analysed by Western 
blotting with anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin 
antibodies. These Western blots are representative of 2 independent experiments.  
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These results confirm that Etoposide induces the p53 pathway in HCT116 cells. The 
decrease in PLK1 levels suggests the possibility that the p53 pathway is down-
regulating protein levels of PLK1.  
To determine whether the decrease in PLK1 protein levels is dependent on p53, 
additional experiments were carried out in parallel in the p53-null derivative of 
HCT116. As shown in Figure 3.2 (A) in the Etoposide time course and in the 
Etoposide titration (B), the levels of PLK1 protein do not decrease in the absence of 
p53. The lack of induction of p21 confirms the absence of a functional p53 pathway. 
Positive controls that were run alongside the p53-null cell lysates confirm that the 
p53 and p21 proteins could be detected by the Western blotting procedure.   
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Figure 3.2: PLK1 down-regulation is absent after Etoposide treatment in HCT116 p53-null cells 
A) HCT116 p53-null cells were treated with 100 µM Etoposide and lysed at 2 h intervals over a 10 h 
period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with anti-
PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These Western 
blots are representative of 3 independent experiments. B) HCT116 p53-null cells were treated with 
increasing concentrations of Etoposide for 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 2 independent experiments.   
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In conclusion these data show that Etoposide induced reduction in PLK1 protein is 
dependent on the presence of p53.   
PLK1 levels are regulated in a cell cycle dependent manner in many cell lines and 
are correspondingly low throughout G1 and S phase but increase throughout the G2 
phase and peak at mitosis (Hamanaka et al., 1995). This effect is mediated by 
transcriptional repression through the promoter element termed CDE/CHR, located 
within the core region of the PLK1 promoter (Uchiumi et al., 1997). Given that p53 
can arrest cells at the G1/S boundary by inducing p21 (Waldman et al., 1995), the 
decrease in PLK1 levels described above could simply reflect p53-dependent G1 
arrest. Alternatively, p53 itself or a downstream target of p53 could mediate the 
repression of PLK1 expression: for example, p21 is known to repress the expression 
of genes such as CDC25C (St Clair and Manfredi, 2006). Before testing these 
possibilities it was necessary to check whether PLK1 levels are indeed cell cycle-
dependent in our experimental system. 
 
3.4 PLK1 protein levels are regulated through the cell cycle 
To determine whether PLK1 levels change throughout the cell cycle, a double 
Thymidine block and release experiment was carried out using U2OS and HCT116 
cells. Thymidine has a negative feedback effect on nucleotide biosynthesis and can 
therefore prevent cells from entering S phase. The removal of the Thymidine then 
allows the cells to enter S phase and proceed throughout the cell cycle 
synchronously. A “double” Thymidine block ensures that the cells are as 
synchronous as possible. To check the synchrony of the cells, Western blots showing 
phosphorylated histone 3 (p-H3), which is a marker of mitosis (Hendzel et al., 1997), 
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and Cyclin A, which is a marker of S/G2 phase were carried out (Pagano et al., 
1992). As shown in Figure 3.3, phosphorylated histone 3 levels are high, as expected 
at around 12 h and 14 h (M phase) and Cyclin A levels are high, as expected, 
between 4 h to around 10 h (S/G2 phase). 
Examination of the PLK1 levels in these synchronous populations confirmed that 
PLK1 levels are elevated during the G2 and M phases of the cell cycle as reported 
for other cell lines (Golsteyn et al., 1995, Hamanaka et al., 1995).  
 
118 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Double Thymidine block and release showing that PLK1 is regulated through the 
cell cycle 
HCT116 wild type cells and U2OS cells were treated with Thymidine (2 mM) for 16 h and then grown 
for 8 h before Thymidine was added again for 16 h. After removal of Thymidine, a plate of cells was 
lysed every 2 h over a 24 h period and a final time point lysed at 24 h. An unsynchronised (Asyn) plate 
of cells was also lysed. Lysates were then analysed by Western blotting with anti-PLK1 antibodies, 
anti-pH3 antibodies, anti-Cyclin A antibodies and anti-β-Actin antibodies. These Western blots are 
representative of 3 independent experiments. 
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These data also support the possibility, as mentioned above, that the decrease in 
PLK1 levels observed after treatment with Etoposide simply reflects a substantial 
p53-mediated arrest at G1/S, a point in the cell cycle where PLK1 levels are 
naturally low. Our next aim was therefore to determine what effect the absence of 
p21 has on the down-regulation of PLK1. 
 
3.5 PLK1 down-regulation by Etoposide is not due to G1/S checkpoint arrest 
In order to test whether PLK1 can still be down-regulated in the absence of p21 (and 
therefore in the absence of a G1/S arrest), the p21-null derivative of HCT116 was 
treated, as before, with Etoposide. As shown in Figure 3.4 (A), the PLK1 protein 
levels decrease initially in the first 10 h. Interestingly, however, at 24 h the levels of 
PLK1 are higher than those in the controls lacking Etoposide or having DMSO 
alone. As shown in Figure 3.4 (A and B) the levels of p53 are found at higher levels 
after treatment with Etoposide but the p53 induction was impaired in comparison 
with the levels achieved in the wild type cells. The titration (B) shows that PLK1 
levels increase with various concentrations of Etoposide. 
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Figure 3.4: PLK1 down-regulation is concomitant with increasing levels of p53 after Etoposide 
treatment in HCT116 p21-null cells 
A) HCT116 p21-null cells were treated with 100 µM Etoposide and lysed at 2 h intervals over a 10 h 
period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 3 independent experiments. B) HCT116 p21-null cells were 
treated with increasing concentrations of Etoposide for 24 h. Lysates were then analysed by Western 
blotting with anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin 
antibodies. These Western blots are representative of 2 independent experiments. 
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These data suggest that the decrease of PLK1 levels is not dependent on p21. In 
order to confirm this, further experiments were carried out and are described below. 
While the results from the p21-null cells suggest that the down-regulation of PLK1 
could occur in the absence of this cell cycle inhibitor, it was necessary to check that 
Etoposide treatment did not result in a G1/S arrest in these cells. To do this, flow 
cytometry was carried out. In this procedure the cells are labelled with BrdU and, 
after harvesting, with a FITC- conjugated antibody. The cells were also labelled with 
propidium iodide to stain the DNA (as described in Chapter 2). The amount of DNA 
in each cell and the proportion of cells that were actively progressing through S 
phase in the time the cells were incubated with BrdU were calculated. Using these 
results, it was then confirmed what percentage of cells there were in each stage of the 
cell cycle (see Appendix). 
Prior to treating the cells with Etoposide, an optimisation experiment was carried out 
in order to determine the most appropriate density of cells for carrying out analysis. 
As shown in Figure 3.5, seeding of the HCT116 parental cells at the higher density 
showed that there were a greater proportion of cells in G2/M. In both p53- null 
derivatives and p21-null derivatives, the cell cycle profiles were very similar at each 
density.  
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Figure 3.5: Cell cycle profiles of HCT116 wild type, p53-null and p21-null at increasing densities 
This figure shows the flow cytometry data of different densities of HCT116 cells and their derivatives. 
Graph A shows the cell cycle profiles of the different densities of HCT116 wild type cells. Graph B, 
shows the HCT116 p53-null cells and Graph C, shows the HCT116 p21-null cells. These graphs are 
representative of 2 independent experiments. 
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Subsequent experiments were therefore carried out at a density of 2.5x105 or 1x106. 
To analyse whether the DNA damaging agent, Etoposide, inhibits the cell cycle at 
the G1/S checkpoint or G2/M checkpoint, individual plates of each cell line were 
treated in the absence or presence of Etoposide. Cells were then examined by flow 
cytometry, as described in Chapter 2 and the percentage of cells in each phase of the 
cell cycle, determined (see Appendix). Figure 3.6 shows that the percentage of 
HCT116 wild type cells in G1 phase and S phase of the cell cycle has decreased 
when they were treated with Etoposide. However, the percentage of cells in G2/M 
phase has increased. Furthermore, the addition of Etoposide in the p53-null cell 
derivatives decreases the percentage of cells in G1 phase. S phase cells increase 
slightly and the number of cells in G2/M increases. In p21-null cells the percentage 
of cells in G1 phase has decreased, likewise the number of cells in S phase has 
decreased. The number of p21-null cells in G2/M phase treated with Etoposide has 
increased compared to the untreated. 
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Figure 3.6: Cell cycle profiles of HCT116 wild type, p53-null and p21-null at two densities in the 
absence and presence of Etoposide 
This figure shows the flow cytometry data of two densities of HCT116 cells (2.5x105 and 1x106) and 
their derivatives in the absence and presence of Etoposide (100 µM). Graph A shows the cell cycle 
profiles of the HCT116 wild type cells in the absence and presence of Etoposide. Graph B, shows the 
HCT116 p53-null cells and Graph C, shows the HCT116 p21-null cells. These graphs are 
representative of 2 independent experiments. 
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Taken together, these results show that the decrease seen in PLK1 levels when cells 
are treated with Etoposide is not due to an inhibition of the cell cycle at the G1/S 
checkpoint when PLK1 levels are low. 
Interestingly, the results also show that G2/M checkpoint inhibition by Etoposide is 
not dependent on either p53 or p21 (Stark et al., 2006, Taylor et al., 2001b). 
Etoposide is a DNA damaging agent which activates many DNA damage pathways, 
including the p53 pathway. Therefore other pathways may also contribute to G2/M 
checkpoint arrest and arrest by Etoposide. 
In order to elucidate whether p53 induction is sufficient to down-regulate PLK1 in 
the absence of DNA damage, similar experiments were carried out with the MDM2 
inhibitor, Nutlin-3 and described in the next Section. 
 
3.6 Induction of p53 levels by Nutlin-3 results in PLK1 down-regulation 
As Nutlin-3 induces p53 and the p53 pathway in a non DNA damage dependent 
manner and induces cell checkpoint arrest (Vassilev et al., 2004), our next aim was 
to determine whether down-regulation of PLK1 by Nutlin-3 is indeed dependent on 
p53. 
To answer this, HCT116 cells and their derivatives were treated with Nutlin-3. 
Figure 3.7 (A), shows HCT116 wild type cells treated with Nutlin-3 over a 24 h 
period. As expected, p53 levels increase over time, which is concomitant with 
increasing levels of p21. PLK1 levels, however, decrease suggesting a role for p53 in 
PLK1 down-regulation. Figure 3.7 (B) shows that with increasing concentrations of 
Nutlin-3, p53 and p21 levels increase. As expected, PLK1 levels decrease.  
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This result shows that Nutlin-3 induces a p53 response which stimulates a decrease 
in PLK1 levels. This suggests that p53 mediates the down-regulation of PLK1 levels. 
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Figure 3.7: PLK1 down-regulation is concomitant with increasing levels of p53 after Nutlin-3 
treatment in HCT116 wild type cells 
A) HCT116 wild type cells were treated with 10µM Nutlin-3 and lysed at 2 h intervals over a 10 h 
period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with anti-
PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These Western 
blots are representative of 3 independent experiments. B) HCT116 wild type cells were treated with 
increasing concentrations of Nutlin-3 for 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 2 independent experiments. 
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Similar to the Etoposide experiments, HCT116 p53-null derivatives were treated 
with Nutlin-3 to verify whether PLK1 down-regulation was dependent upon p53 
Figure 3.8). These cells were treated with Nutlin-3 over a 24 h period (A) and they 
were also treated with increasing concentrations of Nutlin-3 for 24 h (B). The results 
show that when these cells are treated with Nutlin-3 over a 24 h period, PLK1 levels 
stay constant. In the absence of p53, PLK1 down-regulation is abolished. 
Furthermore when cells are treated with increasing concentrations of Nutlin-3, PLK1 
levels stay constant. To confirm there is no p53 and therefore no p21 protein 
produced in this cell line, p53 and p21 Western blots were carried out, alongside 
positive controls for these proteins.  
Results from Figure 3.7 and Figure 3.8 confirm PLK1 down-regulation is dependent 
on p53. However at this stage it was not clear whether PLK1 down-regulation by 
Nutlin-3 was mediated by p53 or induced by a downstream target of p53, such as 
p21. Consequently, similar to the Etoposide treatment, Nutlin-3 experiments were 
carried out in the HCT116 p21-null cell derivatives (Figure 3.9). Once more, 
HCT116 p21-null cells were treated with Nutlin-3 over a 24 h time course (A). 
These cells were also treated with increasing concentrations of Nutlin-3 for 24 h (B). 
To confirm there is no p21 protein produced in this cell line, p21 Western blots were 
performed, alongside positive controls for the proteins.  
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Figure 3.8: PLK1 down-regulation is not shown after Nutlin-3 treatment in HCT116 p53-null 
cells 
A) HCT116 p53-null cells were treated with 10 µM Nutlin-3 and lysed at 2 h intervals over a 10 h 
period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with anti-
PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These Western 
blots are representative of 3 independent experiments. B) HCT116 p53-null cells were treated with 
increasing concentrations of Nutlin-3 for 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 2 independent experiments. 
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 Figure 3.9: PLK1 down-regulation is concomitant with increasing levels of p53 after Nutlin-3 
treatment in HCT116 p21-null cells 
A) HCT116 p21-null cells were treated with 10 µM Nutlin-3 and lysed at 2 h intervals over a 10 h 
period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with anti-
PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These Western 
blots are representative of 3 independent experiments. B) HCT116 p21-null cells were treated with 
increasing concentrations of Nutlin-3 for 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 2 independent experiments. 
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As shown in Figure 3.7, PLK1 levels decrease with the addition of Nutlin-3 and 
decrease with increasing concentrations of Nutlin-3. However, compared to the 
Nutlin-3 treated HCT116 wild type cells (Figure 3.7), PLK1 levels are not abolished 
at the 24 h time point in the p21-null cells. In addition to this, the p53 response is 
much slower, with p53 levels only increasing at the 24 h time point in the p21-null 
derivatives. The p53 response in this cell line, initiated by the addition of Nutlin-3, 
does not appear to be as high as that shown in the HCT116 wild type cells. There 
may be many explanations as to why the p53 response is weaker in this cell line. A 
possibility may be that this is due to an intrinsic factor in this particular derivative of 
HCT116, therefore p21 siRNA knock-down experiments may resolve this issue, as 
discussed later. 
 
3.7 PLK1 down-regulation by Nutlin-3 is not due to G1/S checkpoint arrest 
Overall, results from the Nutlin-3 experiments conclude that the down-regulation of 
PLK1 is dependent on p53. In the absence of p21, down-regulation does occur but 
not to the same extent as when p21 is present. This indicates that p21 may also be 
involved in the down-regulation of PLK1, either through repression or simply 
through the arrest of cells at the G1/S checkpoint.  
To investigate whether down-regulation of PLK1 by Nutlin-3 is due to a repression 
by p53 or p21, or simply down to G1/S checkpoint arrest, Nutlin-3 was added to all 
three types of cell and analysed by flow cytometry (see Appendix). As shown in 
Figure 3.10, there was an increase in the number of HCT116 parental cells in G1 
phase and in G2/M phase of the cell cycle in the presence of Nutlin-3. However, 
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when HCT116 p53-null and p21-null cells were treated with Nutlin-3 there was no 
change to the proportion of cells in each phase of the cell cycle. 
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Figure 3.10: Cell cycle profiles of HCT116 wild type, p53-null and p21-null at two densities in 
the absence and presence of Nutlin-3 
This figure shows the flow cytometry data of two densities of HCT116 cells (2.5x105 and 1x106) and 
their derivatives in the absence and presence of Nutlin-3 (10 µM). Graph A shows the cell cycle 
profiles of the HCT116 wild type cells in the absence and presence of Nutlin-3. Graph B, shows the 
HCT116 p53-null cells and Graph C, shows the HCT116 p21-null cells. These graphs are 
representative of 2 independent experiments. 
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In conclusion, these results show that Nutlin-3 has a different effect on the cell cycle 
to that of Etoposide (Figure 3.6). Nutlin-3 inhibits the cells at the G1/S phase of the 
cell cycle and at the G2/M phase whereas Etoposide gives a mainly G2/M arrest. 
Furthermore the number of cells in S phase following Nutlin-3 treatment has almost 
been completely abolished. Interestingly these results also show that Nutlin-3 is 
unable to cause cell cycle checkpoint block in the absence of p53 or p21, confirming 
that Nutlin-3 functions by inducing p53 and p21. 
In summary, all of the data so far show that the induction of p53, by Etoposide or 
Nutlin-3, down-regulates PLK1. While this can occur in the absence of p21, the data 
suggest that p21 may contribute to this although it is unlikely that this occurs 
through cell cycle arrest. In addition to blocking cell cycle progression, p21 is a 
known repressor of certain genes and therefore it may be possible that p21 can affect 
the expression of PLK1. Alternatively since the induction of the p53 pathway is 
weaker in the p21-null cells there may be other, as yet unknown, changes in these 
cells other than the absence of p21, possibly the result of continuous passage. For 
these reasons, p21 siRNA experiments have been carried out to determine, using an 
independent approach, the extent to which p21 has on the down-regulation of PLK1.  
 
3.8 p21 plays a role in PLK1 repression 
To verify whether p21 contributes to the down-regulation of PLK1, p21 siRNA 
experiments were carried out in HCT116 parental cells. 
In order to silence p21 expression, cells were transfected with siRNA for 48 h. 
However, as p21 levels are undetectable in unstimulated cells, the cells were treated 
in the absence or presence of Nutlin-3, 24 h after transfection with siRNA, to induce 
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the expression of p21. HCT116 were untransfected, mock transfected (which 
accounts for any affects the tranfection reagent or Optimem is having on the cells), 
treated with a scrambled (non-silencing) siRNA which is unspecific to any gene or 
cells were treated with siRNA targeted towards the p21 gene (Figure 3.11). The p21 
Western blot shown in Figure 3.11, shows that the induction of p21 by Nutlin-3 
occurred in the non-transfected, mock transfected and scrambled siRNA transfected 
cells but was not present in non Nutlin-3 treated cells, as expected. However in the 
Nutlin-3 treated and p21 siRNA-transfected cells p21 could not be detected, 
indicating that the siRNA targeted toward the p21 gene has eliminated the 
expression of p21. Furthermore, to show that the p53 pathway had been activated 
p53 was also probed and, as revealed in the p53 Western blot, p53 is induced by the 
addition of Nutlin-3. This coincides with an increase in MDM2, as anticipated. In all 
cases PLK1 levels were depleted when the cells were treated with Nutlin-3. 
However, in the cells in which p21 expression had been silenced, the down-
regulation of PLK1 levels was not as strong as with the control transfections.  
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This result is consistent with the observations made using the HCT116 p21-null 
derivative when treated with Nutlin-3 and confirms that p21 can make a contribution 
to PLK1 down-regulation. 
In addition to the HCT116 cells, the identical experiment was carried out in U2OS 
cells. Similar data were obtained (Figure 3.11), although the contribution made by 
p21 in these cells appeared to be much less significant as compared with the 
HCT116 cells.  
In conclusion, p21 siRNA experiments indicate that down-regulation of PLK1 is 
dependent, but only in part, on p21 and that this may be dependent on the cell type. 
 
3.9 Induction of p53 levels by Cisplatin causes PLK1 down-regulation 
Cisplatin is a platinum based DNA damaging agent, which, like Etoposide and 
Nutlin-3, is able to induce p53 and the p53 pathway (Siddik, 2003). However, 
Cisplatin has a very different mechanism of action in DNA damage compared to that 
of Etoposide, as discussed in Chapter 1.  
As shown in Figure 3.12 (A), p53 levels increase slowly after the addition of 
Cisplatin to HCT116 wild type cells, as expected, concomitant with an increase in 
p21. Notably, PLK1 levels decrease slowly after the addition of Cisplatin. Figure 
3.12 (B), shows levels of p53 and p21 also increase with the addition of increasing 
concentrations of Cisplatin. As expected, PLK1 levels decrease. 
To determine whether the addition of Cisplatin would down-regulate PLK1 levels in 
the absence of p53, similar experiments were carried out in HCT116 p53-null cell 
derivatives, as shown in Figure 3.13 (A), shows PLK1 levels do not change in the 
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absence of p53, when cells are treated with Cisplatin for increasing periods of time. 
Figure 3.13 (B) also shows that PLK1 levels do not change in the absence of p53 
when cells are treated with increasing concentrations of Cisplatin. 
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Figure 3.12: PLK1 down-regulation is concomitant with increasing levels of p53 after Cisplatin 
treatment in HCT116 wild type cells 
A) HCT116 wild type cells were treated with 20 µM Cisplatin and lysed at 2 h intervals over a 10 h 
period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with anti-
PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These Western 
blots are representative of 3 independent experiments. B) HCT116 wild type cells were treated with 
increasing concentrations of Cisplatin for 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 2 independent experiments. 
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 Figure 3.13: PLK1 down-regulation is concomitant with increasing levels of p53 after Cisplatin 
treatment in HCT116 p53-null cells 
A) HCT116 p53-null cells were treated with 20 µM Cisplatin and lysed at 2 h intervals over a 10 h 
period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with anti-
PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These Western 
blots are representative of 3 independent experiments.  B) HCT116 p53-null cells were treated with 
increasing concentrations of Cisplatin for 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 2 independent experiments. 
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To determine whether p21 is involved in the down-regulation of PLK1 by Cisplatin, 
Cisplatin was also added to p21-null cells. As shown in Figure 3.14 (A), there was a 
small decrease in PLK1 which occurred concomitantly with a small increase in p53. 
Figure 3.14 (B) shows that with increasing concentrations of Cisplatin, levels of 
PLK1 decrease. Interestingly the levels of p53 decrease at higher concentrations of 
Cisplatin. 
As with other stimuli, these experiments show that the down-regulation of PLK1 by 
Cisplatin is dependent on p53 and that this can occur in the absence of p21. 
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Figure 3.14: PLK1 down-regulation is concomitant with increasing levels of p53 after Cisplatin 
treatment in HCT116 p21-null cells 
A) HCT116 p21-null cells were treated with 20 µM Cisplatin and lysed at 2 h intervals over a 10 h 
period with a final time point lysed at 24 h. Lysates were then analysed by Western blotting with anti-
PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These Western 
blots are representative of 3 independent experiments.  B) HCT116 p21-null cells were treated with 
increasing concentrations of Cisplatin for 24 h. Lysates were then analysed by Western blotting with 
anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies. These 
Western blots are representative of 2 independent experiments. 
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In conclusion, Etoposide, Nutlin-3 and Cisplatin all induce the expression of p53 in 
HCT116 wild type cells. This coincides with increases in MDM2 and p21 (Figure 
3.20), and most notably, a decrease in PLK1. In the absence of p53 there is no 
decrease in PLK1 with any drug treatment. In the absence of p21 there is a small 
decrease in PLK1 levels when cells are treated with Nutlin-3. These results all point 
towards a possible repression of PLK1 by p53. It is likely that p21 makes a small 
contribution to this effect. 
The requirement of p53, and p21, to down-regulate PLK1 is shown. It is also shown 
that both proteins are involved in checkpoint arrest.  However, questions remain: 
how does p53 act to inhibit the cell cycle at the G2/M checkpoint? Is the down-
regulation of PLK1 all that is required to cause G2/M checkpoint arrest? Since PLK1 
plays a crucial role in the progression through late G2 and M towards cytokinesis, its 
down-regulation may mediate or contribute to the DNA damage induced G2/M 
checkpoint (Bunz et al., 1998, Taylor et al., 2001b). To explore this, PLK1 siRNA 
experiments were carried out.  
 
3.10 p53 acts through a coordinated mechanism to repress PLK1 
Results so far show that there are three drug treatments that result in the down-
regulation of PLK1. To determine whether elimination of PLK1 would replicate or 
mimic the Nutlin-3 or Etoposide mediated G2/M checkpoint arrest observed in the 
flow cytometry experiments, PLK1 silencing (siRNA) experiments were carried out. 
As shown in Figure 3.15, PLK1 levels were knocked down in the HCT116 cells and 
the p53- and p21-null derivatives. This experiment has included controls to account 
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for any affect the transfection reagents may have had and any unspecific affects the 
siRNA may have had. The knock-down in PLK1 is concomitant with increases in 
protein levels of the mitosis marker phospho-histone 3 (p-H3) and the apoptosis 
marker cleaved PARP (Poly(ADP) Ribose Polymerase) (Kaufmann et al., 1993, 
Oliver et al., 1999). In all three cell lines, interestingly, MDM2 levels decrease with 
decreases in PLK1, but there is no change in p53 protein levels. Furthermore, PLK1 
levels were consistently reduced by a greater extent in the p53 and p21-null 
derivatives compared to the parental (p53-competent) cells.  
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Figure 3.15: PLK1 knock-down by siRNA in HCT116 wild type, p53-null and p21-null cells 
HCT116 wild type cells and their derivatives were treated with Optimem/Lipofectamine RNAiMAX 
only, Optimem/Lipofectamine RNAiMAX with Scrambled DNA (30 pMol) or 
Optimem/Lipofectamine RNAiMAX with PLK1 siRNA (30 pMol). Lysates were then analysed by 
Western blotting with anti-PLK1 antibodies, anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin 
antibodies, anti-phospho histone 3 antibodies, anti-PARP antibodies and anti-MDM2 antibodies. (s.e. 
= short exposure time, l.e. = long exposure time). These Western blots are representative of 4 
independent experiments. 
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Western blots indicate that cells treated with PLK1 siRNA have entered mitosis 
and/or are committed to apoptosis. To confirm these suggestions, the cells were also 
examined by microscopy (Figure 3.16) and by flow cytometry (Figure 3.17).  
 
 
 
 
 The micrographs in Figure 3.16 show that in all three cell lines, untreated cells, 
mock transfected cells and cells transfected with scrambled siRNA have a flat and 
normal morphology. In all three types of cell transfected with PLK1 siRNA, the 
cells’ morphology was round and many were found floating in the medium, 
suggesting that the cells are either undergoing mitosis or going into apoptosis.  
Figure 3.16: PLK1 knock-down by siRNA in HCT116 wild type, p53-null and p21-null cells 
HCT116 wild type cells and their derivatives were treated with Optimem/Lipofectamine RNAiMAX 
only, Optimem/Lipofectamine RNAiMAX with Scrambled DNA (30p Mol) or 
Optimem/Lipofectamine RNAiMAX with PLK1 siRNA (30 pMol). Cells were then observed under 
the microscope and magnified to 200X, then photographed. 
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These micrographs support the observation with the Western blots. When PLK1 is 
knocked out, cells undergo mitosis and apoptosis. To confirm this, cells treated with 
PLK1 siRNA were put through the flow cytometer (see Appendix). Figure 3.17 
shows that the percentage of HCT116 wild type cells that are in G2/M phase and 
apoptosis increase when treated with PLK1 siRNA. Figure 3.17 also shows that the 
proportion of p53-null cells and p21-null cells in G2/M phase increase when they are 
treated with PLK1 siRNA. Similarly, there are increases in the proportion of sub-G1 
cells consistent with the occurrence of apoptosis. The cell cycle profiles of cells 
either untreated, mock transfected or transfected with scrambled siRNA do not 
change, showing that the transfection itself is not having an effect on the result. 
Unfortunately, flow cytometry cannot discriminate between the cells in G2 phase 
and in mitosis. However, when the data from the Western blots is taken into 
consideration it can be concluded that the cells treated with PLK1 siRNA were in 
mitosis and not G2 phase.  
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Figure 3.17: Cell cycle profiles of HCT116 wild type, p53-null and p21-null in the absence and 
presence of PLK1 siRNA 
This figure shows the flow cytometry data HCT116 wild type cells and their derivatives in the absence 
and presence of PLK1 siRNA. Graph A shows the cell cycle profiles of the HCT116 wild type cells in 
the absence and presence of PLK1 siRNA. Graph B, shows the HCT116 p53-null cells and Graph C, 
shows the HCT116 p21-null cells. These graphs are representative of 2 independent experiments. 
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The data presented here indicate that the knock-down of PLK1 in all three cell lines 
does not mimic the arrest mediated by Nutlin-3 and allows the cells to enter and 
arrest within mitosis. Since  p53 arrests cells in G2 but not in M phase it is possible 
that down-regulation of PLK1 alone is not sufficient to prevent the cells from 
entering M phase and may rely on the coordinated action of p53 on this and several 
other genes. 
Our next aim was to determine how p53 down-regulates PLK1 and whether this 
occurs at the transcriptional or post-translational level. Using the same drug 
treatments as previously described, Real-Time TaqMan® PCR was carried out and 
mRNA levels calculated, as described in Section 2.2.14. 
 
3.11 p53 decreases levels of PLK1 mRNA levels 
To determine whether down-regulation of PLK1 occurs at the mRNA level, HCT116 
cells and their derivatives were treated with Etoposide or Nutlin-3, from which RNA 
was extracted and cDNA produced. From the cDNA, TaqMan® Real Time PCR was 
carried out to show if levels of expression of the PLK1 gene, change in the absence 
and presence of Etoposide or Nutlin-3.  
Figure 3.18 shows PLK1 mRNA levels decrease in HCT116 wild type cells when 
treated with Etoposide and Nutlin-3. PLK1 levels do not change in the HCT116 p53-
null cells when treated with Nutlin-3 and increase slightly when treated with 
Etoposide. In p21-null cells treated with Etoposide PLK1 mRNA levels increase. It 
is not clear whether there is decrease in PLK1 mRNA levels mediated by Nutlin-3. 
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Power analysis revealed that the study would have to be replicated at least 6 times 
for such a small effect to be statistically significant. 
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Figure 3.18: Real-Time TaqMan® PCR data of the Etoposide and Nutlin-3 treated HCT116 
Wild Type, p53-null and p21-null cells 
HCT116 wild type (A), p53-null (B) and p21-null (C) cells were treated with Etoposide (20 µM ,100 
µM), Nutlin-3 (10 µM) or DMSO for 24 h. RNA was extracted from the lysed cells (as described in 
Chapter 2) and cDNA produced from the RNA. Real-Time TaqMan® PCR was then performed and 
levels of mRNA calculated. These graphs are representative of 3 independent experiments. Statistical 
analysis was performed using analysis of variance with post hoc Bonferroni test for multiple 
comparisons (* p < 0.05). 
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In conclusion, TaqMan® Real-Time PCR shows that levels of PLK1 mRNA levels 
parallel the changes observed at the protein level. Analysis of variance revealed that 
in the presence of p53, PLK1 levels decrease when HCT116 wild type cells are 
treated with Etoposide and Nutlin-3. In the absence of p53 there is no decrease 
suggesting that PLK1 repression at the mRNA level is dependent on p53. PLK1 
mRNA levels in p21-null cells increase in the presence of Etoposide. Time 
permitting other time points would also have been followed up, to discover whether 
mRNA levels differed at other time points compared to the protein levels.  
Our next aim was to elucidate the mechanism by which p53 mediates PLK1 down-
regulation and whether any other proteins may be involved in these events. One 
plausible mechanism, suggested by the data so far, is transcriptional repression. This 
can involve either binding site overlap or even squelching of transcriptional 
activators but very commonly involves the recruitment of chromatin remodelling 
proteins, such as histone deacetylases (HDACs), therefore the next Section explores 
whether HDACs are involved in PLK1 repression via p53. 
 
3.12 Histone deacetylases may be involved in repression of PLK1 
In order to determine whether p53 down-regulates PLK1 mRNA levels through a 
repression mechanism involving histone deacetylases, an experiment was carried out 
using the HDAC inhibitor, Trichostatin A (TSA). As shown in Figure 3.19, HCT116 
cells (parental and p53-null) were treated with either: TSA, Nutlin-3, both TSA and 
Nutlin-3 or DMSO. The data indicate that TSA alone inhibits the expression of 
PLK1. Nutlin-3, also shown previously, represses PLK1 to very low levels. 
Interestingly however, when cells were treated with both drugs, TSA rescued the 
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PLK1 levels to the levels of TSA alone. Western blotting of acetyl-histone 3 (acetyl-
H3) shows that the TSA drug itself is active and has caused an increase in acetylated 
H3 as expected. Western blotting confirmed that Nutlin-3 stimulated an increase in 
p53, p21 and MDM2.  
 
 
 
 
 
 
Figure 3.19: Trichostatin A (TSA) causes a decrease in the levels of PLK1 protein independent 
of p53 but alleviates p53 mediated PLK1 down-regulation 
HCT116 wild type and p53-null derivatives were treated with Nutlin-3 (10 µM), TSA (1 µM) or both 
for 24 h. Lysates were then analysed by Western blotting with anti-PLK1 antibodies, anti-p53 
antibodies, anti-p21 antibodies, anti-β-Actin antibodies, anti-acetyl-H3 antibodies and anti-MDM2 
antibodies. These Western blots are representative of 4 independent experiments. 
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These data fit with the idea that p53 may repress the expression of PLK1 through a 
mechanism involving the recruitment of HDAC to the PLK1 promoter. 
 
3.13 Concluding Remarks 
Down-regulation or repression by p53 is an exciting area of research that has 
previously received less attention than analysis of the activation of gene expression 
by p53. This chapter shows and discusses the down-regulation of a particular protein 
(or oncogene), PLK1, by the transcription factor and tumour suppressor, p53. PLK1 
is a cell cycle regulated protein and required for progression through G2 phase and 
mitosis (Hamanaka et al., 1995, Petronczki et al., 2008). It is also a protein that is 
deregulated and/or overexpressed in many types of cancer (Holtrich et al., 1994, 
Kneisel et al., 2002).  
Data in this chapter show that treating particular cell lines, such as HCT116 with 
drugs such as Etoposide and Nutlin-3 causes PLK1 levels to decrease. However 
levels do not decrease in the absence of p53. These conclusions are exemplified in 
the experiment as shown in Figure 3.20. Increases in p53 occur with increases in 
MDM2, p21, 14-3-3 (three well-characterised targets of p53) (Ko and Prives, 1996). 
To eliminate the possibility that the observed decrease in PLK1 levels was simply 
the result of p21 induced G1/S checkpoint arrest (i.e. arresting the cells at a point 
where the levels of PLK1 are normally low) flow cytometry was carried out. This 
data confirmed that down-regulation of PLK1 did not occur as a result of the 
inhibition of the cells cycle when PLK1 levels are low. This down-regulation has 
been further confirmed by data from our lab (Dr Sharon King) which suggest that 
induction of p53 in SAOS2 cells that have inducible p53, down-regulates PLK1; 
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(SAOS2 cells do not have Rb and therefore do not arrest at G1/S (Qin et al., 1995, 
Weinberg, 1995)). 
 
 
Figure 3.20: PLK1 down-regulation is dependent on p53 and, in part, p21  
HCT116 wild type, p53-null and p21-null cells were treated with Etoposide (100 µM), Nutlin-3 (10 
µM) or Cisplatin (20 µM) for 24 h. Cells were then lysed and analysed by Western blotting with anti-
PLK1 antibodies, anti-p53 antibodies, anti-MDM2 antibodies, anti-14-3-3 antibodies, anti-p21 
antibodies and anti-β-Actin antibodies.  
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p21 may have a growth arrest independent role to play in down-regulation of PLK1. 
For example, down-regulation of PLK1 by Nutlin-3 still occurs in p21-null cells but 
is less potent than in the parental cell line. Similarly, silencing of p21 expression in 
p21 siRNA experiments indicated that p21 makes a contribution to the down-
regulation of PLK1. 
Flow cytometry experiments were carried out to determine whether these drugs were 
affecting the cell cycle profile of the cells and inhibiting the cell cycle at the point 
when PLK1 levels are naturally low. The data confirmed that cells do not arrest at 
the G1/S checkpoint when p53 or p21 are absent. Interestingly, DNA damaging 
reagent Etoposide caused a G2 block that was not dependant on either p53 or p21. It 
is likely, in this case, that Etoposide being a DNA damaging reagent, is activating 
the ATM/CHK2 pathway leading to a p53-independent G2 cell cycle arrest (Bartek 
and Lukas, 2003, Eymin et al., 2003). Nutlin-3, on the other hand, displayed a G1 
block and G2 block, which was noticeably dependent on p53 and p21 as it occurred 
only in the parental cells (Nutlin-3 activates the p53 pathway by inhibiting the 
interaction of p53 with MDM2). Taken together, the data indicate that activating p53 
is sufficient to down-regulate PLK1, independently of its ability to arrest cells at 
G1/S.  
Interestingly, the knock-down of PLK1 does not cause G2/M checkpoint arrest and 
cells become blocked in mitosis and undergo apoptosis. Therefore, this suggests that 
inhibition of PLK1 alone is not sufficient to mediate the G2/M checkpoint and that 
p53 may act in a coordinated mechanism in which it requires coordinate regulation 
of additional genes to mediate the G2/M checkpoint block. Alternatively, since 
G2/M arrest can occur independently of p53 (at least transiently), down-regulation of 
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PLK1 may serve to enforce the arrest by eliminating one of the key factors required 
for passage through mitosis. This would fit with the idea that the function of p53 lies 
in its ability to maintain the G2/M checkpoint as opposed to activating it. 
To determine whether PLK1 down-regulation occurs at the transcriptional level, 
PLK1 mRNA levels were measured. The data indicate that down-regulation occurs 
at mRNA level. Therefore, our aim was to determine how p53 acts to down-regulate 
PLK1 and what other factors this may involve. 
The down-regulation of PLK1 at the mRNA level suggested that p53 might repress 
PLK1 expression. Repression often occurs through the recruitment of proteins such 
as HDACs that remodel chromatin such that it is less accessible to the transcriptional 
apparatus. HDACs are well-established inhibitors of gene expression and so a further 
experiment was carried out to determine whether the mechanism of p53 repression 
of PLK1 involves the recruitment of HDACs. The initial data showing that the 
HDAC inhibitor TSA can relieve the down-regulation of PLK1 in response to 
Nutlin-3 treatments fits with the suggestion that HDACs are involved in repression 
of PLK1.  
Overall the results in this chapter give evidence of a repression mechanism of PLK1 
that is dependent on p53 and partly on p21. The next chapter explores the 
mechanism by which p53 and perhaps p21 carry out repression of PLK1 and 
provides a model by which this may occur.   
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Chapter 4: p53 repression of PLK1 
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4.1 Background 
PLK1 is down-regulated by p53 however the mechanism by which it does this is 
unclear. p53 may act directly through proposed p53 responsive elements (p53 REs), 
like that of Survivin (Hoffman et al., 2002, Riley et al., 2008) or indirectly such as 
the activation of p21, which may have an effect through other regions of the PLK1 
promoter (Shiyanov et al., 1996, Uchiumi et al., 1997). It is also possible that p53 
can interfere with important factors such as NF-Y (Imbriano et al., 2005). 
 This Chapter describes the use of several complementary approaches to determine 
whether p53 mediates transcriptional repression of PLK1. Firstly, the PLK1 promoter 
was cloned into a Luciferase reporter vector, which was then transfected into 
HCT116 p53-null and SAOS2 cells. Luciferase assays were then carried out on the 
lysates to determine whether p53 causes a decrease in Luciferase levels (i.e. as a 
read-out of p53 transcriptional function). Other techniques were also employed, such 
as Chromatin immunoprecipitations, to establish whether p53 acts directly on the 
PLK1 promoter and, if so, where this occurs. Furthermore, an electrophoretic-
mobility shift assay was also carried out to confirm, in vitro, the binding of p53 to a 
proposed p53 RE.  
Lastly this Chapter explores whether p21 has a role to play at the promoter level in 
the repression of PLK1.  
 
4.2 Aims 
The aim of this Chapter was to explore the mechanism(s) by which p53 represses 
PLK1. 
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4.3 Cloning of the PLK1 promoter into a Luciferase reporter vector 
As suggested in the previous Chapter, PLK1 is down-regulated by p53 and, in part, 
p21. The PLK1 promoter contains many potential targets for site-specific 
transcription factor binding including sites including an E2F binding site, CDE (cell 
cycle-dependent element)/CHR (cell cycle gene homology domain) repressor 
element and CCAAT box, as shown in Figure 4.1. The promoter sequence of 
human PLK1 (accession number X90725) was also screened for potential p53 
binding sites using software developed at Dundee to detect p53 binding sites (by Ms 
Sieu Chin, Dr J-C Bourdon’s group, non-commercial). The algorithms employed by 
this computer programme detect the consensus sequence of a p53 responsive element 
which is made up of the following: PuPuPuCA/TT/AGPyPyPy. The computer 
programme detects any potential site that contains two to three purines (G/C) at the 
start of the sequence followed by a C and either an A or T. The C is not 
interchangeable. The programme also detects sites that contain two to three 
pyrimidines (A/T) followed by a G and either an A or C. The G is not 
interchangeable. The final algorithm employed takes into account any spacer that 
occurs in p53 responsive element. This is usually 0-13 bp long.  
This approach identified three potential p53 binding sites, two of which were 
overlapping (p53RE1) as shown in Figure 4.1. The sequence of PLK1 promoter 
which was cloned into the Luciferase reporter vector is shown between the yellow 
highlighted primers (Figure 4.1) 
p53 may act directly at the p53 REs to repress PLK1. On the other hand, based on 
published analyses of other promoters (St Clair et al., 2004) the induction of p21, by 
p53, may repress PLK1 in conjunction with or independently of p53. p21 may 
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repress PLK1 through the CDE/CHR element (Lucibello et al., 1995, Uchiumi et al., 
1997) and/or through the E2F binding site (Shiyanov et al., 1996). There are also 
additional sites, through which repression may occur (discussed in Chapter 1). In this 
Chapter we explore repression of PLK1 by p53 through the p53 REs and investigate 
whether this may involve p21 repression of PLK1 through the CDE/CHR element. 
Future study will reveal whether repression occurs though other domains. 
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Figure 4.1: Diagram of PLK1 promoter showing proposed sites, determined sites and other 
elements 
Diagram of PLK1 promoter depicting the proposed p53 responsive elements (red) and E2F binding 
site (blue), ccaat box (pink), CDE/CHR repressor elements (purple), transcriptional and translational 
start sites (green) and the PCR primers (yellow) used to amplify the PLK1 promoter. Arrows indicate 
base pairs that correspond to the p53 consensus sequence. 
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The PLK1 promoter was cloned into a Luciferase reporter vector (pGL3) as shown in 
Figure 4.2. 
  
  
The pGL3 vector, as shown in Chapter 2, has a cloning site which is directly 
upstream of a Luciferase gene and therefore the cloning of the PLK1 promoter into 
this vector allows transcription of the Luciferase gene and expression of Luciferase. 
Consequently, the levels of Luciferase are a reflection or read-out of the activation of 
transcription and translation of the PLK1 promoter. The cloning of the promoter into 
Figure 4.2: Cloning of the PLK1 promoter into the Luciferase reporter vector, pGL3, via the 
pSC-B vector 
The cloning of the PLK1 promoter involved the amplification of the promoter by PCR which was then 
ligated into the vector, pSC-B. This was then excised by restriction digest into two fragments. The 
fragment containing the PLK1 promoter was then ligated into pGL3.  
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this particular vector allows us to measure the effects of ectopically expressed wild 
type and mutant p53 proteins on expression from the PLK1 promoter. Moreover, if 
down-regulation of expression requires an element(s) within this promoter it would 
underpin the idea that p53 represses PLK1 expression. 
To create the PLK1promoter/pGL3 plasmid, the PLK1 promoter DNA was amplified 
from a BAC clone, as described in Chapter 2, using PCR (Figure 4.3). The PCR 
product was then excised from the agarose gel and purified before being ligated into 
the pSC-B plasmid vector from the StrataClone™ Blunt PCR Cloning Kit, as 
described in Chapter 2. The PLK1 promoter is ligated into the pSC-B plasmid vector 
prior to ligation in to pGL-3 plasmid as PCR products can be directly ligated into the 
pSC-B vector. 
 
After ligation, the plasmid was then used to transform StrataClone SoloPack 
competant bacteria to Ampicillin resistance. Plasmid DNA was then purified from 
the bacteria for further use. To verify that the fragment containing the PLK1 
promoter was inserted correctly into the vector and the ligation was successful, a 
double restriction digest was carried out. Using restriction enzymes, XhoI and 
BamHI, the plasmid was digested and two fragments of size, 2384 and 3388 Kb 
Figure 4.3: PCR amplification of the PLK1 
promoter 
PLK1 promoter DNA was amplified from a BAC 
clone as described in Chapter 2. A PCR reaction 
containing no DNA was also performed and run 
on the gel to show there is no DNA 
contamination. 
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(which were of the size expected from this digest) were observed as shown in Figure 
4.4.  These enzymes were chosen as the plasmid contains both these restriction sites 
and the digest would give two DNA products of these predicted sizes. 
 
 
 
To clone the PLK1 promoter into the pGL3 Luciferase reporter vector further double 
restriction enzyme digests were carried out. Using KpnI and BamHI restriction 
enzymes, the PLK1 promoter was removed from the pSC-B vector (Figure 4.5). 
These two enzymes were chosen because the insert containing the PLK1 promoter is 
flanked by KpnI and BamHI restriction sites and are complementary sites to the 
vector flanked with sites KpnI and BglII. Using KpnI and BglII restriction enzymes, 
the pGL3 vector was digested into a linear form of the plasmid (Figure 4.5). After 
digestion, the PLK1 promoter, size 2.3 Kb and pGL-3, size 4.8 Kb were excised from 
the agarose gel and purified. The PLK1 promoter was then ligated into the pGL3 
Luciferase reporter vector, as described in Chapter 2. 
Figure 4.4: Double restriction enzyme 
digestion of PLK1promoter/pSC-B plasmid 
The PLK1promoter/pSC-B plasmid was 
digested using the restriction enzymes XhoI 
and BamHI. 
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Subsequent to ligation, the plasmid was then used to transform competent E.coli 
DH5 α to Ampicillin resistance. Plasmid DNA was then purified from the bacteria 
for further use. To show that the fragment containing the PLK1 promoter was 
inserted into the correct vector and the ligation was successful, a double restriction 
digest was carried out. Using restriction enzymes, XbaI and KpnI, the plasmid was 
digested and two fragments of size, 4045 and 3062 Kb were observed (which were of 
the size expected from this digest) as shown in Figure 4.6. These enzymes were 
chosen as the plasmid contains both these restriction sites and the digest would give 
two DNA products of a predicted size. 
 
 
Figure 4.5: Double restriction enzyme 
digestions of PLK1promoter/pSC-B 
plasmid and pGL3 vector 
PLK1promoter/pSC-B plasmid was 
digested using the restriction enzymes 
KpnI and BamHI, which create two 
bands of size 2.3 and 3.5 Kb. The pGL3 
vector was digested using the restriction 
enzymes KpnI and BglII, giving a band 
of size, 4.8 Kb. 
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Furthermore, sequencing (DNA analysis Facility, University of Dundee) was carried 
out to verify that the promoter had been correctly inserted into the plasmid and that 
no undesired mutations had arisen. 
The construction of this plasmid has allowed us to determine whether p53 represses 
PLK1 at the promoter and is described in the next Section. 
 
4.4 p53 represses expression from the PLK1 promoter 
To determine whether p53 mediates PLK1 repression, the PLK1promoter/pGL3 
plasmid was initially transfected into H1299 cells (which are p53-null). Results 
showed that the pGL3 vector alone was subject to express Luciferase in increasing 
amounts of p53. This indicated that p53 alone was causing Luciferase expression 
from an area in the pGL3 vector. Therefore HCT116 p53-null cells were used, and 
the plasmid was transfected into HCT116 p53-null cells together with increasing 
amounts of p53 expression plasmid, and a plasmid encoding Renilla Luciferase as 
internal standard (described in Chapter 2).  
Figure 4.6: Double restriction enzyme 
digestion of PLK1promoter/pGL3 
plasmid  
PLK1promoter/pGL3 plasmid was 
digested using the restriction enzymes 
KpnI and XbaI. 
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After 24 h, cells were lysed and Luciferase assays carried out, as described in 
Chapter 2. Levels of Luciferase are normalised to levels of Renilla. As shown in 
Figure 4.7 (A), as wild type p53 levels increase the expression of Luciferase 
decreased. At 300 ng of p53 plasmid, the decrease in levels of expression of 
Luciferase, had reached a plateau, which was reached long before this concentration. 
To confirm that the reduction in Luciferase levels was dependent on wild type p53 
function, various forms of mutant p53 were substituted for the wild type p53. These 
included: the R175H mutant, which is unable to bind to DNA because of a 
conformational change in the site-specific DNA binding domain. The R273H mutant, 
which has a mutation at the DNA binding domain which does not cause a 
conformational change but which eliminates a residue important for DNA contact 
and the L22Q/W23 mutant, which has two mutations in the TAD1 (trans-activating 
domain) region of p53 that binds to the co-activator, p300 (corresponding p53 
residues 25 and 26, in murine cells, are required for p53 dependent activation and 
repression (Hammond et al., 2006)). As shown in Figure 4.7, neither the R175H nor 
the R273H mutants repress the expression of Luciferase. Since neither of these 
mutants has DNA binding ability it is likely that site-specific DNA binding is 
required for p53 to mediate PLK1 repression. This Figure also shows that the 
L22Q/W23S mutant of p53, which cannot trans-activate gene expression, is also 
unable to repress expression of Luciferase from PLK1 promoter.  
In conclusion these results show that only wild type p53 can repress PLK1 
expression through the PLK1 promoter.  
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To demonstrate that the p53 plasmid had been transfected into cells and levels of p53 
increased with increasing amounts of p53 plasmid, Western blots were performed 
(Figure 4.8). This Figure confirms that p53 levels increase dose-dependently. 
However, it was not possible to detect p21 levels under these conditions.  
 
 
 
 
Our collaborator had shown by ChIP that p53 interacts with the PLK1 promoter in 
proximity to p53RE2 but had not been able to detect p53 either at p53RE1 or at the 
core promoter (Sam Nicol, unpublished data). While I was unable to follow up on 
these ChIP experiments because of technical problems (see Discussion) I decided to 
test whether the p53RE2 played an important role in the repression. In order to do 
this, the site was mutated, as shown in Figure 4.9, using site directed mutagenesis.  
Figure 4.8: p53 levels increase in a dose-dependent manner  
HCT116 p53-null cells were transfected with either wild type p53 plasmid or mutant p53 plasmids 
R175H, R273H or L22Q/W23S together with PLK1promoter/pGL3 plasmid or empty pGL3, Renilla 
plasmid and empty PCDNA3 plasmid. Lysates were then analysed by Western blotting with anti-p53 
antibodies, anti-p21 antibodies and anti-β-Actin antibodies.  
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The mutated plasmid was then transfected into HCT116 p53-null cells, in the same 
manner as the previous Luciferase plasmid transfections, and Luciferase assays were 
performed. As shown in Figure 4.10 (A), as p53 levels increased the levels of 
Luciferase expression from the wild type promoter decreased in a manner similar to 
that seen in Figure 4.7 (A). However, when the mutant PLK1 promoter was used, the 
basal level of expression was much lower suggesting that we had inadvertently 
changed an activator binding site that is important for full activity. The data also 
suggested that there was still some level of p53 responsiveness. One trivial 
explanation for the loss of basal activity is that undesired mutations were introduced 
elsewhere during the mutagenesis reaction. To check this, the plasmid was sequenced 
from the beginning of the promoter to the end of the Luciferase gene. Sequencing 
results showed that no other mutation was introduced into the plasmid (data not 
shown). Additionally I remade the mutant plasmid from the original plasmid a 
second time. This second independently-mutated plasmid gave identical results to the 
first one. 
 
Figure 4.9: p53 Responsive element 2 (p53RE2) mutation of the PLK1promoter/pGL3 
plasmid 
The PLK1 promoter was mutated at three residues (blue) in the p53 RE2 (red). 
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Figure 4.10 (B) shows that p53 protein levels increase dose-dependently. It was not 
possible to detect p21 levels under these conditions.  
Figure 4.10: Relative Luciferase levels of transfected PLK1promotermutant/pGL3 in the 
presence of increasing amounts of p53 in HCT116 p53-null cells 
A) The p53 plasmid was transfected together with Renilla plasmid and either the 
PLK1promoter/pGL3 or PLK1promotermutant/pGL3 plasmid or empty pGL3 plasmid and also empty 
PCDNA3 plasmid into HCT116 p53-null cells. After 24 h cells were lysed and a Luciferase assay 
carried out on the lysates. Luciferase activity levels were then read by a luminometer. Variations in 
transfection efficiencies were corrected by determining the ratio of activity of Luciferase to Renilla. 
This graph is representative of 3 independent experiments. Statistical analysis was performed using 
analysis of variance with post hoc Bonferroni test for multiple comparisons (* p < 0.05). B) HCT116 
p53-null cells were transfected with wild type p53 plasmid together with 
PLK1promotermutant/pGL3, Renilla plasmid and empty PCDNA3 plasmid. Lysates were then 
analysed by Western blotting with anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin 
antibodies.  
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One caveat of using the HCT116 cells is that they may arrest at G1/S in response to 
p53 expression. For this reason, therefore, the Luciferase transfections were carried 
out in SAOS2 cells. SAOS2 cells are p53 and Rb null and as a result cannot be 
inhibited at the G1/S checkpoint. Thus if repression still occurs in these cells, arrest 
at G1/S can be ruled out as the mechanism of repression. As shown in Figure 4.11 
(A), increasing p53 levels caused a corresponding decrease in levels of expression of 
Luciferase via the wild type PLK1 promoter. Likewise, similar to experiments in the 
HCT116 p53-null cells, mutant p53 plasmids were also transfected into SAOS2 cells. 
As shown in Figure 4.11 (B), the R175H mutant does not cause repression of 
Luciferase via the PLK1 promoter. Similarly, the L22Q/W23S mutant (Figure 4.11 
(C) and (D)) also do not cause repression of Luciferase. However, notably, the 
R273H mutant causes a significant increase in the levels of Luciferase. This mutant 
has been found by other authors to bind to target promoters in a gain of function 
capacity (Di Agostino et al., 2006).  
In conclusion, repression of the expression of Luciferase via the PLK1 promoter is 
dependent on wild type p53 and is unlikely to be caused simply by halting the cells at 
a point in the cell cycle where PLK1 protein levels are low. 
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To demonstrate that the p53 plasmid had been transfected into SAOS2 cells and 
levels of p53 increased with increasing amounts of p53 plasmid, Western blots were 
performed (Figure 4.12). This Figure confirms that p53 levels increase dose-
dependently. 
 
 
 
 
 
Again, similar to experiments carried out in the HCT116 p53-null cells, SAOS2 cells 
were also transfected with increasing amounts of p53 plasmid together with the 
PLK1promotermutant/pGL3 vector. Similar to experiments in HCT116 cells (Figure 
4.10) the basal level of expression was much lower (Figure 4.13).  
Figure 4.12: p53 levels increase in a dose-dependent manner  
SAOS2 cells were transfected with either wild type p53 plasmid or mutant p53 plasmids R175H, 
R273H or L22Q/W23S together with PLK1promoter/pGL3 plasmid or empty pGL3, Renilla plasmid 
and empty PCDNA3 plasmid. Lysates were then analysed by Western blotting with anti-p53 
antibodies, anti-p21 antibodies and anti-β-Actin antibodies. 
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Figure 4.13 (B) confirms that the p53 plasmid was transfected into the SAOS2 cells 
and p53 protein levels increased dose dependently. 
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As discussed in the previous Chapter, p21 also has a role to play in the down-
regulation of various cell-cycle regulated proteins. It is therefore possible that the 
Figure 4.13: Relative Luciferase levels of transfected PLK1promotermutant/pGL3 in the presence 
of increasing amounts of p53 in SAOS2 cells 
A) The p53 plasmid was transfected together with Renilla plasmid and either the PLK1promoter/pGL3 or 
PLK1promotermutant/pGL3 plasmid or empty pGL3 plasmid and also empty PCDNA3 plasmid into 
SAOS2 cells. After 24 h cells were lysed and a Luciferase assay carried out on the lysates. Luciferase 
activity levels were then read by a luminometer. Variations in transfection efficiencies were corrected by 
determining the ratio of activity of Luciferase to Renilla. This graph is representative of 4 independent 
experiments. Statistical analysis was performed using analysis of variance with post hoc Bonferroni test 
for multiple comparisons (* p < 0.05). B) SOAS2 cells were transfected with wild type p53 plasmid 
together with PLK1promotermutant/pGL3, Renilla plasmid and empty PCDNA3 plasmid. Lysates were 
then analysed by Western blotting with anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin 
antibodies.  
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repression of PLK1 is actually mediated by p21 and that p53 plays an indirect role by 
stimulating p21 levels. To test this idea, PLK1promoter/pGL3 plasmid was 
transfected into SAOS2 cells, together with increasing amounts of a p21 expressing 
plasmid in the absence of p53. 
As shown in Figure 4.14 (A), low levels of p21 plasmid transfected into SAOS2 cells 
do not repress the expression of Luciferase via the PLK1 promoter. However, at 
significantly higher levels of p21 plasmid (300 ng) the data suggest that p21 can 
indeed repress the expression of Luciferase. 
Figure 4.14 (B) confirms that p21 was transfected into SAOS2 cells and p21 protein 
levels increased dose dependently. 
 
 
179 
 
 
 
 
 
 
 
 
 
 
 
 
 
These results show that p21 may have a part to play in the repression of PLK1. 
Although unclear at this stage, p21 repression may be mediated through many 
pathways, such as the repression through  the E2F1 binding site (Shiyanov et al., 
Figure 4.14: Relative Luciferase levels of transfected PLK1promoter/pGL3 in the presence of 
increasing amounts of p21 in SOAS2 cells 
A) The p21 plasmid was transfected together with Renilla plasmid and either the PLK1promoter/pGL3 
or empty pGL3 plasmid and also empty PCDNA3 plasmid into SAOS2 cells. After 24 h cells were 
lysed and a Luciferase assay carried out on the lysates. Luciferase activity levels were then read by a 
luminometer. Variations in transfection efficiencies were corrected by determining the ratio of activity 
of Luciferase to Renilla. This graph is representative of 3 independent experiments. Statistical analysis 
was performed using analysis of variance with post hoc Bonferroni test for multiple comparisons (* p 
< 0.05). B) SOAS2 cells were transfected with p21 plasmid together with PLK1promoter/pGL3 or 
pGL3 plasmid, Renilla plasmid and empty PCDNA3 plasmid. Lysates were then analysed by Western 
blotting with anti-p53 antibodies, anti-p21 antibodies and anti-β-Actin antibodies.  
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1996) or the CDE/CHR element (Uchiumi et al., 1997). p21 represses many genes 
through the CDE/CHR element in the gene promoter (Kidokoro et al., 2008, Taylor 
et al., 2001a, Zhu et al., 2002). 
To determine whether p53 causes PLK1 repression through the CDE/CHR element, a 
mutagenesis reaction was carried out in which both the CDE and CHR elements in 
the PLK1 promoter of the PLK1promoter/pGL3 plasmid were mutated, as shown in 
Figure 4.15.  
 
 
 
This plasmid was then transfected into SAOS2 cells and Luciferase assays carried 
out. As shown in Figure 4.16 (A), the double mutant PLK1 promoter plasmid 
expresses higher levels of Luciferase compared to the wild type PLK1 promoter 
plasmid, consistent with published data indicating that this element mediates cell 
cycle dependent repression of PLK1 (Uchiumi et al., 1997). In the presence of 
increasing amounts of transfected p53 plasmid, the levels of Luciferase expressed 
from the PLK1promoterCDE/CHRmutant/pGL3 plasmid decreases. In conclusion 
repression by p53 does not occur through the CDE/CHR element and it is likely p53 
induced p21 does not repress PLK1 expression through the CDE/CHR element. 
Figure 4.15: CDE/CHR element mutations of the PLK1promoter/pGL3 plasmid 
The PLK1 promoter was mutated at certain residues (blue) in the CDE/CHR element (purple). 
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These data overall suggest that neither p53 nor p21 repress the expression of PLK1 
through the CDE/CHR element in the PLK1 promoter, however, it does not exclude 
the repression of PLK1 through any other domains. Therefore future mutagenesis 
Figure 4.16: Relative Luciferase levels of transfected PLK1promoterCDE/CHRmutant/pGL3 
plasmid in the presence of increasing amounts of p53 in SAOS2 cells 
A) The p53 plasmid was transfected together with Renilla plasmid, PLK1promoter/pGL3 plasmid, 
PLK1promoterCDE/CHRmutant/pGL3 or empty pGL3 plasmid, and empty PCDNA3 plasmid into 
HCT116 p53 null cells. After 24 h cells were lysed and a Luciferase assay carried out on the lysates. 
Luciferase activity levels were then read by a luminometer. Variations in transfection efficiencies 
were corrected by determining the ratio of activity of Luciferase to Renilla. This graph is 
representative of 3 independent experiments. Statistical analysis was performed using analysis of 
variance with post hoc Bonferroni test for multiple comparisons (* p < 0.05). B) SOAS2 cells were 
transfected with p53 plasmid together with PLK1promoterCDE/CHRmutant/pGL3 plasmid, Renilla 
plasmid and empty PCDNA3 plasmid. Lysates were then analysed by Western blotting with anti-p53 
antibodies, anti-p21 antibodies and anti-β-Actin antibodies.  
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experiments of these domains may shed light on the mechanism of PLK1 repression 
by p53 and p21. ChIP data from our collaborators suggest that p53 does not interact 
with any of the other elements in the core promoter region. 
 
4.5 p53 binds at the p53 responsive element 2  
To determine, in vitro, whether p53 binds to the proposed p53 responsive element 2, 
an electrophoretic mobility shift assay (EMSA) was carried out. As described in 
Chapter 2, oligo-nucleotides containing the wild type or mutated sequence of the p53 
responsive element were incubated in the presence or absence of p53. Using this 
method we are able to detect the p53 bound oligo-nucleotide (probe). To further 
show that it is indeed p53 that has bound to the oligo-nucleotide, the antibody 
PAb421 was added (Hupp et al., 1992). This particular antibody activates the cryptic 
site specific DNA binding activity of p53 (Hupp et al., 1992), therefore enhancing 
the site specific DNA binding, as measured by a higher intensity of the p53 bound 
peptide in the gel (Figure 4.17). As shown in the Figure, p53 binds to the wild type 
oligonucleotide probe, however p53 binding to the mutated oligo-nucleotide is 
reduced. In the presence of PAb421 the complex has been super-shifted and the site-
specific DNA binding of p53 to the oligo-nucleotide has increased as shown by the 
intensity of the band. However, there is a decrease of p53 binding to the mutated 
oligo-nucleotide in the presence of the antibody compared to the wild type oligo-
nucleotide. p53 binds to the control TL oligo-nucleotide, but in the presence of the 
antibody there is no increase in intensity of the band indicating that there is no 
increase in DNA binding and DNA binding of p53 to the TL oligo-nucleotide is 
unspecific, as expected.  On the other hand, p53 binds only to the PG oligo-
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nucleotide in the presence of the antibody indicating that there is only site-specific 
binding of p53 to the PG oligo-nucleotide, as expected. 
 
 
 
 
These results show that p53 binds to the wild type oligo-nucleotide with more 
affinity than the mutated oligo-nucleotide and further activation of the site-specific 
DNA binding activity of p53 confirms this. Overall this suggests that p53 is indeed 
binding to the p53 responsive element 2, in vitro.  
 
Figure 4.17: Electro-phoretic mobility shift assay shows p53 binds to the PLK1 promoter DNA 
and binds with a lower specificity to the mutant PLK1 promoter DNA 
Electro-phoretic –mobility shift assay. Labelled oligo-nucleotides were incubated in the absence and 
presence of p53 protein, which were themselves incubated in the absence or presence of the antibody, 
PAb421 and run on a non-SDS PAGE gel. (n= 4). 
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4.6 p53 levels increase on the p53 responsive element after DNA damage  
To elucidate whether p53 binds to the p53 responsive element in vivo, semi-
quantitative chromatin immunoprecipitations (ChIP) were carried out by our 
collaborators (Katie Schumm, Sam Nicol).Their results showed that there was no p53 
at the CAATT box or at the p53 RE1. Additionally, they showed that p53 is present 
at the p53 RE2 and increases when cells are treated with DNA damaging agents. 
Interestingly there was a decrease in the levels of acetylated histone-3 when cells are 
treated with DNA damaging agents. Furthermore, controls indicated that there was 
no p53 present at the GAPDH promoter. There were no changes in the levels of 
acetylated histone-3 at the GAPDH promoter.  
However, to determine whether Nutlin-3 causes an increase in the levels of p53 at 
this region, further ChIP experiments and PCR reactions were carried out by myself. 
As shown in Figure 4.18, the levels of p53 at the p21 promoter increase in the 
presence of Etoposide or Nutlin-3, as expected, and no background DNA was picked 
up in the no antibody PCR reaction. To determine whether there are increases in p53 
binding to the PLK1 promoter, further ChIP experiments and PCR reactions were 
carried out and show that there was a high background of DNA in the no antibody 
controls. Unfortunately, despite making many individual changes to the ChIP 
protocol, we were unable to reduce the background DNA to a level that permitted 
unequivocal interpretation of data. The conditions used were sufficient to give 
reproducible data when analysing the p21 gene. One additional issue with the PLK1 
promoter was finding the most suitable primer pair to provide confidence in the ChIP 
data. 
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Our results suggest that the ChIP protocol was efficient, however I was unable to 
conclude whether p53 binds to the p53RE2, using this method. However, since the 
writing of this thesis and the technical advances in the ChIP technique in our lab 
during this time, members of our lab show quantitatively that Nutlin-3 increases the 
amount of p53 at RE2. 
 
4.7 Concluding Remarks 
When addressing whether the PLK1 promoter was repressed by p53 through 
proposed p53 responsive elements, it was necessary to clone the PLK1 promoter into 
a reporter vector. Using HCT116 p53-null cells and SAOS2 we created a system 
where the PLK1 promoter reporter vector could be transfected together with 
increasing amounts of either p53 or p21 and determine whether repression was 
Figure 4.18 Chromatin Immunoprecipitations show that levels of p53 at the p21 promoter 
increase after DNA damage  
ChIP was carried out and PCR was performed to show whether p53 was present at p53 RE2 on the 
PLK1 promoter and whether p53 was present on the p21 promoter. 
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caused by either protein. Our data show that p53 is able to repress PLK1 and p21 
may have a small part to play in this repression.  
Furthermore, our system allowed us to determine where within the PLK1 promoter 
repression was achieved and rules out other domains which might occur through, 
such as the CDE/CHR element (Lucibello et al., 1995, Uchiumi et al., 1997). Future 
study will reveal whether repression occurs though other as yet undefined domains. 
Our data show that p53 carries out repression of PLK1 at the proposed p53 
responsive element 2.  
To further elucidate the mechanism by which p53 represses PLK1 promoter at this 
element, EMSA was carried out and confirmed that p53 binds to p53 RE2. This 
suggested that the mechanism by which p53 mediates repression is through its 
transcription factor ability, confirmed by mutant p53 in the Luciferase experiments. 
ChIP, carried out by our collaborators, further confirm that p53 directly represses 
PLK1 through the p53 RE2. Overall the results in this Chapter show that there is a 
repression mechanism of PLK1 that is dependent on p53 and partly on p21. 
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Chapter 5: Conclusions and  
Discussion 
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p53 is a well characterised transcription factor that is activated in response to a range 
of cellular stresses. A variety of genes that are transcriptionally activated by p53 
have been studied in depth including p21, 14-3-3 and GADD45 (Riley et al., 2008). 
However, gene profiling studies have indicated that most targets of p53 are actually 
repressed by p53 (Kho et al., 2004, Riley et al., 2008). This thesis shows that PLK1, 
which is essential for progression of the cell cycle in G2 and M, is an important and 
significant target for p53 mediated repression and p53 regulated G2/M arrest.  
Previous to this thesis, we (Dr Sylvia Dias, data not published) and others (Ando et 
al., 2004, Kho et al., 2004) showed that PLK1 protein levels are down-regulated in 
response to DNA damage. My studies, described in this thesis, explore the 
mechanisms of PLK1 down-regulation by DNA damage and show that p53 is both 
necessary and sufficient to mediate this effect not only in response to DNA damage 
but also to other stimuli that induce p53. These observations were made following 
treatments in the well characterised human colon cancer cell line, HCT116 and its 
p53-null derivative (Bunz et al., 1998) with three different types of drug: Etoposide, 
which causes DNA double strand breaks, Cisplatin, which promotes the formation of 
DNA adducts and Nutlin-3, which activates p53 in a non-DNA damage dependent 
manner by inhibiting the interaction with its negative regulator, MDM2. The 
observation that Nutlin-3 can stimulate down-regulation of PLK1 in the absence of a 
DNA damage stimulus suggests that well-characterised stimuli that induce p53 
independently of DNA damage (e.g. oncogenes, hypoxia) are also likely to down-
regulate PLK1 levels and show a similar biological outcome. This however remains 
to be tested experimentally.  
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My results also show that mRNA levels are down-regulated following induction of 
p53 in a non-DNA damage dependent manner. These data are consistent with the 
idea that p53 can regulate PLK1 mRNA levels either by a transcriptional mechanism 
or perhaps through changes in mRNA turnover. The data from the Luciferase 
experiments (discussed below) strongly favour a mechanism that involves p53-
mediated repression of the PLK1 promoter. 
This thesis has not only dissected the direct repression of PLK1 by p53 but has also 
taken into consideration the possibility that p53 can indirectly down-regulate PLK1. 
PLK1 expression is under tight control throughout the cell cycle due to the presence 
of a CDE/CHR repression element located within the PLK1 promoter (Uchiumi et 
al., 1997) . Thus PLK1 is found at low levels during G1 and S phase but levels 
increase in G2 and peak in mitosis, due to cell cycle mediated relief of this 
repression. During stressed conditions p53 induces cell cycle arrest at the G1/S 
checkpoint by activating expression of the CDK1 inhibitor, p21 (el-Deiry et al., 
1993, Weinberg and Denning, 2002) and in doing so the cell cycle arrests at a point 
where PLK1 levels are at their lowest (G1/S). To confirm that PLK1 levels cycle in 
the HCT116 cell line, as has been observed in other cell lines, a double Thymidine 
block and release was carried out (Figure 3.3). This experiment verified that PLK1 
levels are cell cycle regulated in HCT116 cells and raised the issue of whether the 
drug treatments were simply causing a cell cycle arrest at a stage where PLK1 levels 
are low. Therefore to eliminate possible indirect p53 cell cycle regulated repression 
of PLK1, two experiments were carried out. In the first, p21 expression (p21 
mediates the G1/S arrest) was silenced in HCT116 cells and in U2OS cells. 
Subsequent induction of p53 still led to down-regulation of PLK1 levels suggesting 
that p21 (and therefore G1/S arrest) was not sufficient to mediate this effect. 
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However the down-regulation of PLK1 was slightly less efficient suggesting that 
p21 may contribute to this effect. In the second approach, HCT116 p21-null 
derivatives were treated with each of the drugs used to induce p53. This analysis 
confirmed that Nutlin-3 was still able to down-regulate PLK1 but only weakly when 
compared with the parental cells. Down-regulation in response to Etoposide or 
Cisplatin was lost (but interestingly not at earlier time points). Analysis of the 
treated and untreated HCT116 cells by flow cytometry confirmed that neither the 
p53-null nor the p21-null derivatives were able to undergo a G1/S arrest yet PLK1 
levels could still be down-regulated. While these observations indicate repression of 
PLK1 by p53 can still occur in the absence of p21, the induction of p53 and p53 
down-stream gene expression in the HCT116 p21-null derivatives was very weak. It 
is therefore impossible to gain any further useful information about any specific role 
that p21 may play in PLK1 regulation from the use of this cell line. 
To examine the involvement of p53 directly on PLK1 repression, Luciferase reporter 
assays were carried out and results show that wild type p53 directly represses PLK1 
through the promoter. This experiment involved the construction of a plasmid which 
allowed expression from the PLK1 promoter to be assessed in vivo, in the presence 
of increasing quantities of a p53 expressing plasmid. The titration of mutant forms of 
p53, which either have lost the ability to bind to DNA or have alterations in the N-
terminal domain (which is normally required for trans-activation but it is also 
thought to play a role in trans-repression (Hammond et al., 2006)) did not lead to 
PLK1 repression. These results confirm that wild type p53 alone is sufficient to 
repress PLK1 and that repression requires both the N-terminal domain and site-
specific DNA binding activities of p53.  
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In order to determine any possible contribution of p21 in a transcriptional capacity, 
p21 expressing plasmid was titrated into cells for the Luciferase experiment. The 
results show that p21 can repress PLK1 expression but to a smaller extent to that of 
p53. Technically, it was extremely difficult to show whether the levels of expression 
of p21 achieved using the p21 plasmid matched those obtained from endogenous 
p21 expression following transfection of the p53 plasmid. The extent of any 
contribution of p21 towards inhibiting PLK1 expression therefore remains uncertain. 
Independently of its ability to induce G1/S block, this thesis clearly shows p53 
represses PLK1 directly, therefore the next aim was to discover where on the PLK1 
promoter p53 was able to carry out its repression function. Earlier reports described 
that some promoters such as the Survivin and CDC25C promoters were regulated by 
p53 through p53 responsive elements (Hoffman et al., 2002, St Clair et al., 2004) 
and this led us to look for similar elements in the PLK1 promoter. We identified 
(with the help of our colleague Dr Jean Christophe Bourdon) two possible p53 
responsive elements in the PLK1 promoter, termed RE1 and RE2. To find out 
whether p53 binds to the p53 RE2 (the more compact of these two sites) in vitro, 
EMSA was carried out. This analysis confirmed that there is sequence specific 
binding of p53 to this site, as mutation of this site decreased binding of p53. To 
determine whether p53 could repress PLK1 through the p53 responsive element(s), 
p53 RE2 on the PLK1 promoter of the reporter plasmid was subsequently mutated at 
a half site in the p53 consensus sequence and was transfected into cells together with 
increasing amounts of p53 expressing plasmid. Luciferase assays carried out on 
these cells gave an unexpected result and showed that PLK1 expression was 
significantly reduced because of this mutation. It was first thought that there may 
have been a mutation introduced elsewhere into the vector after mutagenesis and 
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therefore the entire plasmid was sequenced. Sequencing results showed no other 
mutations in the vector. However, in the event that another mutation was not picked 
up in the sequencing, the mutagenesis reaction was carried out a second time and the 
vector transfected into cells. The Luciferase assays showed the same result. After 
eliminating the possibility that another mutation was introduced that affected 
Luciferase expression these results suggest that mutation of this site in RE2 causes a 
disruption to the binding site of an as yet unidentified activator of PLK1 expression 
and that perhaps part of the mechanism by which p53 represses PLK1 may be 
through competitive displacement, which is a common mechanism for p53-
dependent repression as described by St Clair et al., 2006.  
Previous publications also show that p53 and p21 may act to repress gene promoters, 
such as the CDC25C promoter, through both the p53 responsive element and the 
CDE/CHR element (St Clair et al., 2004) and that p53 binds directly to this sequence 
to repress gene expression. As the PLK1 promoter has an already identified 
CDE/CHR element, described by Uchiumi et al., 1997 it was therefore logical to 
mutate the CDE/CHR element to elucidate whether p53 may be acting through this 
site to repress PLK1 expression. Results show that mutation of the CDE/CHR gives 
rise to a substantial increase the in the expression of Luciferase. This was expected 
as mutation of this domain abrogates repression of PLK1 in both G1 and S phases of 
the cell cycle. However, contrary to results shown by St Clair et al., 2004, who 
mutated the CDE/CHR element in the CDC25C promoter and found that mutation 
reduces repression of CDC25C expression by both p53 and p21, the results here 
show that mutation of the CDE/CHR element in the PLK1 promoter has no effect on 
p53 repression of PLK1 expression suggesting that repression of PLK1 expression 
by p53 is not dependent on the CDE/CHR element.  
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Given that the results described above suggest that p53 represses PLK1 expression 
via the RE2 on the PLK1 promoter, I therefore sought to carry out Chromatin 
immunoprecipitation experiments to find out whether p53 binds directly to this 
region in the PLK1 promoter and also to rule out the binding of p53 to other sites, 
such as RE1 and the CDE/CHR element. I also sought to show if levels of p53 at this 
region increased following the induction of p53 expression by Etoposide and Nutlin-
3. As already discussed in Chapter 4, ChIP experiments were carried out by our 
collaborators (Katie Schumm, Sam Nicol). Their results showed that there was no 
p53 at the CAATT box or at the p53 RE1. Additionally, they showed that levels of 
p53 are present at the p53 RE2 and increase when cells are treated with DNA 
damaging agents. Interestingly there was a decrease in the levels of acetylated 
histone-3 when cells are treated with DNA damaging agents. Unfortunately, despite 
making many individual changes to the ChIP protocol, I was unable to remove 
background DNA which was picked up by the PLK1 promoter p53 RE2 primers and 
therefore could not conclude whether there was an increase in p53 levels at the RE2 
in the presence of Nutlin-3.  
However, new data from our lab (carried out by Sharon King and Lynnette Marcar 
and obtained due to a significant improvement of the ChIP technology used in the 
lab) show quantitatively and reproducibly that p53 levels do indeed increase in the 
presence of Nutlin-3 at the RE2 and that p53 binds to RE1 even in the absence of 
stimuli such as Nutlin-3 or the DNA damaging agent, Etoposide at low levels. They 
also confirm that, interestingly, levels of acetyl-histone 3 decrease at RE2 in 
response to these drugs, indicating a role for PLK1 repression by histone 
deacetylases.   
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To confirm the involvement of HDACs in the repression mechanism, HCT116 and 
their p53-null derivatives were treated with the HDAC inhibitor Trichostatin A 
(TSA).  TSA alone caused PLK1 repression which may be a result of TSA relieving 
repression of an as yet unknown PLK1 negative regulator. As established earlier, 
Nutlin-3 almost abolished levels of PLK1 however the presence of both treatments 
recovered levels of PLK1 to the same level of TSA alone. These results support the 
idea that p53-mediated down-regulation of PLK1 may occur through a mechanism 
that involves both p53 and p53 recruited HDAC transcriptional expression.  
This thesis demonstrates the direct repression of PLK1 by p53 and rules out cell 
cycle regulated repression of PLK1 as the major (indirect) mechanism by which p53 
can repress expression of this gene. This project identifies two potential and perhaps 
overlapping mechanisms of repression of PLK1 by p53. These are shown in Figure 
5.1.  
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Figure 5.1: Two potential mechanisms of p53 repression of PLK1  
This thesis suggests two mechanisms by which p53 repress PLK1 expression. Model I shows p53 
could do this through competitive displacement of an activator of PLK1 expression, Model II shows 
p53 could do this through the recruitment of HDACs.  
 
This thesis shows that p53 is both necessary and sufficient for down-regulation of 
PLK1 and advances the understanding by which p53 down-regulates PLK1 that 
previous publications  have suggested or inferred (Ando et al., 2004, Incassati et al., 
2006, Kho et al., 2004, Ree et al., 2003, Smits et al., 2000, Sur et al., 2009).  
Given the importance of p53 in cell cycle arrest, PLK1 knock-down experiments 
were subsequently carried out to elucidate whether the simple removal of PLK1 in 
cells would replicate the results seen in the drug treated cells. Several previous 
publications show that PLK1 knock-down causes defects in bipolar spindle 
formation and cytokinesis, growth inhibition, and apoptosis induction in human 
cancer cell lines (Guan et al., 2005, Liu and Erikson, 2003, Liu et al., 2006, Yim and 
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Erikson, 2009). These reports also show that p53-null cells are more sensitive to 
PLK1 depletion and have a higher number of cells undergoing apoptosis. Notably 
they also show that PLK1 depletion leads to cell death in cancer cells where it does 
not in normal cells and that the absence of p53 as well as PLK1 leads to cell death of 
normal cells. The PLK1 siRNA results in this thesis, consistent with these previous 
studies, show that  PLK1 knock-down causes the cells to arrest in mitosis, as shown 
by flow cytometry, changes in cellular morphology and the presence of high levels 
of phosphorylated histone 3, a marker of mitosis. There is also an increase in the 
number of cells in apoptosis shown by the presence of cleaved PARP, a marker of 
apoptosis. This result shows that PLK1 knock-down does not replicate the results 
seen with the drug treatments, which show cell cycle checkpoint arrest at G1/S 
and/or G2/M (the drug treated cells are more likely in G2 rather than M phase as the 
cell morphology of these cells did not show the rounded up appearance characteristic 
of mitotic cell when harvested). Interestingly, the number of cells in both mitosis 
and apoptosis rise dramatically in the absence of p53 or p21.  
These results are very intriguing and perhaps the most plausible explanation to why 
PLK1 knock-down cannot replicate G2/M checkpoint arrest is that p53 actually 
orchestrates a series of simultaneous events, such as down-regulation of CDC25C 
and Cyclin B (Stark and Taylor, 2006) as well as PLK1, to cause cell cycle arrest at 
the G2/M checkpoint and inhibit the cell cycle before it moves into mitosis. The 
reduction of PLK1 by siRNA causes DNA damage (Yim and Erikson, 2009), severe 
mitotic catastrophe and inhibition of mitosis and because of this the cells cannot 
undergo further proliferation and become apoptotic. p53 arrests the cells at the G2/M 
checkpoint (in addition to the G1/S checkpoint) in the cell cycle before mitotic 
catastrophe and apoptosis need occur. Furthermore the absence of p53 or p21 
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accentuates the number of cells in apoptosis and therefore suggests that p53 plays a 
protective role which is a role also suggested by other authors (Guan et al., 2005, 
Sur et al., 2009, Yim and Erikson, 2009). 
In the overall regulation of the cell cycle this project supports and advances the 
knowledge of regulation of the cell cycle by p53 and the mechanistic insight by 
which p53 carries this out, as shown in Figure 5.2. 
 
Figure 5.2: Cell cycle regulated and direct repression of PLK1 by p53 
Incorporating the two proposed mechanisms by which p53 represses PLK1, this model shows that 
p53 directly represses PLK1 and mediates the block of the cell cycle at the G2/M checkpoint. 
However, this diagram does not show the other genes that are trans-activated and repressed as part of 
the G2/M checkpoint, for example CDC25C and Cyclin B, by p53.  
 
This model shows that there are still questions to answer in regard to the exact 
mechanism by which p53 represses PLK1. One important question is: are HDACs 
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recruited to the p53 RE and if so are they recruited to the RE by p53? Imbriano et 
al., 2005 suggest a model whereby the p53-NFY-CCAAT box complex binds to 
HDACs to repress gene expression however, they show that this complex is required 
but not sufficient for HDAC recruitment. ChIP data shown by our collaborators 
show no occurrence of p53 at the PLK1 promoter CCAAT box, therefore this data 
suggests that it is unlikely that HDAC recruitment and trans-repression by this 
mechanism occurs at the PLK1 promoter. 
Other authors have suggested that HDACs are recruited to sequence specific DNA-
binding transcriptional repressors by the co-repressor protein, mSin3a (Pazin and 
Kadonaga, 1997). p53 is one such transcriptional repressor that binds to mSin3a 
which in turn binds to HDACs and together mediate trans-repression (Murphy et al., 
1999) (for review see (Ho and Benchimol, 2003)). Some authors even suggest that 
HDACs may be recruited directly to p53 or through other mediator proteins such as 
N-CoR or SMRT (Juan et al., 2000, Pazin and Kadonaga, 1997). Taken together 
these data therefore suggest that a future experiment that could be carried out and 
that would find out whether HDACs are found at p53RE2, would be to ChIP certain 
HDACs, to elucidate whether they are recruited to this site. With more time and 
using methods such as the ChIP re-ChIP method, it may be possible to 
immunoprecipitate HDACs alongside p53 on the PLK1 promoter and provide 
insight as to whether this mechanism of repression may occur at the PLK1 promoter. 
 HDACs are known for the ability to remove acetylation groups from histones but 
they also mediate the reduction of acetylation of p53, which ultimately inhibits p53 
trans-activation (Juan et al., 2000). These authors suggest that there are two 
mechanisms by which p53 represses gene expression with the use of HDACs: the 
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first is that HDACs enhance p53 repression of genes by the removal of histone 
acetylation and the second is that HDACs deacetylate p53, in doing inhibiting trans-
activation of gene expression by p53. Recently, Kruse et al, 2009 describe a trans-
repression mechanism whereby p53 is held on the DNA in a repressed state due to 
the binding of MDM2 to p53. Acetylation of p53 activates p53 by inhibiting the 
interaction of p53 to MDM2 (Li et al., 2002), thereby allowing p53 to activate gene 
expression. Also contrary to data shown by Juan et al., 2000, other studies show that 
the binding of mSin3a to p53 stabilises p53 by inhibiting p53 proteasomal 
degradation by MDM2 (Zilfou et al., 2001). This suggests that HDACs do not 
inhibit p53 trans-activation nor mediate MDM2 mediated proteasomal degradation 
of p53.  
Taken these data, and the data that show that p53 is found on the PLK1 promoter 
regardless of stress (EMSA and ChIP), together, could it be that the mechanism of 
repression by p53 is the simple removal of MDM2 from p53 and that this would 
allow the mSin3a-HDAC complex to bind to p53 and mediate p53 repression of 
PLK1? This might explain why Nutlin-3 can induce PLK1 repression and reduce 
PLK1 levels so effectively compared to the two other p53 activating agents 
described in this thesis. Given that DNA damage leads to the phosphorylation and 
destruction of MDM2, this model would also fit with the observations that Etoposide 
and Cisplatin can also repress PLK1.  
In respect with the competitive displacement model, experiments to identify the 
activator of PLK1 expression found at p53RE2 would be ideal to ascertain whether 
p53 competes with this protein, causing transcriptional repression, and would 
support the model that competitive displacement contributes to the mechanism by 
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which p53 represses PLK1, as suggested by St Clair et al., 2004 at the CDC25C 
promoter.  
As to other sites located in the PLK1 promoter, to support the data that suggest that 
the CCAAT box is not involved in p53 repression, perhaps mutation of the CCAAT 
box and Luciferase assays will confirm that p53 repression is independent of the 
CCAAT box and rule out this possible mechanism of repression of PLK1 by p53. 
However, mutation of the CCAAT may eliminate expression of PLK1 altogether. It 
may also be interesting to mutate the E2F binding site to rule out possible p21 
involvement in PLK1 repression at this site. 
PLK1 knock-down is a potential therapeutic approach to cancer as suggested by data 
that show that cancer cells are more sensitive to knock-down than normal cells and 
the induction of mitotic arrest and apoptosis is further increased in cells with 
defective p53 (Guan et al., 2005, and as data in this thesis show). The presence of 
p53 in normal cells clearly gives these cells a level of protection when PLK1 is 
knocked down or inhibited by inhibitors, whilst p53 defective cancer cells treated 
with PLK1 inhibitors will undergo apoptosis. Thus PLK1 inhibition or knock-down 
provides a selective treatment to cancer cells.  
The data in this thesis support the model that p53 has a substantial effect on the 
levels of PLK1. Some authors even suggest that in the absence of p53, levels of 
PLK1 increase (Sur et al., 2009), although my own data comparison of parental and 
p53-null HCT116 cells do not support this. This project provides a model of the 
mechanism by which p53 regulates PLK1 and how mutation or loss of p53 in 
tumour cells can contribute towards unregulated PLK1 levels in these cells and 
therefore an increase in proliferation of cancer cells.  
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The work described in this thesis further expands our understanding of the 
mechanism by which PLK1 is deregulated in cancer cells and the role p53 has in 
regulating PLK1 in normal cells. Mutation of p53 in cancer cells prevents PLK1 
repression and therefore allows cancer cell proliferation. Targeting and inhibiting 
PLK1 could therefore be utilised in cancer therapy. The clinical potential of PLK1 
inhibitors in cancer therapy is an active area of research and PLK1 inhibitors are 
already in early clinical development. These include  BI 2536, BI 6727, GSK461364 
and HMN-214 (Schoffski, 2009). Some are also in advanced preclinical 
development, for example NMS-1, CYC-800, DAP-81, and LC-445.  
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Introduction
The p53 tumor suppressor is a potent transcription factor that 
plays a pivotal role in preventing tumor development.1-4 p53 is 
induced in response to a variety of cellular stresses including 
DNA damage, leading mainly to the onset of apoptosis or cell 
cycle arrest at the G
1
/S and G
2
/M boundaries. In addition to 
activating the expression of a wide range of genes involved in 
these processes, p53 also represses the expression of many genes 
required for cell survival and cell cycle progression, including 
several involved in the G
2
/M transition.5,6 p53-mediated repres-
sion is still only partly understood and its ability to repress G
2
/M 
promoters may involve various mechanisms including interaction 
with the CCA AT-binding transcription factor NF-Y, direct bind-
ing to p53-responsive elements, and/or influence via the CDE/
CHR (cell cycle-dependent element/cell cycle genes homology 
region).7-9
The Polo-Like Kinases are a family of serine/threonine pro-
tein kinases that are structurally and functionally related to the 
prototypic Drosophila melanogaster family member, Polo.10-13 
pLK1 is a critical mediator of G2/M cell cycle transition that is inactivated and depleted as part of the DNA damage-
induced G2/M checkpoint. Here we show that downregulation of PLK1 expression occurs through a transcriptional 
repression mechanism and that p53 is both necessary and sufficient to mediate this effect. Repression of PLK1 by p53 
occurs independently of p21 and of arrest at G1/S where pLK1 levels are normally repressed in a cell cycle-dependent 
manner through a CDe/CHR element. Chromatin immunoprecipitation analysis indicates that p53 is present on the 
PLK1 promoter at two distinct sites termed p53Re1 and p53Re2. Recruitment of p53 to p53Re2, but not to p53Re1, is 
stimulated in response to DNA damage and/or p53 activation and is coincident with repression-associated changes in 
the chromatin. Downregulation of PLK1 expression by p53 is relieved by the histone deacetylase inhibitor, trichostatin A, 
and involves recruitment of histone deacetylase to the vicinity of p53Re2, further supporting a transcriptional repression 
mechanism. Additionally, wild type, but not mutant, p53 represses expression of the PLK1 promoter when fused upstream 
of a reporter gene. Silencing of PLK1 expression by RNAi interferes with cell cycle progression consistent with a role in the 
p53-mediated checkpoint. these data establish PLK1 as a direct transcriptional target of p53, independently of p21, that 
is required for efficient G2/M arrest.
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Mammalian PLK1 plays a pivotal role in the maturation of cen-
trosomes, entry into M phase, spindle formation and cytokine-
sis.10,13 More recently, PLK1 was found to contribute to DNA 
synthesis where it plays a role in pre-replication complex for-
mation.14 PLK1 expression occurs at low levels during the early 
phase of the cell cycle and is mediated by a repression mechanism 
involving a promoter element termed CDE/CHR (cell cycle-
dependent element/cell cycle gene homology region). However, 
its levels accumulate throughout S and G
2
 phase with a sharp 
increase in enzymatic activity occurring prior to the onset of M 
phase.15-18 PLK1 is oncogenic and constitutive expression of the 
enzyme causes transformation of NIH3T3 cells.19 Additionally, 
PLK1 is upregulated in many human malignancies including 
colon cancer and is widely considered to be a potential therapeu-
tic target.13
p53 plays a critical role in the maintenance of the G
2
/M 
checkpoint6 and is protective against DNA damage-induced cell 
death.20 PLK1 is phosphorylated and inactivated by ATM fol-
lowing DNA damage, leading to arrest at the G
2
/M boundary.21 
Similarly, DNA damage induces downregulation of PLK1 in an 
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a p53-dependent manner as a critical component of the G
2
/M 
checkpoint and have implications for PLK1 levels in tumor cells 
lacking functional p53.
Results
PLK1 is downregulated in a p53-dependent manner. To deter-
mine whether PLK1 levels were regulated in response to DNA 
damage, three independent cell lines, MCF-7, OSA and U2OS 
cells (each of which have a wild type p53 response to DNA 
damage) were treated for 24 hours with the DNA methylating 
agent, cis-platin. As expected, the drug induced an increase in 
p53 levels in each cell type (Fig. 1A); a corresponding increase in 
p53-Ser15 phosphorylation was observed in the MCF-7 cells that 
have significantly higher basal levels of wild type p53. Notably, 
in each case, the levels of PLK1 protein were decreased follow-
ing the treatment with cis-platin (Fig. 1A). Further analysis, by 
quantitative RT-PCR, indicated that a corresponding decrease 
in the level of PLK1 mRNA was observed (Fig. 1B) consistent 
with the idea the reduced levels of PLK1 protein reflect reduced 
levels of mRNA expression. In a control analysis, an increase in 
MDM2 expression was observed in all three lines confirming that 
the p53 response to DNA damage was intact in each of these 
ATM/ATR-dependent fashion coincident with increases in p53 
and p21.22-24 Several studies have suggested that this is depen-
dent upon p53 and/or p21,25-28 but either have not provided any 
mechanistic insight or have attributed the downregulation to 
the CDE/CHR element,28 a conclusion that could be explained 
by a p53-mediated G
1
/S arrest. Notably, PLK1 is required for 
recovery from DNA damage-induced G
2
 arrest29 while consti-
tutively active mutants of PLK1 can override the G
2
/M check-
point.23 These observations underscore the critical contribution 
of PLK1 activity towards this checkpoint and led us to examine 
the relationship between PLK1 and the p53 pathway in greater 
depth.
In the present study we confirm that PLK1 is downregu-
lated following DNA damage. We show conclusively that p53 
is both necessary and sufficient to mediate this effect and that it 
does so through direct repression of PLK1 expression. We find 
that p53 is present at two distinct sites in the PLK1 promoter 
and that its recruitment to one of these is further stimulated by 
DNA damage in a manner that is coincident with local changes 
in histone deacetylation favoring a closed chromatin structure. 
We also eliminate p21-mediated repression through the CDE/
CHR element as a major factor in PLK1 repression. These data 
are consistent with the idea that PLK1 is quickly suppressed in 
Figure 1. DNA damage downregulates pLK1 protein and mRNA levels in a p53-dependent manner. (A) MCF-7, OSA and U2-OS cells (all expressing 
wild type p53) were treated with 20 μM Cis-platin for 24 h. Cells were lysed and western blotting performed with antibodies as indicated. (B) MCF-7, 
OSA and U2-OS cells were treated as in (A). RNA was extracted and steady-state levels of mRNA encoding pLK1 and MDM2 were determined by real-
time quantitative pCR. (C) U2OS cells were treated with 20 μM cis-platin or -etoposide. Cells were harvested at the indicated times and examined by 
western blotting. (D) HCt116 p53+/+ or p53-/- cells were treated with 20 μM Cis-platin for 24 h. Cells were lysed and western blotting performed with 
antibodies as indicated.
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endogenous MDM2 levels are barely detectable, were infected 
with adenoviruses expressing wild type MDM2 or, as a control, 
GFP. Treatment of the cells with Nutlin-3, in the absence or pres-
ence of MDM2, had no effect on PLK1 levels ruling out this 
trivial explanation (Fig. 2D). (The MDM2 levels were slightly 
higher in the presence of Nultin-3 consistent with the idea that 
the drug may inhibit the ability of MDM2 to mediate its own 
destruction). While the data favor a mechanism whereby p53 can 
lines. Treatment of the U2OS cells over 
a 24 h period with cis-platin or with the 
DNA strand break-inducer, etoposide, 
confirmed that PLK1 levels decrease 
coincidently with increased p53 levels 
and activation (Ser15 phosphorylation), 
and indicate that reduced PLK1 levels 
occur in response to more than one 
type of DNA damage-inducing drug 
(Fig. 1C).
To determine whether the decrease 
in PLK1 levels was dependent upon 
the presence of p53, HCT116 cells 
(HCT116+/+) or an HCT116 deriva-
tive lacking expression of full-length 
p53 (HCT116-/-),30 were treated with 
cis-platin. While a significant deple-
tion of PLK1 levels was again noted in 
the p53-competent cells, no changes 
in PLK1 were evident in the p53-null 
cells (Fig. 1D). These data indicate 
that cis-platin-induced PLK1 deple-
tion is dependent upon wild type p53. 
Control analyses showed that increased 
expression of 14-3-3σ, MDM2 and p21 
occurred only in the p53-competent 
cells confirming that the p53 pathway 
was functional only in the HCT116+/+ 
cells (Fig. 1D).
p53 is necessary and sufficient to 
mediate decreased PLK1 levels. To 
explore further the contribution of the 
p53 pathway towards downregulation 
of PLK1 HCT116 cells were treated 
with increasing amounts of Nutlin-3 
which blocks the interaction of p53 
with its binding site in the N-terminus 
of MDM2.31 Following this treat-
ment, a dose-dependent increase in 
p53 levels was accompanied by match-
ing increases in the levels of p21, 14-3-
3σ and MDM2 (Fig. 2A). Notably, a 
dose dependent decrease in PLK1 levels 
was also observed. These changes were 
apparent only in the HCT116+/+ cells 
and not in the HCT116-/- cells, again 
consistent with a critical role for p53 in 
PLK1 reduction. Additionally, treat-
ment of the HCT116+/+ cells, but not the HCT116-/- cells, with 
Nutlin-3 resulted in a dose-dependent decrease in PLK1 mRNA 
(Fig. 2B). Furthermore, a time course analysis showed that the 
reduction in PLK1 levels was co-incident with the accumulation 
of p53 and p21 (Fig. 2C). Strictly speaking, Nutlin-3 is an MDM2 
inhibitor, raising the possibility that the changes in PLK1 levels 
could arise as a result of inhibition of a p53-independent function 
of MDM2. To address this issue, the HCT116-/- cells, in which 
Figure 2. Nutlin-3 induces p53-mediated downregulation of pLK1. (A) HCt116 p53+/+ or p53-/- cells 
were treated with 0–10 μM Nutlin-3 or DMSO as vehicle control. the cells were lysed and western 
blotting was performed with the indicated antibodies. (B) HCt116 cells were treated as in (A) and the 
steady-state levels of mRNA encoding pLK1 and MDM2 were determined by real-time quantitative 
pCR. (C) HCt116 p53+/+ cells were treated with 5 μM Nutlin-3 for 0–24 h. Cells were lysed and western 
blotting performed with the antibodies as indicated. (D) HCt116 p53-/- cells were infected with 
recombinant viruses Ad-MDM2 or Ad-GFp at an MOI of 50 for 4 h. the cells were then treated with 10 
μM Nutlin-3 for 24 h and lysed before western blotting was performed with the indicated antibodies. 
(e) HCt116 p53 wild-type cells were treated with 10 μg/ml Cycloheximide and cell lysates prepared at 
the indicated time points after addition. western blotting was then performed with the antibodies as 
indicated.
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repress PLK1 expression, it is also possible that 
p53 may promote the turnover of PLK1 protein. 
However, analysis of the decay of PLK1 protein in 
the absence of Nutlin-3 indicated that its half life 
(determined by cycloheximide-chase) was not sig-
nificantly different when compared with the decay 
rate following treatment of the cells with Nutlin-3 
(compare Fig. 2E and C). It is already established 
that PLK1 is degraded through the ubiquitin-pro-
teasome pathway, most likely mediated by APC 
(reviewed in ref. 10).
PLK1 levels have been reported to be low dur-
ing the early stages of the cell cycle and accumulate 
throughout S and G
2
 phases.15-18 These published 
observations were verified in the present study 
(Suppl. Fig. 1). This effect is mediated through a 
repressor element, termed CDE/CHR, that oper-
ates during the early phase of the cell cycle.18 The 
reduced level of PLK1 protein and -mRNA could 
therefore simply reflect the accumulation of cells at 
G
1
/S following a p53-dependent cell cycle arrest. 
To explore this possibility, SAOS-2 cells were used 
together with a derivative line (SAOS-2/p53,32) in 
which wild type mouse p53 is inducibly expressed 
using a doxycycline-inducible promoter. (SAOS-2 
cells, which lack endogenous p53, also lack Rb 
and cannot therefore arrest at G
1
/S). Upon treat-
ment of the SAOS-2/p53 cells with doxycycline, 
p53 was induced in a dose-dependent (Fig. 3A) 
and time-dependent (Fig. 3C) manner leading to 
increases in the levels of p21 protein and—mRNA; 
(p21 is both a p53 target and is primarily respon-
sible for mediating p53-dependent G
1
/S arrest). 
Significantly, the levels of PLK1 protein (Fig. 3A 
and C) and mRNA (Fig. 3B) were depleted fol-
lowing induction of p53. These changes were not 
observed following doxycycline treatment of the 
parental SAOS-2 cells that lack the inducible p53. 
These data indicate that downregulation of PLK1 
expression can be achieved in the absence of a 
p53-dependent G
1
/S arrest.
Using a parallel approach, the expression of 
p21 was silenced in two independent cell lines 
using siRNA (Fig. 4A). Following treatment of 
the cells with Nutlin-3, significant downregu-
lation of PLK1 levels were still observed even 
though there was no detectable p21 in the silenced 
cells. It should be noted, however, that the down-
regulation of PLK1 by Nutlin-3 was slightly less 
efficient in the p21-silenced cells as compared with 
the control treatments (especially in the HCT116 
cells) suggesting that p21 is likely to make a minor 
contribution to this effect. To confirm this result, 
p21 expression was silenced in SAOS-2/p53 cells. 
Again, downregulation of PLK1 expression was 
independent of the presence of p21 (Fig. 4B). 
Figure 3. Downregulation of pLK1 levels in SAOS-2 cells following inducible ectopic 
expression of p53. SAOS-2 cells and a derivative line that ectopically expresses mouse 
p53 in a doxycycline-inducible manner32 were treated for 24 h in the presence of increas-
ing amounts of doxycycline. After harvesting, the cell extracts were analysed by western 
blotting (A) or quantitative Rt-pCR (B) to determine the levels of pLK1, p53, p21 and, as 
control, actin. the cells were also treated with 0.5 mM doxycycline for up to 34 h prior 
to harvesting. the levels of pLK1, p53, p21 and actin were subsequently determined by 
western blotting (C).
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transcriptional repression. Acetylated H3 was also observed in 
the vicinity of p53RE1 but was unaltered following stimulation 
of p53, indicating that the interaction of p53 with this region 
of the promoter did not mediate repression-associated chromatin 
remodeling.
To confirm that PLK1 expression is downregulated by a 
p53-dependent repression mechanism, HCT116 parental cells 
and the HCT116-p53-/- derivatives were treated with the histone 
deacetylase (HDAC) inhibitor, trichostatin A (TSA). Treatment 
of the cells with TSA alone led to a reduction in PLK1 levels inde-
pendently of p53 (Fig. 6A): this observation probably reflects the 
widespread involvement of HDACs in regulating gene expres-
sion; (its p53-independent effect on PLK1 expression is most 
plausibly explained if TSA relieves expression of a PLK1 negative 
regulator). However, treatment of the parental cells, but not the 
PLK1 levels were also measured in HCT116+/+ cells null 
for p21 30 as compared with the HCT116+/+ and HCT116 
p53-/- cells following induction of p53 (Suppl. Fig. 2). 
The data indicate that downregulation of PLK1 levels 
by all three stresses (etoposide, Nutlin-3 and cis-platin) 
is partially impaired in the absence of p21, particularly 
at the time point measured (24 h post-treatment: see A). 
Nutlin-3, which is the most potent of these treatments in 
terms of inducing the p53 response, still retains significant 
ability to downregulate PLK1 levels. Notably, however, 
etoposide was also able to downregulate PLK1 levels in the 
p21-null cells at earlier time points although less robustly 
in comparison with the parental cells, and concomitantly 
with a much reduced induction of p53 (as measured by the 
increase in p53 levels and the induction of p53-responsive 
genes such as MDM2 and 14-3-3σ [Suppl. Fig. 2A and 
C], and with a partial recovery by 24 h). Flow cytometry 
confirmed that Nutlin-3 induces both a G
1
/S and G
2
/M 
block in the wild type cells but cell cycle arrest is abol-
ished in the cells lacking p53 or p21 (Suppl. Fig. 2B). This 
observation suggests that the p53-dependent decrease in 
PLK1 levels cannot simply be attributed to an arrest at 
G
1
/S where the PLK1 levels are naturally low.
p53 binds directly to the PLK1 promoter and inhib-
its PLK1 transcription. The downregulation of PLK1 
at both the protein and mRNA levels is consistent with 
the idea that p53 can mediate transcriptional repression 
of PLK1. If such a mechanism occurs then it should be 
possible to detect the presence and/or recruitment of p53 
to the PLK1 promoter. To test this idea, chromatin immu-
noprecipitation (ChIP) experiments were carried out. Two 
potential p53 binding sites were observed in the PLK1 pro-
moter at positions -2,067 to -2,016 (termed p53 responsive 
element 1 [p53RE1]) and -816 to -785 (p53RE2; Fig. 5A): 
the latter site contains two contiguous canonical p53 half-
sites.5 Accordingly, PCR primers were designed to permit 
analysis of each of these two regions. Additionally, given 
that p53 can repress promoters via interactions with fac-
tors operating within core promoter elements (for exam-
ple through interaction with the CCAAT box-associated 
NF-Y transcription factor7 or the CDE/CHR elements20) 
PCR primers were designed to permit analysis of the core pro-
moter region. ChIP analysis of the PLK1 promoter revealed that 
p53 was present within both of the regions encompassing puta-
tive p53 consensus binding sites (p53RE1 and p53RE2 respec-
tively: Fig. 5B and C, left hand parts) but could not, however, 
be detected within the core promoter region containing the 
CAATT and CDE/CHR elements (Fig. 5D). As control, no p53 
was detected on the GAPDH promoter (Fig. 5E). Interestingly, 
when p53 was induced either through treatment with etoposide 
or Nutlin-3 a modest increase in the levels of recruitment of p53 
were observed at the region of the PLK1 promoter containing 
p53RE2, but not that containing p53RE1. This was accompa-
nied by a striking decrease in the level of acetylated histone H3 
present at p53RE2 (Fig. 5C, right hand side), consistent with 
structural changes in the chromatin normally associated with 
Figure 4. Downregulation of pLK1 can occur following elimination of p21. (A) 
expression of p21 in HCt116 cells or U2OS cells was silenced by siRNA. Control 
cells were untreated (Unt), mock-transfected (Mock), or transfected with a 
non-silencing siRNA. Cells were subsequently treated with 5 μM Nutlin-3 for for 
24 h prior to harvesting. Western blotting was subsequently performed with 
the antibodies as indicated. (B) expression of p21 in SAOS-2 cells expressing 
p53 under an IptG-inducible system (or parental cells lacking p53, as control) 
was silenced by siRNA treatment as in (A). Western blotting was subsequently 
performed with the antibodies as indicated.
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presence of HDAC1 is enriched within the vicin-
ity of p53RE2 in response to etoposide treatment 
consistent with the idea that HDAC1 is recruited 
to the promoter as part of the repression mecha-
nism. In contrast, the presence of HDAC1 on the 
p53-stimulated p21 promoter was reduced under 
these conditions, as might be expected with activa-
tion of this promoter (Fig. 6B).
To determine whether p53 can bind specifically 
to the PLK1 promoter, EMSA experiments were 
carried out using complementary DNA oligonucle-
otides representing p53RE2 (Fig. 7: p53RE2 was 
examined because it is responsive to stimuli that 
activate p53 [see above] and is located in the vicin-
ity of the repression-associated histone deacety-
lation events). Bacterially-expressed p53 bound 
to the p53RE2 promoter element and its binding 
was both shifted and stimulated by the anti-p53 
C-terminal antibody, PAb421. (The p53 protein 
has both a site-specific binding function [encom-
passed within the core domain of the protein] and 
a non-specific DNA binding function [located at 
the C-terminus]: the PAb421 antibody is an established activa-
tor of the site-specific-, but not the non-specific-DNA binding 
function of p53).33 p53 was still able to interact with a mutant 
of the p53RE2 response element in which three base pairs were 
changed. However, this binding, although super-shifted by 
PAb421, was not stimulated by the antibody suggesting that it 
occurred through the non-specific binding function of p53. By 
comparison, similar differences in site-specific and non-specific 
binding are illustrated in the controls for p53/DNA binding 
where the appropriate sequences used by Hupp and colleagues 
p53-/- cells, with Nutlin-3 alone led to a significant downregula-
tion of PLK1 levels over and above that seen with TSA alone. 
This inhibition was relieved in the presence of TSA where the 
PLK1 levels recovered to the level of PLK1 in the cells that had 
been treated with TSA alone. These data support the idea that 
p53-mediated downregulation of PLK1 expression occurs via 
HDAC-mediated transcriptional repression. To provide a more 
focussed examination of the involvement of histone deacetylase, 
quantitative ChIP analysis was carried out using an antibody 
that recognizes HDAC1 (Fig. 6B). The data indicate that the 
Figure 5. p53 is recruited to the PLK1 promoter in 
response to DNA damage. (A) Schematic showing 
the PLK1 promoter. the positions of the two putative 
p53 responsive elements (p53Re1 and p53Re2) are 
shown together with the CAAtt box and the CDe/CHR 
element. the numbers in parentheses indicate the posi-
tions of these elements relative to the transcriptional 
start site. the arrows show the positions of primers/
probes designed to examine these regions by quantita-
tive ChIp. the sequences of the regions containing po-
tential p53 responsive elements p53Re1 and p53Re2 are 
shown beneath and the bases within these elements 
are shown in upper case. Quarter sites are indicated by 
arrows. the sequence information is taken from Gen-
bank sequence X90725. (B–e) HCt116 cells were treated 
with 50 μM etoposide (etop), 10 μM Nutlin-3 (Nutl) or 
were untreated (Un) as control. Cells were harvested af-
ter 8 h and the presence of p53 and acetylated histone 
H3 on the p53Re1 (B) and p53Re2 (C) regions of the PLK1 
promoter were determined by ChIp. Control immuno-
precipitations were carried out using IgG. ChIp analyses 
was extended to the core promoter region where the 
CAAtt box and CDe/CHR elements are located (D). As a 
negative control, the GApDH promoter was examined 
for the presence of p53 (e). the measurements were 
carried out in triplicate and the results are representa-
tive of three independent experiments.
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Figure 6. Histone deacetylase activity contributes to downregulation of pLK1 by p53. (A) HCt116 parental cells or the p53-null derivative were treated 
with 1 μM trichostatin A (tSA) alone, 10 μM Nutlin-3, or a combination of these two drugs. Cells were lysed after 24 h and western blotting performed 
with antibodies as indicated. (B) HCt116 cells were treated for 8 h with 50 μM etopoide. Chromatin immunoprecipitation analysis was carried out us-
ing an antibody that recognizes HDAC1.
Figure 7. p53 binds directly to the p53Re2 sequence. (A) eMSA was carried out using radiolabeled dsDNA probes corresponding to the p53Re2 
sequence (lanes 1–3) and a mutant derivative (lanes 4–6) in which three base pairs were substituted to destroy the p53 binding site consensus: (the 
sequence GTG CAT GCT t was changed to GTG gAT tgT T [with the changed bases shown in lower case]). (B) eMSA showing the binding of p53 to the 
control sequences pG (comprising a canonical p53 responsive element, lanes 1–3) and tL (comprising a sequence unrelated to a canonical p53 binding 
site, lanes 4–6). these reagents are established tools with which to measure site-specific p53 binding.33
8 Cell Cycle Volume 9 Issue 20
promoter [data not shown]). Interestingly, repression mediated 
by increasing amounts of p53 reached a threshhold (with gener-
ally 20–40% of the activity remaining) beyond which further 
increases in the amount of p53 had no further effect. Two tumor-
associated inactive mutants of p53 that cannot bind DNA failed 
to repress the PLK1 promoter (Fig. 8B and C). Additionally 
the L22Q/W23S mutant of p53 (Fig. 8D), which is inactive in 
transactivation,34 was also unable to repress the PLK1 promoter 
suggesting that this domain participates in the repression mecha-
nism. (Others have established previously that this region of p53 
also contributes to transcriptional repression).35 Mutation of the 
CDE/CHR element did not eliminate repression by p53 (Fig. 
were employed.33 These data support the idea that p53RE2 con-
stitutes an effective p53 binding site.
p53 represses the expression of the PLK1 promoter in a 
promoter-reporter assay. To determine whether p53 can directly 
repress expression from the PLK1 promoter, 2.4 kb of the pro-
moter was cloned upstream of a luciferase reporter gene (Fig. 8). 
The promoter-luciferase plasmid was transfected into SAOS-2 
cells (Fig. 8) or HCT116-p53-/- cells (Suppl. Fig. 3) together with 
increasing amounts of a plasmid expressing wild type human 
p53. These analyses showed that very low levels of p53 (low nano-
gram amounts of plasmid) inhibit expression (Fig. 8A; similar 
levels of p53 are required to stimulate the expression from the p21 
Figure 8. p53 represses expression of the PLK1 promoter. SAOS-2 cells were transfected in triplicate with increasing amounts a plasmids encoding wild 
type or mutant p53 or p21, together with promoter/(Firefly) luciferase vectors containing a wild type or mutated PLK1 promoter and, as an internal 
standard, a plasmid expressing Renilla luciferase. Cell extracts were made 24 h after transfection and the levels of luciferase were determined. the 
graphs show the ratios of firefly luciferase/Renilla luciferase with error bars representing the standard deviations. Western blots shown under each 
graph show representative increases in the levels of expression of p53 or p21 with actin as loading control.
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9C), suggested that they had entered mitosis before undergo-
ing p53-independent apoptosis. When p53 or p21 were absent 
there was no G
1
/S arrest with the outcome that there was a higher 
proportion of cells at G
2
/M and a significantly increased level of 
apoptosis. These data suggest that p53 may play an additional role 
by protecting the cells from loss of PLK1, presumably by holding 
a proportion of the cells at the G
1
/S boundary. The finding that 
8E) indicating that p53-mediated 
repression occurs independently of 
this important repressor element: 
however, the basal levels of expres-
sion from the PLK1 promoter 
increased by 2–3-fold consistent 
with published data indicating that 
this element mediates cell cycle-
dependent repression of PLK1.18 
Titration of a plasmid encoding 
active p21 (which was able to arrest 
cells at G
1
/S [data not shown]) had 
no significant effect on expression 
from the PLK1 promoter although 
the trend over several experiments 
suggested the possibility of a small 
contribution by p21 (Fig. 8F).
To determine whether the 
repression was mediated through 
p53RE2, the same three muta-
tions that were present in the 
mutant p53RE2 element used in 
the EMSA experiments (Fig. 7) 
were introduced into the PLK1 
promoter-luciferase plasmid. PLK1 
promoter-luciferase analysis with 
this mutant promoter indicated that 
the p53 responsiveness does indeed 
appear to be diminished (Fig. 8G). 
Additionally, however, there was a 
striking reduction in the basal level 
of expression suggesting that one or 
more of the bases we had changed 
are vital to maintaining basal PLK1 
expression (Fig. 8G). This observa-
tion suggests the possibility that the 
binding site for a stimulatory factor 
may overlap with the p53 binding 
site.
PLK1 depletion causes a 
mitotic arrest leading to p53-inde-
pendent apoptosis. PLK1 plays an 
essential role in the transition of 
the cell cycle from late G
2
 phase, 
throughout mitosis to cytokinesis10 
and its downregulation has been 
proposed to contribute to the G
2
/M 
checkpoint.22-24 To determine the 
outcome of downregulating PLK1 
levels on cell cycle progression PLK1 expression was silenced by 
siRNA. Knock-down of PLK1 in the HCT116 (p53+/+) cells (Fig. 
9A) led to cell cycle arrest at both the G
1
 and G
2
/M phases of the 
cycle with a small proportion of the cells undergoing apoptosis 
as evidenced by flow cytometry (Fig. 9B), and PARP cleavage 
(Fig. 9A). The presence of increased levels of phosphorylated his-
tone H3 in these cells, and their rounded-up appearance (Fig. 
Figure 9. Silencing of PLK1 expression leads blocks cell cycle progression and initiates apoptosis. PLK1 
expression in parental HCt116 cells, and in the p53-null and p21-null derivatives, was silenced by siRNA 
transfection. the cells were harvested 24 h after transfection. (A) western blotting was performed with 
the antibodies as indicated. (B) Cell were analysed by Flow cytometry. A set of data is shown that is repre-
sentative of three independent experiments. (C) the cells were examined by phase contrast microscopy.
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Our data also demonstrate that PLK1 satisfies the five con-
ditions that normally constitute a p53-responsive gene.5 These 
are: (a) presence of a demonstrable p53-responsive element in the 
promoter (Figs. 7 and 8); (b) downregulation at the RNA and 
protein level by wild type, but not mutant, p53 (Figs. 1–3 and 8); 
(c) p53 regulation conferred on a test gene through the respon-
sive element (Fig. 8); (d) the presence of p53 on the endogenous 
promoter within the vicinity of the response element as revealed 
by ChIP (Fig. 5); and (e) sequence-selective binding of p53 to the 
RE in vitro (Fig. 7). Our data support and significantly extend 
previous observations suggesting that PLK1 may be downregu-
lated by a p53-dependent repression mechanism.21-24,26,27
Several laboratories have examined the outcome of silencing 
expression of PLK1 and broadly agree that depletion of PLK1 
leads to several defects associated with the transition through 
mitosis and cytokinesis, resulting in mitotic catastrophe and/
or apoptosis.14,38-44 Interestingly, PLK1 depletion has also been 
reported to lead to DNA damage.14,41 Since p53 mediates the 
repression of PLK1 (both at the levels of expression and post-
translational modification [this study: reviewed in ref. 22–27]), 
we re-examined the effects of depleting PLK1 to determine the 
likely consequence of its downregulation following p53 induc-
tion. Consistent with published studies, we find that PLK1 
knock-down arrests the cells not in G
2
 but in mitosis, as judged 
by flow cytometry profile, cellular morphology and the presence 
of phosphorylated histone-H3 (a marker for mitotic cells; Fig. 
9). Notably, these cells fail to complete mitosis (as evidenced 
by the reduction in the G
1
 peak [in the p53-null and p21-null 
derivatives]—i.e., they are not re-entering cycle) and undergo 
apoptosis, as shown by the presence of a sub-G
1
 population of 
cells together with the appearance of cleaved PARP. These obser-
vations raise some curious questions about the impact of inducing 
p53 on late cell cycle events. On the one hand, the downregula-
tion of PLK1 by p53 could lead indirectly to apoptosis by allowing 
cells to progress towards mitosis when they lack this critical mito-
sis orchestrator. Arguing against this, however, is the observation 
that downregulation of PLK1 does not lead to any significant 
increase in apoptosis when it is achieved through inducing p53 
(as judged by the lack of any increase in the sub-G
1
 population—
see Suppl. Fig. 2). A more plausible explanation is that p53 stably 
maintains arrest in G
2
 through a series of events including down-
regulation of CDC25C, Cyclin B1, CDC2, Stathmin, MAP4, 
etc., (reviewed in ref. 6 and 45) that are by necessity coordinated 
and inter-dependent, and that it is within this context that the 
inhibition of PLK1 functions as an important and integral ele-
ment in this orchestration. We also note that arrest in mitosis fol-
lowed by apoptosis occurs not only in the HCT116 parental cells 
but also in the p53-null and p21-null derivatives (Suppl. Fig. 2). 
Strikingly, however, the level of apoptosis is significantly greater 
in the absence of p53, and even greater still when p21 is absent. 
A protective effect of p53, consistent with these observations, has 
also been noted by others.14,27,38,41,42 We suggest, from the flow 
cytometry profiles in Supplementary Figure 2B, that the ability 
of p53 and/or p21 to arrest the cells in G
1
 may afford this pro-
tection, at least in part, by preventing the cells from progressing 
to the G
2
/M stages of the cell cycle where the absence of PLK1 
loss of PLK1 permits the cells to enter M phase but terminate 
in apoptosis is consistent with the idea that p53 may mediate 
a checkpoint that leads to cell death through the downregula-
tion of PLK1. Alternatively, however, it is possible that a G
2
/M 
cell cycle arrest may indeed involve p53-mediated depletion of 
PLK1, but may additionally require other p53-coordinated events 
to hold the cells at the G
2
/M boundary thereby halting any com-
mitment towards undergoing cell death.
Discussion
In the present study we show that PLK1 protein and -mRNA lev-
els are depleted in response to DNA damage-inducing agents in 
a p53-dependent manner. Moreover, the use of Nutlin-3, which 
inhibits the p53-MDM2 interaction,31 or expression of p53 via 
an inducible system demonstrated that induction of p53 alone is 
sufficient to achieve this effect in the absence of DNA damage. 
These data suggest that PLK1 is likely to be a target of p53 not 
only following DNA damage but also in response to other stimuli 
that induce a p53 response. The data also suggest that p53 can 
mediate these effects by directly repressing expression of PLK1. In 
support of this idea we find that p53 is recruited to two distinct 
regions within the PLK1 promoter. In one case (p53RE1) this is 
associated with an open chromatin structure that is unaffected by 
p53 stimulation. In the other case however (p53RE2) the chro-
matin conformation becomes closed (as evidenced by loss of his-
tone acetylation) in response to p53 activation and increased p53 
recruitment (Fig. 5). The involvement of histone deacetylase in 
the p53-dependent downregulation of PLK1 additionally supports 
a repression model (Fig. 6). At present we do not know what addi-
tional components are required for this repression mechanism, 
nor do we know the sequence of events involved or the means by 
which the repression is regulated. We have, however, been able 
to rule out certain mechanisms. For example, p21-dependent or 
-independent repression via the CDE/CHR element, while rel-
evant to some promoters (reviewed in ref. 20), and which has pre-
viously been suggested by others to mediate the ability of p53 to 
regulate PLK1 levels,28 does not appear to be a major contributor 
to repression of PLK1 (Figs. 4, 5 and 8 and Suppl. Fig. 2). The 
finding that p53 could not be detected close to the transcriptional 
start site (Fig. 5) also suggests that the inhibition of DNA-bound 
NF-Y that occurs in promoters such as the CDC2 and Cyclin B2 
promoters is unlikely to mediate repression of PLK1.7
The finding that mutation of the p53 responsive element, 
p53RE2, leads to a loss in basal PLK1 expression suggests that 
a transcription factor that is crucial for maintaining basal PLK1 
levels binds to a site that overlaps with p53RE2. It also raises 
the possibility that part of the repression mechanism may involve 
“competitive displacement” by p53, a mechanism that is known 
to mediate repression of several other p53-responsive promot-
ers,20,36,37 in some cases (e.g., CDC25C20) as part of a dual repres-
sion mechanism. Initial analysis of the p53RE2 sequence suggests 
a list of at least 20 different transcription factors that could bind 
to this region. Identifying this factor will therefore be an impor-
tant goal in exploring the elements of this repression mechanism 
in depth.
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Gene silencing using siRNA. HCT116 and U2OS cells 
were transfected with PLK1 or p21 siRNA (ON-TARGETplus 
SMARTpool L-003290-00 or L-003471-00 respectively 
Dharmacon) using Lipofectamine (for U2OS cells) or by reverse 
transfection using Lipofectamine RNAiMAX Transfection 
Reagent (for HCT116 cells) in a 6-well plate according to the 
manufacturers’ instructions.
Real-time (Taqman) RT-PCR. Total RNA was isolated from 
cells using the RNeasy Mini Protocol according to the manufac-
turer’s instructions (Qiagen Ltd.,) cDNA was synthesized using 
standard reverse transcription PCR techniques. Steady-state lev-
els of mRNA encoding PLK1 and MDM2, were determined by 
real-time quantitative PCR as described previously.46 The prim-
ers and probe for PLK1 amplification were as follows.
PLK1 Forward primer: 5'-GGA TCA CAC CAA GCT CAT 
CTT G-3'
PLK1 Reverse primer: 5'-CCC GCT TCT CGT CGA TGT-3'
PLK1 Probe: 5'-CCC ACT GAT GGC AGC CGT GAC C-3'
The primers and probes for MDM2 were as follows.
MDM2 Forward primer: 5'-CAA GTT ACT GTG TAT 
CAG GCA GGG-3'
MDM2 Reverse primer: 5'-CCT TCC ATC ACA TTG CAA 
CAG A-3'
MDM2 Probe: 5'-TTG GAA ATG CAC TTC ATG CAA 
TGA AAT GAA TCC-3'
Antibodies and western blot analysis. SDS-PAGE and 
western blotting was carried out using standard conditions. 
Nitrocellulose membranes were probed for the presence of PLK1 
(antibodies PL2 and PL6, Zymed Laboratories Inc.,), p53 (anti-
body DO1, Moravian Biotechnology; or CM-1,47), p53 phospho-
Ser15 (Ab-3, Calbiochem), MDM2 (SMP14, D12, Santacruz 
Biotechnology, Inc.; or 4B2, Moravian Biotechnology), p21 
(H-164, Santacruz Biotechnology, Inc.,), 14-3-3σ (sc-7683, 
Santacruz Biotechnology, Inc.,), phospho-Histone H3 (06-
570, Upstate Biotechnology), acetyl-lysine (4G12, Upstate 
Biotechnology), HDAC1 (sc-6298, Santacruz Biotechnology, 
Inc.,) or actin (20-33, Sigma-Aldrich). Secondary antibodies 
used were HRP-conjugated rabbit anti-mouse (DAKO), -goat 
anti-rabbit (DAKO) or -donkey anti-goat (sc-2020, Santacruz 
Biotechnology, Inc.). Proteins were detected by enhanced che-
miluminescence according to the manufacturer’s instructions 
(Pierce Biotechnology, Inc.).
Cell lysis. Cells were lysed in 50 mM Tris-HCl, pH 7.5, 1% 
NP-40, 0.25% Sodium deoxycholate, 150 mM NaCl, 5 mM 
EDTA, 50 mM Sodium fluoride, 1 mM Sodium orthovana-
date, 1 mM Benzamidine and a protease inhibitor cocktail 
(Calbiochem), left on ice for 10 mins, followed by centrifugation 
at 13,000 rpm for 10 mins at 4 degrees. The soluble fractions 
were collected.
Infection with recombinant adenovirus. Recombinant 
viruses Ad-MDM2, Ad-GFP and Ad-CON have been described 
elsewhere.48 HCT116-/- cells were grown to 80% confluency and 
infected at an MOI of 50, followed by an incubation period at 
37°C for 4 h (35). Cells were then treated with 10 μM Nutlin-3,31 
and incubated at 37°C for a further 24 h. Extracts were analyzed 
by western blotting.
becomes a critical problem. Additionally, however, the recent 
demonstration that PLK1 is required for pre-replication complex 
formation during DNA synthesis, and consequently that deple-
tion of PLK1 leads to DNA damage,14,41 suggests that p53 may be 
alerted to abnormally low PLK1 levels through the DNA damage 
pathways and provides additional protection by blocking entry 
into and/or progression through S phase.
Our data are also consistent with the growing awareness 
that p53 status may have a profound influence on PLK1 levels 
in tumors.27 Our findings thus provide mechanistic insight into 
how mutation of p53 or loss of p53 function, during tumorigen-
esis can lead to, or contribute towards, unregulated PLK1 levels 
and, consequently, to an augmented hyper-proliferative drive. 
They also support the idea, expressed by other researchers,27,38,42 
that an intact p53 pathway may assist the selective treatment of 
tumor cells with PLK1 inhibitors by affording a level of protec-
tion to normal cells.
Materials and Methods
Cell culture. Cells were maintained in McCoy’s 5a medium 
(Biosera; HCT116 [p53+/+, p53-/- and p21-/-] colon carcinoma 
cells30) were maintained in McCOY’s 5a medium (Biosera) or 
Dulbecco’s modified Eagle’s medium (Biosera; OSA, U2OS, 
MCF-7 and SAOS-2), supplemented with 10% heat-inactivated 
fetal bovine serum (Biosera), penicillin (100 IU/ml)/streptomy-
cin (100 μg/ml) (Invitrogen) and 2 mM Glutamine (Invitrogen). 
Cultures were maintained at 37°C in a humidified 5% CO
2
 
atmosphere.
Flow cytometry. Cells were treated with 5 μM Nutlin-3 
or untreated as control, for 24 h. Cells were analyzed by flow 
cytometry following labeling with BrdU and propidium iodide 
as described previously.32
Luciferase reporter assays. A PLK1-luciferase reporter plas-
mid was constructed by cloning 2.3 kb of the human PLK1 pro-
moter (base numbers 1,590–3,893 from the Genbank sequence 
X90725) upstream of the firefly luciferase gene in the plasmid 
pGL3-basic (Promega). Cells (3 x 104/well) were seeded onto a 
24-well plate and transfected in triplicate using Fugene (Roche) 
as indicated in the figure legends. Transfected cells were har-
vested 24 hr post-transfection by adding 100 μl of passive lysis 
buffer (Promega) per well. 20 μl of protein extract was ana-
lyzed in a luminometer using the Dual Luciferase Reporter 
Assay Kit (Promega). Variations in transfection efficiencies 
were corrected by determining the Renilla luciferase activity of 
the sample.
Site-directed mutagenesis. Point mutations at the CDE/
CHR site in the PLK1 promoter-luciferase plasmid were gen-
erated using the Stratagene Quik-Change system according to 
the manufacturer’s instructions. The complementary mutant 
oligonucleotides were as follows with the mutant bases shown 
underlined:
Coding strand oligonucleotide: 5'-GTA ACG TTC CCA 
TAT CCG CGT TCA CAT TCG GGG AGG AG-3'
Non-coding strand oligonucleotide: 5'-CTC CTC CCC 
GAA TGT GAA CGC GGA TAT GGG AAC GTT AC-3'.
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CAATT box Forward primer: 5'-ATC CCC GCG GCC 
AAT-3'
CAATT box Reverse primer: 5'-TCC TCC CCG AAT TCA 
AAC G-3'
CAATT box Probe: 5'-CGC GCA GGC TTT TGT AAC 
GTT CCC-3'
p21 promoter, distal p53 binding site Forward primer: 5'-GTG 
GCT CTG ATT GGC TTT CTG-3'
p21 promoter, distal p53 binding site Reverse primer: 5'-CTG 
AAA ACA GGC AGC CCA AG-3'
p21 promoter, distal p53 binding site, probe: 5'-TGG CAT 
AGA AGA GGC TGG TGG CTA TTT TG-3'
For the quantitative ChIP analysis, U20S or HCT116 cells 
were treated with up to 50 μM Etoposide, 20 μM Cis-platin or 
10 μM Nutlin-3 for 6 or 8 h and chromatin immunoprecipita-
tion was performed as described previously.32,49
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Quantitative chromatin immunoprecipitation (ChIP). The 
promoter sequence of human PLK1 (accession number X90725) 
was screened for potential p53 binding sites using in-house soft-
ware. This approach identified potential p53 binding sites at posi-
tions, relative to the transcriptional start site, -2,086 to -2,016 (p53 
binding site-1 [p53RE-1]) and -816 to -785 (p53 binding site-2 
[p53RE2]). The sequence of these regions is given in Figure 5A. 
Primers and probes for quantitative chromatin immunoprecipita-
tion analysis were designed using Primer Express software (Applied 
Biosystems) to allow amplification of the regions encompassing 
the two potential p53 binding sites and, additionally, the CAAT 
and CDE/CHR signals (both of which are located close to the 
transcriptional start site). The primers and probes were as follows:
p53 binding site-1 Forward primer: 5'-CAC TGT GCC TAA 
ACT GTT CGT ACA-3'
p53 binding site-1 Reverse primer: 5'-CAC ATA TGA AAA 
TCT GAC TCC CAG AA-3'
p53 binding site-1 Probe: 5'-TGT GGG TTA TGC CCA 
ACA TCT GCT TTC-3'
p53 binding site-2 Forward primer: 5'-TGC TAG GCA TTC 
TTC CAA CCT T-3'
p53 binding site-2 Reverse primer: 5'-GAA TTT CCC AGG 
GCC TAA AAT AG-3'
p53 binding site-2 Probe: 5'-CCT CCC TCT GAC CAA 
GAA ACT GAG TGT CC-3'
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